blautia
p
significantli
decreas
day
c
hiranoni
p
day
blautia
p
remain
decreas
day
ecoli
remain
unchang
day
p
decreas
day
p
faecalibacterium
remain
unchang
day
p
increas
day
p
group
statist
signific
differ
identifi
administr
amoxicillinclavulan
acid
doxycyclin
profound
effect
certain
bacteri
group
potenti
associ
dysbiosi
kitten
sever
studi
report
intestin
microbi
dysbiosi
dog
chronic
enteropathi
limit
data
avail
microbiota
gene
function
patholog
dog
determin
function
attribut
microbiom
essenti
understand
role
host
metabol
diseas
aim
studi
compar
function
role
fecal
microbiota
healthi
dog
dog
ce
fecal
dna
shotgun
sequenc
fecal
sampl
collect
healthi
dog
dog
chronic
enteropathi
ce
fecal
dna
extract
use
commerci
kit
powersoil
qiagen
function
character
shotgun
sequenc
read
kegg
databas
perform
use
next
gener
sequenc
order
identifi
rel
abund
specif
metabol
pathway
wilcoxon
test
use
comparison
gene
abund
group
signific
set
q
phylum
level
low
abund
bacteroidet
observ
dog
ce
compar
healthi
control
dog
vs
q
fusobacteria
also
significantli
increas
healthi
control
vs
q
pathway
enrich
analysi
bacteri
metagenom
show
total
metabol
modul
differenti
abund
studi
group
gene
carbohydr
metabol
biosynthesi
amino
acid
lysin
threonin
histidin
isoleucin
tryptophan
leucin
serin
vitamin
ascorb
thiamin
riboflavin
decreas
dog
ce
gene
involv
transport
molecul
homeostasi
mainten
oxid
stress
glutathion
biosynthesi
increas
ce
data
present
previou
report
intestin
microbi
dysbiosi
dog
ce
new
find
result
show
alter
microbi
metabol
dog
ce
compar
healthi
dog
character
reduct
amino
acid
biosynthesi
carbohydr
metabol
studi
includ
transcriptom
analysi
warrant
defin
consequ
microbiota
dysfunct
dog
ce
proteinlosingenteropathi
ple
syndrom
caus
variou
diseas
includ
idiopath
inflammatori
bowel
diseas
primari
lymphangiectasia
lymphoma
sever
acut
gastroenter
certain
breed
predisposit
softcoat
wheaten
terrier
well
known
clinic
experi
suggest
pug
ple
respond
poorli
treatment
describ
literatur
aim
current
studi
assess
whether
pug
breed
demonstr
wors
respons
treatment
ple
breed
dog
retrospect
studi
compar
respons
treatment
pug
diagnos
ple
five
referr
centr
unit
kingdom
approv
studi
grant
univers
liverpool
research
ethic
committe
group
nonpug
dog
also
diagnos
ple
within
period
select
comparison
ple
defin
gastrointestin
diseas
result
serum
albumin
laboratori
refer
interv
could
explain
anoth
caus
factor
associ
surviv
assess
use
simpl
statist
mannwhitney
test
chisquar
test
appropri
cox
proport
hazard
regress
initi
factor
test
individu
use
simpl
regress
multipl
regress
model
creat
subsequ
refin
backward
stepwis
elimin
best
model
found
total
pug
diagnos
ple
compar
dog
breed
simpl
regress
analysi
factor
associ
surviv
p
pug
breed
p
diet
use
treatment
p
receiv
immunosuppress
therapi
p
treatment
cobalamin
p
howev
factor
remain
final
model
pug
breed
diet
use
treatment
respect
dog
pug
breed
associ
greater
hazard
die
compar
nonpug
hazard
ratio
hr
ci
p
whilst
fed
hydrolys
diet
associ
lesser
hazard
risk
death
fed
diet
compar
lowfat
diet
hr
ci
p
compar
diet
includ
highlydigest
diet
hr
ci
p
conclus
studi
demonstr
associ
pug
breed
poorer
respons
treatment
ple
compar
breed
research
undertaken
underli
caus
abstract
disclosur
report
ajg
employe
univers
liverpool
post
financi
support
royal
canin
also
own
mar
petcar
ajg
also
receiv
financi
remuner
provid
educ
materi
speak
confer
consult
work
mar
petcar
remuner
project
unrel
work
report
manuscript
author
declar
conflict
interest
measur
serum
folat
pointless
retrospect
analysi
preval
clinic
signific
hypoor
hyperfolataemia
dog
chronic
enteropathi
petrelli
salavati
royal
dick
school
veterinari
studi
roslin
institut
edinburgh
unit
kingdom
assess
serum
folat
sf
routin
perform
dog
chronic
enteropathi
ce
often
conjunct
serum
cobalamin
tradit
combin
use
differenti
intestin
malabsorpt
dysbiosi
despit
fact
diagnost
prognost
valu
serum
cobalamin
well
document
preval
hypoand
hyperfolataemia
clinic
prognost
valu
assess
scrutinis
dog
ce
aim
studi
determin
preval
sf
abnorm
dog
ce
well
relationship
laboratori
paramet
outcom
file
dog
present
chronic
gastrointestin
gi
sign
week
durat
retrospect
evalu
exclus
criteria
lack
sf
assess
supplement
folat
cobalamin
beforehand
dog
fn
mn
fe
median
age
rang
includ
hypofolataemia
present
hyperfolataemia
remain
dog
normal
sf
valu
initi
dog
divid
group
accord
final
diagnosi
ce
n
gi
diseas
n
nongi
diseas
n
sf
valu
significantli
differ
across
group
kruskalw
p
divid
ce
dog
differ
subgroup
food
fre
antibiot
steroidrespons
sre
proteinlos
enteropathi
ple
differ
sf
valu
observ
anova
p
dog
group
sf
statu
low
normal
high
signific
differ
serum
cobalamin
p
alkalin
phosphatas
p
cholesterol
p
total
calcium
p
identifi
anova
dunn
post
hoc
test
multivari
analysi
confirm
correl
sf
cobalamin
p
well
cholesterol
p
total
calcium
p
howev
none
correl
linear
spearman
p
kaplan
maier
analysi
followup
surviv
time
sf
statu
show
signific
differ
conclus
sf
associ
gi
diseas
subgroup
ce
improv
clinic
sign
surviv
associ
sf
statu
studi
diagnost
prognost
benefit
assess
sf
dog
chronic
gi
sign
could
detect
futur
prospect
studi
assess
folat
supplement
ce
dog
hypofolataemia
acceler
clinic
improv
influenc
outcom
prognosi
acut
haemorrhag
diarrhoea
syndrom
ahd
dog
often
treat
antibiot
due
potenti
risk
bacteri
transloc
gastrointestin
tract
blood
stream
howev
recent
studi
indic
antibiot
alway
necessari
accord
danish
antibiot
use
guidelin
companion
anim
antibiot
recommend
routin
treatment
ahd
indic
hospit
dog
sever
affect
overal
condit
sign
system
inflamm
sir
sepsi
aim
studi
evalu
sever
diseas
outcom
hospit
dog
acut
haemorrhag
diarrhoea
receiv
antibiot
studi
perform
retrospect
observ
studi
base
inform
medic
record
dog
acut
haemorrhag
diarrhoea
unknown
aetiolog
hospit
univers
hospit
companion
anim
period
signal
concurr
diseas
clinic
diseas
time
hospit
consecut
day
treatment
prior
hospit
day
hospitalizationeuthanasia
laboratori
result
regist
patient
clinic
diseas
score
accord
ahdsscor
system
number
sir
criteria
tachycardia
hr
tachypnea
rr
hyper
hypothermia
c
c
leucocytosi
wbc
l
leukopenia
wbc
l
band
neutrophilia
andor
hypoglycaemia
glucos
mmoll
record
onehundr
seventytwo
dog
exclud
analysi
due
suspect
drug
induc
diseas
vaccin
n
anaesthet
n
corticosteroid
nsaid
n
alimentari
foreign
bodi
n
treatment
antibiot
hospit
n
dog
obviou
caus
diarrhoea
found
receiv
support
treatment
intraven
fluid
therapi
n
antiemet
n
gastroprotect
n
surviv
discharg
dog
two
dog
euthan
due
financi
constraint
reluct
owner
proceed
treatment
due
advanc
age
one
brachycephal
dog
suffer
respiratori
crisi
respiratori
arrest
nonrespons
resuscit
surviv
dog
hospit
averag
day
rang
day
mean
ahdsscor
hospit
rang
mean
ahdsscor
hour
hospit
rang
abstract
dog
met
sir
criteria
hospit
none
dog
degen
leftshift
result
suggest
antimicrobi
therapi
dog
acut
haemorrhag
diarrhoea
may
alway
necessari
dog
even
sirscriteria
met
recent
studi
shown
alter
faecal
bile
acid
ba
profil
dog
chronic
enteropathi
potenti
contribut
clinic
sign
studi
aim
assess
faecal
ba
concentr
dog
acut
haemorrhag
diarrhoea
syndrom
ahdsd
time
compar
healthi
control
dog
hcd
twentyf
ahdsd
hcd
enrol
faecal
ba
concentr
measur
ga
chromatographymass
spectrometri
day
ahdsd
day
hcd
statist
analysi
perform
friedman
test
comparison
ba
time
ahdsd
unpair
ttest
mannwhitneytest
comparison
ahdsd
hcd
p
day
concentr
lithochol
acid
significantli
lower
ahdsd
hcd
p
day
total
faecal
ba
significantli
increas
ahdsd
p
compar
hcd
precis
primari
ba
significantli
increas
ahdsd
day
p
significantli
higher
concentr
cholic
acid
p
secondari
ba
significantli
decreas
p
significantli
lower
concentr
deoxychol
acid
p
ursodeoxychol
acid
udca
p
dog
ahdsd
show
signific
decreas
total
primari
ba
concentr
p
significantli
lower
concentr
cholic
acid
p
deoxychol
acid
p
day
compar
day
conclus
ahdsd
show
alter
faecal
ba
profil
compar
hcd
howev
faecal
ba
profil
normal
rapidli
suggest
ba
dysmetabol
seem
play
major
role
pathophysiolog
ahd
pimobendan
frequent
use
offlabel
treatment
cat
congest
heart
failur
chf
secondari
hypertrophi
cardiomyopathi
hcm
concern
exist
regard
safeti
pimobendan
subset
cat
hcm
dynam
outflow
tract
obstruct
hocm
purpos
studi
evalu
safeti
toler
pimobendan
cat
chf
secondari
hocm
compar
nonobstruct
hcm
medic
record
cat
chf
hocm
nonobstruct
hcm
two
tertiari
referr
hospit
review
demograph
clinicopatholog
echocardiograph
treatment
data
collect
compar
group
includ
inform
regard
possibl
advers
effect
pimobendan
averag
age
cat
year
differ
hocm
hcm
p
compar
cat
hcm
cat
hocm
like
manifest
chf
pulmonari
edema
versu
p
less
like
pleural
effus
versu
p
higher
incid
heart
murmur
cat
hocm
p
clinic
variabl
differ
group
pimobendan
typic
initi
date
chf
diagnosi
median
time
diagnosi
chf
initi
pimobendan
day
initi
dose
pimobendan
mgkg
everi
hour
dose
frequenc
escal
point
chf
manag
case
differ
hocm
hcm
cat
clinic
sign
could
potenti
repres
advers
effect
pimobendan
vomit
diarrhea
anorexia
lethargi
newonset
arrhythmia
note
hcm
cat
hocm
cat
p
base
pattern
time
resolut
sign
gener
ascrib
recurr
chf
rather
pimobendan
administr
pimobendan
discontinu
due
advers
effect
cat
nonobstruct
hcm
experienc
lethargi
nausea
hour
follow
pimobendan
administr
resolv
pimobendan
discontinu
pimobendan
discontinu
addit
cat
either
owner
unabl
administ
medic
n
chf
resolv
n
case
chf
precipit
acut
extern
event
fluid
overload
inject
glucocorticoid
administr
cat
experienc
acut
advers
hemodynam
effect
hypotens
cardiovascular
collaps
follow
pimobendan
administr
result
studi
suggest
pimobendan
welltoler
cat
cardiomyopathi
chf
regardless
presenc
dynam
outflow
tract
obstruct
systol
heart
murmur
sm
commonli
diagnos
healthi
cat
aim
studi
determin
whether
aortosept
angl
aosa
associ
sm
cat
hypothesis
sm
relat
presenc
septal
bulg
systol
anterior
motion
mitral
valv
sam
increas
aortic
flow
veloc
aov
novemb
februari
client
own
cat
refer
cardiolog
evalu
prospect
examin
regardless
presenc
systol
murmur
cat
abstract
pathway
disrupt
cardiovascularren
axi
dog
incomplet
defin
renal
endothelin
system
may
play
key
role
regul
blood
pressur
sodium
homeostasi
kidney
also
mediat
vascular
dysfunct
profibrot
inflammatori
chang
increas
cardiovascular
risk
peopl
urinari
marker
renal
vascular
tubular
activ
could
provid
insight
chang
renal
signal
contribut
cardiovascularren
interact
dog
hypothesis
renal
activ
increas
advanc
canin
chronic
cardiac
renal
diseas
pilot
studi
compar
cystatin
c
marker
renal
injurydysfunct
concentr
surplu
urin
four
abstract
complet
balanc
diet
one
test
one
control
evalu
prospect
random
doubleblind
multicent
studi
effect
clinic
biochem
echocardiograph
paramet
fortyfour
clientown
cat
asymptomat
hypertroph
cardiomyopathi
ahcm
cat
diastol
interventricular
septum
ivsd
andor
left
ventricular
wall
lvwd
thick
mm
includ
inform
ownercons
examin
nonsed
fast
cat
month
test
control
diet
includ
auscult
bodyweight
bw
bodi
condit
score
bc
echocardiographi
wall
clinic
environ
stress
cat
therebi
affect
blood
pressur
bp
record
aim
investig
differ
clinic
set
order
sequenc
set
perform
affect
bp
record
healthi
cat
ninetysix
healthi
cat
prospect
includ
health
examin
includ
physic
examin
echocardiographi
hematolog
biochemistri
blood
pressur
measur
highdefinit
oscillometr
hdo
devic
cuff
tail
three
clinic
set
cat
taken
carrier
place
examin
tabl
veterinarian
present
cat
carrier
veterinarian
present
cat
carrier
without
veterinarian
present
owner
abstract
human
type
dm
aim
studi
evalu
chang
fecal
microbiota
fecal
unconjug
ba
profil
dog
naturallyoccur
dm
insulin
therapi
compar
healthi
control
dog
hc
aim
naturallypass
fecal
sampl
left
serum
sampl
obtain
diagnost
propos
adult
dog
dm
collect
fecal
sampl
clinic
healthi
dog
use
control
popul
addit
serum
folat
cobalamin
ctli
assess
dm
group
exclud
presenc
caus
dysbiosi
dm
dog
fed
diet
known
use
antibiot
within
previou
month
exclud
dna
extract
fecal
sampl
prior
quantit
pcr
qpcr
analysi
data
bacteri
group
compil
calcul
microbiota
dysbiosi
index
di
concentr
proport
fecal
unconjug
primari
cholicchenodeoxychol
secondari
lithodeoxyursodeoxychol
ba
measur
use
ga
chromatographi
mass
spectrometri
platform
unpair
test
mannwhitney
u
test
compar
median
valu
hc
dm
dog
signific
set
p
median
di
statist
differ
hc
dm
dog
hd
vs
dm
p
neg
dysbiosi
index
di
indic
normobiosi
present
dm
dog
four
dog
dm
dysbiot
di
index
tli
folat
cobalamin
concentr
normal
dog
dm
though
two
dog
cobalamin
level
ngl
signific
differ
group
total
ba
proport
secondari
ba
respect
p
p
result
preliminari
studi
confirm
associ
natur
pass
fece
collect
healthi
kitten
receiv
antibiot
group
kitten
receiv
amoxicillinclavulan
acid
day
group
kitten
receiv
doxycyclin
day
group
part
standard
treatment
upper
respiratori
tract
infect
kitten
approxim
month
age
diet
antiparasit
treatment
prior
sampl
collect
fecal
sampl
collect
day
antibiot
treatment
group
group
respect
end
antibiot
administr
dna
extract
sampl
qpcr
perform
total
bacteria
turicibact
spp
faecalibacterium
spp
streptococcu
spp
escherichia
coli
e
coli
blautia
spp
fusobacterium
spp
clostridium
hiranoni
c
hiranoni
bifidobacterium
spp
data
test
normal
distribut
appropri
statist
analys
use
either
repeat
independ
measur
statist
signific
set
p
correct
multipl
comparison
use
appropri
day
signific
differ
identifi
among
group
day
signific
increas
e
coli
p
decreas
total
bacteria
p
blautia
p
c
hiranoni
p
faecalibacterium
p
group
compar
group
day
ecoli
p
significantli
increas
group
compar
group
group
e
coli
significantli
decreas
p
faecalibacterium
significantli
increas
p
time
group
total
bacteria
p
destruct
intestin
barrier
microbiota
dysbiosi
especi
around
time
wean
repres
import
mechan
allerg
sensit
consequ
young
dog
surviv
canin
parvoviru
cpv
infect
develop
chronic
gastrointestin
disord
later
live
unknown
adult
dog
sever
intestin
lesion
also
increas
risk
develop
chronic
gastrointestin
disord
aim
studi
evalu
whether
dog
acut
hemorrhag
diarrhea
syndrom
ahd
higher
preval
chronic
enteropathi
later
life
forti
dog
diagnos
ahd
followup
least
month
avail
includ
studi
histor
control
group
dog
without
histori
gastroenter
includ
enabl
risk
assess
dog
owner
ask
complet
questionnair
percentag
dog
sign
chronic
enteropathi
group
compar
use
fisher
exact
test
signific
differ
ahd
control
dog
concern
develop
chronic
enteropathi
ahd
control
p
observ
time
ahd
median
year
rang
year
control
median
year
rang
year
result
studi
suggest
dog
experi
episod
ahd
increas
risk
develop
chronic
gastro
sixteen
dog
stage
mmvd
includ
prospect
intervent
studi
echocardiogram
perform
present
hour
follow
singledos
pimobendan
twodimension
mmode
doppler
imag
record
right
parastern
left
apic
standard
view
dog
left
atrial
volum
measur
use
biplan
arealength
method
three
timepoint
immedi
mv
open
onset
pwave
mv
closur
reservoir
conduit
activ
pump
function
calcul
previous
describ
ten
dog
mv
regurgit
volum
calcul
subtract
forward
stroke
volum
aortic
outflow
veloc
time
integr
multipli
aortic
crosssect
area
total
left
ventricular
lv
stroke
volum
endsystol
lv
volum
subtract
enddiastol
lv
volum
measur
use
simpson
method
disc
mv
regurgit
fraction
calcul
percentag
regurgit
volum
total
stroke
volum
pair
student
ttest
wilcoxon
signedrank
test
use
compar
result
compar
baselin
la
volum
significantli
lower
postpimobendan
measur
immedi
mv
open
p
pwave
onset
p
mv
closur
p
howev
la
conduit
reservoir
activ
pump
function
chang
significantli
mv
regurgit
fraction
postpimobendan
significantli
lower
p
compar
baselin
forward
stroke
volum
significantli
increas
p
total
stroke
volum
chang
significantli
studi
suggest
despit
acut
reduct
la
volum
pimobendan
may
exert
measur
effect
la
function
benefici
decreas
left
atrial
volum
appear
result
acut
reduct
mv
regurgit
fraction
mechan
pimobendan
reduc
regurgit
fraction
thought
associ
improv
forward
flow
secondari
inotrop
vasodilatori
effect
addit
reduc
enddiastol
lv
dimens
minimis
secondari
function
mitral
regurgit
disclosur
report
retrospect
evalu
safeti
toler
pimobendan
cat
obstruct
versu
nonobstruct
hypertroph
cardiomyopathi
normal
echocardiograph
exam
normal
blood
pressur
systol
pressur
mmhg
euthyroid
includ
studi
cat
normal
diastol
thick
left
ventricl
isol
basal
septal
hypertrophi
ibsh
mm
sam
also
includ
aosa
measur
right
parastern
five
chamber
view
base
publish
guidelin
dog
total
cat
examin
fulfil
inclus
criteria
left
parastern
sm
found
cat
cat
murmur
audibl
stress
auscult
sm
associ
narrow
aosa
p
higher
preval
ibsh
p
higher
aov
p
compar
cat
without
murmur
ibsh
increas
age
increas
mm
per
year
aosa
decreas
age
p
reduct
per
year
aosa
narrow
cat
ibsh
p
ibsh
alway
present
cat
aosa
aosa
differ
cat
without
sam
p
nonlinear
correl
aosa
aov
conclus
aosa
angl
remodel
interventricular
septum
may
correl
caus
systol
murmur
appar
healthi
cat
find
resembl
sigmoid
septum
found
human
consid
morpholog
variant
ventricular
septum
age
relat
associ
systol
murmur
disclosur
report
accuraci
noninvas
determin
pulmonari
arteri
pressur
dog
myxomat
mitral
valv
diseas
mmvd
eighteen
measur
pair
therefor
use
comparison
paspc
paspd
blandaltman
analysi
linear
regress
statist
signific
bia
paspc
paspd
mean
differ
mmhg
confid
interv
mmhg
mmhg
detect
limit
agreement
techniqu
wide
mmhg
mmhg
regress
analysi
fail
identifi
signific
linear
associ
two
techniqu
r
p
conclus
paspd
estim
poorli
agre
paspc
measur
dog
affect
mmvd
acvim
stage
c
dog
paspd
could
underor
overestim
paspc
mmhg
therefor
caution
use
interpret
paspd
disclosur
report
michel
borgarelli
receiv
financi
support
ceva
sant
animal
work
relat
abstract
left
atrial
tear
dog
myxomat
mitral
valv
diseaseclin
present
echocardiograph
featur
longterm
surviv
conclus
dog
mmvd
associ
lat
bear
high
mortal
risk
especi
first
week
post
event
howev
surviv
critic
time
lat
seem
significantli
impact
longterm
surviv
disclosur
report
echocardiograph
evalu
left
ventricular
dimens
systol
function
hour
percutan
closur
patent
ductu
arteriosu
dog
claretti
piantedosi
piscitelli
b
serrano
lopez
e
boz
l
mazzoni
de
rosa
navalon
calvo
p
ciaramella
c
bussadori
clinica
veterinaria
gran
sasso
milano
itali
depart
veterinari
medicin
anim
product
univers
federico
ii
napoli
itali
ar
veterinaria
barcelona
spain
one
hundr
twenti
dog
enrol
valu
effect
load
condit
chang
left
ventricular
volum
patent
ductu
arteriosu
pda
occlus
acdo
use
standard
echocardiographi
anim
divid
pure
breed
n
mix
breed
n
subsequ
pure
breed
dog
divid
basi
size
breed
belong
group
small
size
n
medium
size
n
larg
size
n
moreov
anim
divid
three
class
base
age
month
month
month
signific
reduct
examin
paramet
lvidd
lvid
edv
esv
edvi
esvi
fs
observ
ductal
closur
evalu
rel
percentag
differ
rdp
echocardiograph
paramet
show
closur
signific
reduct
higher
small
size
breed
larg
size
breed
dog
signific
differ
relat
breed
size
observ
rpdf
variabl
signific
interact
effect
breed
size
age
class
observ
rpdedvi
f
p
six
month
age
signific
differ
rpdedvi
reduct
month
signific
reduct
small
size
larg
size
breed
dog
occlus
observ
conclus
data
seem
indic
small
breed
dog
show
greater
toler
congenit
volum
overload
reason
could
possibl
delay
pda
closur
month
allow
weight
gain
make
easier
intervent
procedur
hand
larg
breed
dog
submit
ductal
closur
soon
possibl
order
avoid
excess
lv
wall
stress
disclosur
report
delay
electrolyt
deplet
azotemia
furosemid
rate
continu
infus
model
adin
c
atkin
h
ru
g
wallac
univers
florida
gainesvil
unit
state
america
north
carolina
state
univers
raleigh
unit
state
america
intraven
furosemid
mainstay
treatment
acut
congest
heart
failur
dog
howev
potenti
delay
effect
hydrat
electrolyt
renal
function
studi
studi
sought
evalu
paramet
normal
dog
receiv
furosemid
continu
rate
infus
cri
without
reninangiotensinaldosteron
system
inhibitor
ten
healthi
dog
studi
random
crossov
design
dog
oral
receiv
either
placebo
benazepril
benazepril
spironolacton
day
prior
furosemid
cri
mg
kghr
bodi
weight
bw
renal
valu
serum
electrolyt
pack
cell
volum
total
protein
measur
oral
medic
hour
furosemid
cri
hour
variabl
compar
timepoint
treatment
loss
bw
cri
exceed
recoveri
hour
hemoconcentr
occur
incomplet
return
baselin
hour
blood
urea
nitrogen
creatinin
unchang
cri
increas
ae
hour
serum
sodium
chang
cri
decreas
hour
serum
chlorid
decreas
hour
return
baselin
hour
hypochlorem
metabol
alkalosi
increas
anion
gap
present
hour
normal
hour
differ
treatment
found
furosemid
crirel
biochem
chang
delay
hour
other
evid
hour
partial
improv
hour
normal
dog
find
implic
clinic
patient
renal
dysfunct
receiv
higher
dose
longer
furosemid
infus
disclosur
report
studi
fund
ceva
sant
animal
dr
adin
receiv
fund
american
kennel
club
canin
health
foundat
unrel
studi
chang
renal
endothelin
activ
cardiac
renal
chronic
diseas
dog
group
dog
present
r
sv
healthi
n
chronic
kidney
diseas
ckd
iri
stage
serum
creatinin
n
cardiac
diseas
acvim
classif
n
noncardioren
chronic
diseas
n
urin
freecatch
ownercollect
morn
appoint
sampl
exclud
contain
activ
sediment
store
c
batch
analysi
cystatin
c
measur
commerci
elisa
index
urinari
creatinin
concentr
enzymat
method
comparison
oneway
anova
yield
nontransform
residu
kruskalw
dunn
post
hoc
test
use
signific
p
mark
increas
excret
dog
stage
c
heart
diseas
iqr
pgmg
n
compar
healthi
dog
pgmg
iqr
p
excret
also
increas
stage
heart
diseas
pgmg
iqr
p
n
although
lesser
degre
predominantli
due
increas
dog
mmvd
pgmg
iqr
p
n
rather
nonmmvd
cardiac
diseas
pgmg
iqr
al
increas
ckd
chronic
diseas
group
statist
signific
contrast
ckd
markedli
increas
urinari
cystatin
c
excret
limit
detect
ngmg
iqr
p
modest
increas
p
observ
dog
chronic
diseas
ngmg
iqr
none
heart
diseas
stage
renal
activ
increas
congest
heart
failur
surprisingli
also
increas
mmvd
congest
develop
neither
increas
associ
renal
injuri
consequ
chronic
diseas
state
renal
may
mediat
pathophysiolog
cardiovascularren
interact
mmvd
differ
isol
ckd
develop
congest
heart
failur
disclosur
report
high
grade
av
block
third
degre
av
block
cat
retrospect
studi
epicardi
pacemak
implant
focus
signal
present
surviv
spalla
ga
smith
dj
connolli
royal
veterinari
colleg
potter
bar
unit
kingdom
third
degre
atrioventricular
block
avb
characteris
complet
atrioventricular
av
dissoci
caus
independ
atrial
ventricular
rhythm
persist
third
degre
avb
pavb
commonli
describ
anoth
form
avb
av
dissoci
intermitt
iavb
also
recognis
cat
avb
associ
underli
cardiac
system
diseas
present
clinic
sign
associ
form
avb
includ
weak
lethargi
syncop
clinic
sign
particular
syncop
present
epicardi
pacemak
implant
repres
effect
treatment
aim
studi
retrospect
assess
present
echocardiograph
data
comorbid
outcom
cat
diagnos
avb
pavb
iavb
singl
referr
hospit
includ
underw
pacemak
implant
non
parametr
test
kaplan
meier
curv
log
rank
test
perform
sixtyfour
cat
includ
period
fortythre
cat
pavb
iavb
median
age
present
year
differ
avb
type
p
thirtyf
cat
male
femal
fortyfour
cat
refer
cardiac
complaint
syncop
arrhythmia
dyspnoea
cat
nonspecif
sign
lethargi
cat
avb
incident
find
cat
iavb
like
present
syncop
event
p
median
durat
clinic
sign
prior
present
day
twentynin
cat
echocardiograph
chang
left
ventricular
hypertrophi
chamber
dilat
cat
present
congest
heart
failur
chf
fortyf
cat
one
comorbid
common
hyperthyroid
diabet
mellitu
azotaemia
fifteen
cat
underw
epicardi
pacemak
implant
mainli
cat
iavb
five
cat
minor
complic
lead
dislodg
pacemak
undersens
exit
block
cat
show
clinic
sign
sinc
implant
fortyseven
cat
die
allcaus
mortal
median
surviv
time
day
differ
surviv
observ
cat
present
chf
p
iavb
p
comorbid
p
pacemak
placement
p
death
due
cardiac
caus
occur
fewer
cat
shorter
surviv
allcaus
mortal
day
p
chf
present
associ
cardiac
death
p
result
studi
show
variabl
outcom
cat
avb
cardiac
death
occur
minor
cat
associ
chf
present
cat
comorbid
affect
allcaus
mortal
pacemak
implant
control
clinic
sign
major
cat
disclosur
report
dietinduc
reduct
cardiac
wall
thick
troponini
cat
asymptomat
hypertroph
cardiomyopathi
thick
measur
mid
lvwd
ivsd
apic
ivsd
level
record
maximum
max
sumand
number
area
mm
n
blood
analysi
includ
ntprobnp
ultrasensit
troponini
ctni
serum
amyloid
saa
insulin
glucos
linear
gener
mix
model
analyz
diet
time
diettim
interact
signific
level
signific
diettim
interact
heartrat
p
p
test
control
diet
show
signific
decreas
time
maxivsd
p
nivsd
p
sumivsd
p
mivsd
p
maxlvwd
p
nlvwd
p
sumlvwd
p
mlvwd
p
n
ivsd
lvwd
p
p
ctni
p
signific
chang
bw
bc
effect
cardiac
medic
observ
cat
left
atrium
remodel
separ
significantli
decreas
nivsd
p
sumivsd
p
mlvfwd
p
revers
effect
primari
echocardiograph
paramet
ahcm
decreas
ctni
observ
test
diet
research
need
evalu
effect
clinic
outcom
disclosur
report
canin
sa
studi
describ
financi
support
royal
canin
sa
biomark
discoveri
cat
cardiomyopathi
cardiomyopathi
frequent
cat
diagnosi
reli
combin
physic
examin
thorac
radiographi
electrocardiographi
echocardiographi
addit
last
decad
assay
measur
circul
biomark
heart
diseas
cardiac
troponin
ntermin
probrain
natriuret
peptid
ntprobnp
becom
avail
cat
assay
proven
use
diagnosi
felin
cardiomyopathi
although
certain
case
may
less
reliabl
therefor
aim
studi
detect
new
circul
protein
may
improv
identif
cat
affect
cardiomyopathi
use
biomark
discoveri
clientown
cat
prospect
enrol
evalu
compris
complet
blood
count
biochem
profil
determin
blood
pressur
measur
thorac
radiographi
echocardiographi
base
diagnosi
cat
alloc
group
name
symptomat
cardiomyopathi
sign
congest
heart
failur
group
cmsx
asymptomat
cardiomyopathi
group
cmasx
respiratori
diseas
group
respd
system
diseas
without
system
hypertens
group
sysd
healthi
control
group
healthi
plasma
sampl
process
untreat
follow
enrich
lowabund
protein
submit
mass
spectrometri
protein
profil
compar
statist
softwar
put
biomark
evalu
western
immunoblot
experi
eightynin
cat
includ
sysd
healthi
cmsx
cat
hypertroph
cardiomyopathi
restrict
cardiomyopathi
lung
edema
identifi
pleural
effus
aortic
thromboembol
cmasx
cat
hypertroph
cardiomyopathi
mass
spectrometri
sever
differenti
protein
identifi
among
group
put
biomark
test
western
immunoblot
protein
protein
differenti
detect
cmsx
compar
other
particular
protein
identifi
cat
cmsx
plasma
sampl
cat
cmasx
respd
sysd
healthi
visibl
band
respect
p
protein
detect
plasma
cat
cmsx
cmasx
sysd
band
detect
respd
healthi
p
data
suggest
novel
put
biomark
differenti
cat
symptomat
cardiomyopathi
studi
higher
number
cardiomyopath
cat
differ
symptomat
statu
mandatori
optim
test
evalu
sensit
specif
candid
biomark
disclosur
report
grant
sardegna
ricerch
incent
polari
research
blood
pressur
measur
high
definit
oscillometri
differ
clinic
set
healthi
cat
present
set
sequenc
clinic
set
random
record
made
set
combin
effect
set
sequenc
associ
lower
systol
sbp
mean
arteri
map
diastol
bp
dbp
bp
measur
owner
cat
carrier
last
sequenc
p
heart
rate
higher
bp
measur
cat
examin
tabl
first
sequenc
p
measur
made
cat
examin
tabl
higher
coeffici
variat
cv
found
sbp
map
dbp
hr
p
conclus
measur
bp
cat
carrier
gave
lower
bp
hr
cv
compar
measur
examin
tabl
sequenc
affect
bp
lower
valu
record
made
last
owner
time
might
influenc
result
disclosur
report
pleural
effus
protect
arteri
thromboembol
felin
congest
heart
failur
f
busato
zoia
drigo
san
marco
veterinari
clinic
veggiano
itali
univers
padova
padova
itali
aortic
thromboembol
ate
frequentlyseen
cardiac
complic
cat
left
atrial
la
enlarg
consid
risk
factor
dog
activ
coagul
follow
fibrinolysi
occur
type
pleural
effus
dog
pleural
effus
type
ascit
secondari
congest
heart
failur
chf
show
enhanc
system
fibrinolysi
may
decreas
clot
format
therefor
aim
studi
determin
whether
cardiopath
cat
pleural
effus
less
like
develop
aortic
thromboembol
ate
cat
without
pleural
effus
crosssect
studi
retrospect
evalu
clientown
cat
heart
diseas
present
cat
includ
underw
full
echocardiographi
evalu
thorac
radiograph
cat
divid
group
without
chf
group
cardiogen
pulmonari
edema
group
pleural
effus
group
frequenc
ate
among
group
compar
chisquar
test
la
diamet
laaorta
ratio
la
ao
also
compar
cat
without
ate
ttest
also
among
group
anova
follow
tamhan
posthoc
analysi
studi
includ
cat
group
group
group
sixtyon
cat
time
present
ate
overal
preval
la
cat
ate
ae
mm
significantli
p
bigger
cat
without
ate
ae
la
ao
cat
ate
ae
significantli
p
higher
cat
without
ate
ae
frequenc
ate
statist
p
differ
among
group
group
group
group
la
significantli
f
p
increas
cat
group
ae
mm
group
ae
mm
compar
group
ae
mm
signific
differ
present
group
la
ao
significantli
f
p
increas
cat
group
ae
group
ae
compar
group
ae
signific
differ
present
group
expect
cat
chf
edema
pleural
effus
bigger
la
compar
cat
without
chf
moreov
also
cat
ate
present
larger
la
atrium
compar
cat
without
ate
nevertheless
pleural
effus
present
frequenc
ate
remain
low
despit
enlarg
la
disclosur
report
iatrogen
heart
murmur
new
caus
systol
murmur
cat
l
ferasin
e
kilkenni
h
ferasin
specialist
veterinari
cardiolog
consult
ltd
alton
unit
kingdom
lumbri
park
veterinari
specialist
alton
unit
kingdom
heart
murmur
commonli
detect
appar
healthi
cat
doppler
echocardiograph
evalu
ultim
requir
identifi
caus
blood
flow
turbul
respons
clinic
find
howev
even
doppler
echocardiographi
occasion
fail
demonstr
origin
murmur
cat
nevertheless
year
observ
appli
gentl
pressur
right
side
chest
wall
cat
ultrasound
probe
provoc
test
induc
temporari
narrow
right
ventricular
infundibulum
dynam
right
ventricular
outflow
obstruct
subsequ
caus
blood
flow
turbul
also
observ
similar
phenomenon
reproduc
gentli
press
stethoscop
head
right
wall
chest
induc
audibl
murmur
auscult
aim
studi
evalu
effect
increas
pressur
ultrasound
probe
chest
wall
cat
undergo
echocardiograph
examin
increas
right
ventricular
outflow
veloc
evok
blood
flow
turbul
anatom
area
clinic
record
appar
healthi
cat
dynam
rightsid
systol
heart
murmur
underw
echocardiographi
retrospect
review
cat
blood
flow
turbul
infundibular
tract
induc
provoc
test
imag
acquisit
right
parastern
short
axi
view
level
heart
base
function
structur
abnorm
echocardiograph
examin
includ
studi
n
median
age
year
mean
bodi
weight
ae
kg
median
murmur
grade
cat
includ
studi
present
laminar
blood
flow
colour
doppler
assess
right
infundibular
tract
howev
turbul
could
subsequ
visualis
follow
provoc
test
similarli
provoc
test
caus
increas
peak
systol
veloc
latepeak
scimitarlik
profil
characterist
dynam
midsystol
obstruct
outflow
peak
systol
veloc
normal
distribut
pretest
ae
ms
posttest
ae
ms
differ
ae
ms
statist
signific
pair
sampl
test
p
result
studi
confirm
murmur
cat
iatrogen
origin
caus
pressur
ultrasound
probe
chest
wall
postul
similar
phenomenon
evok
press
stethoscop
head
chest
wall
disclosur
report
echocardiograph
cvc
pocu
find
dog
dmvd
present
januari
januari
retrospect
review
acvim
stage
recent
administr
diuret
record
dog
signific
right
side
heart
diseas
pericardi
effus
exclud
pocu
cvc
cineloop
obtain
echocardiograph
evalu
use
longitudin
subxyphoid
view
dog
place
right
later
recumb
cvc
maxim
minim
diamet
measur
index
aortic
diamet
cvc
dmax
ao
cvc
dmin
ao
cvc
ci
calcul
one
singl
observ
unawar
diseas
sever
acvim
stage
perform
measur
subject
assess
cvc
fat
flat
normal
cvc
paramet
compar
acvim
stage
use
fisher
exact
test
kruskalw
ancova
use
assess
effect
acvim
stage
diuret
treatment
cvc
paramet
data
express
median
rang
dog
dmvd
includ
acvim
stage
c
recent
receiv
diuret
cvc
paramet
associ
acvim
stage
cvc
dmin
ao
significantli
larger
wherea
cvc
ci
significantli
reduc
dog
acvim
stage
c
compar
acvim
stage
pvalu
cvc
dmax
ao
differ
dog
acvim
stage
compar
stage
pvalu
signific
associ
subject
fat
cvc
advanc
dmvd
stage
acvim
c
pvalu
ancova
reveal
cvc
paramet
influenc
acvim
stage
diuret
administr
cvc
pocu
paramet
cvc
dmin
ao
cvc
ci
correl
diseas
sever
patient
dmvd
could
use
identifi
dog
need
hospit
increas
risk
decompens
disclosur
report
echocardiograph
determin
left
ventricular
volum
indic
obtain
two
view
dog
show
good
agreement
cardiologist
obtain
estim
differ
view
index
bodi
size
normal
comparison
individu
classifi
rang
diseas
sever
howev
todat
studi
compar
estim
obtain
differ
view
perform
one
group
investig
examin
specif
breed
therefor
examin
agreement
two
method
obtain
lv
volum
estim
dog
rang
diseas
diseas
state
also
gener
refer
interv
lv
volum
indic
five
investig
contribut
echocardiograph
data
dog
one
dog
exclud
analys
lv
dog
measur
triplic
use
simpson
singl
plane
method
either
right
parastern
long
axi
view
left
apic
view
systol
diastol
measur
averag
two
method
compar
use
limitsofagr
analys
volum
index
bodyweight
bodi
surfac
area
ref
studi
suggest
littl
differ
exist
estim
lv
volum
two
echocardiograph
view
estim
interchang
dog
rang
cardiac
diseas
diseas
sever
addit
data
provid
refer
limit
volum
index
weight
mathemat
physiolog
appropri
index
surfac
area
disclosur
report
causal
mechan
predispos
factor
natur
cours
supraventricular
tachycardia
svt
atrial
fibril
af
well
describ
peopl
lesser
extent
dog
svt
welldescrib
cat
report
af
limit
aim
studi
describ
signal
clinic
find
outcom
cat
svt
versu
cat
af
fortyfour
clientown
cat
includ
retrospect
studi
cat
svt
af
cat
examin
novemb
april
inclus
criteria
avail
mm
ecg
concurr
echocardiograph
studi
continu
variabl
compar
group
use
twosampl
ttest
mannwhitney
u
test
categor
variabl
summaris
use
chisquar
fisher
exact
test
kaplanmei
surviv
curv
gener
assess
impact
rhythm
diagnosi
presenc
ventricular
arrhythmia
left
atrial
diamet
heart
rate
congest
heart
failur
statu
cardiac
death
differ
surviv
group
compar
use
mantelcox
logrank
comparison
kaplanmei
surviv
curv
overal
common
present
respiratori
distress
cat
follow
lethargi
n
collaps
n
cat
af
slower
median
heart
rate
rang
bpm
compar
cat
svt
rang
bpm
p
cat
af
cardiac
chamber
remodel
wherea
cat
svt
structur
abnorm
left
atrial
diamet
significantli
larger
af
cat
mm
compar
mm
svt
cat
p
median
surviv
day
cat
af
compar
day
cat
svt
p
cat
present
sign
chf
wors
overal
surviv
p
rhythm
diagnosi
ventricular
arrhythmia
left
atrial
size
heart
rate
impact
surviv
statu
cat
af
svt
advanc
cardiac
remodel
median
left
atrial
size
greater
cat
af
svt
cat
svt
evid
cardiac
remodel
suggest
svt
cat
alway
consequ
atrial
enlarg
disclosur
report
electrocardiograph
pattern
ventricular
preexcit
dog
perego
r
pariaut
ns
mois
lombardo
mateo
panero
r
santilli
clinica
veterinaria
malpensa
samar
itali
depart
clinic
scienc
cornel
univers
ithaca
unit
state
america
ventricular
preexcit
vpe
describ
activ
portion
ventricular
myocardium
along
accessori
pathway
ap
occur
sooner
electr
impuls
conduct
along
normal
hispurkinj
system
ventricular
preexcit
document
dog
ap
aim
studi
explor
electrocardiograph
ecg
featur
vpe
identifi
ecg
criteria
determin
ap
locat
speci
record
privatelyown
dog
document
ap
retrospect
review
dog
ecg
detail
electrophysiolog
map
analyz
dog
classifi
three
group
accord
posit
ap
antero
midsept
right
posterior
right
later
right
posterosept
ecg
measur
differ
beat
perform
follow
paramet
pdelta
wave
interv
segment
durat
durat
morpholog
axi
ms
dq
dr
dr
ds
durat
morpholog
axi
descript
statist
perform
quantit
variabl
normal
distribut
valu
assess
shapirowilk
wtest
mean
median
quartil
standard
deviat
calcul
kruskalw
oneway
analysisofvariancebyrank
test
use
evalu
differ
posit
delta
wave
measur
lead
dog
vpe
manifest
intermitt
common
dqr
complex
morpholog
lead
ii
multipl
peak
qr
rr
rr
found
dog
right
posterior
right
later
ap
taller
dr
ds
respect
lead
p
ii
p
antero
midsept
ap
taller
dr
lead
iii
p
taller
ds
lead
v
p
result
studi
suggest
local
ap
use
surfac
ecg
criteria
possibl
addit
studi
need
test
use
dr
ds
dr
amplitud
guid
subsequ
radiofrequ
cathet
ablat
procedur
disclosur
report
use
cut
balloon
techniqu
treatment
subvalvular
pulmonari
stenosi
perego
lombardo
r
santilli
clinica
veterinaria
malpensa
samar
itali
subvalvular
pulmon
stenosi
sp
classifi
two
subtyp
infundibular
isp
subinfundibular
sisp
isp
primari
due
fix
obstruct
right
ventricular
rv
outflow
tract
secondari
right
ventricular
concentr
hypertrophi
caus
pulmon
stenosi
furthermor
sisp
also
defin
doubl
chamber
right
ventricl
dcrv
highpressur
superior
chamber
lowpressur
inferior
chamber
aim
studi
describ
treatment
isp
dcrv
dog
cat
cut
balloon
cb
techniqu
retrospect
studi
includ
patient
dog
cat
diagnos
isp
dcrv
case
underw
dilat
mm
diamet
length
cm
cb
follow
dilat
high
pressureballoon
patient
maximum
outflow
veloc
vmax
maximum
pressur
gradient
pgmax
tricuspid
regurgit
maximum
veloc
trvmax
right
atrial
ra
area
rv
systol
function
estim
measur
procedur
hr
month
procedur
right
atrial
ventricular
pressur
procedur
mean
diamet
stenosi
mm
dog
revers
right
atrioventricular
remodel
procedur
could
complet
dog
cat
probabl
small
bodi
size
andor
sever
ra
remodel
imped
us
advac
stiff
cb
softer
guid
preliminari
result
indic
possibl
applic
cb
dilat
treatment
isip
dcrv
disclosur
report
imag
clinic
featur
canin
right
atrial
appendag
aneurysm
singlecentr
crosssect
studi
dog
disclosur
report
predictor
reoccurr
congest
sign
dog
acvimstag
c
myxomat
mitral
valv
diseas
mmvd
dietari
lemon
balm
fish
peptid
enhanc
efficaci
ltryptophan
reduc
urinari
cortisol
stress
marker
cat
ic
jeusett
g
tami
c
torr
fernandez
tvarijonaviciut
j
ceron
salasmani
j
affin
petcar
sa
lhospitalet
de
llobregat
spain
corbera
de
llobregat
spain
interlabumu
univers
murcia
murcia
spain
psychiatri
forens
medicin
autonom
univers
barcelona
bellaterra
spain
object
studi
test
efficaci
two
diet
supplement
either
ltryptophan
diet
u
ltryptophan
plu
lemon
balm
melissa
officinali
l
fish
peptid
diet
us
reduct
urinari
cortisol
stress
marker
cat
ten
coloni
cat
firstli
receiv
control
adult
cat
diet
diet
c
five
week
randomli
assign
two
group
test
diet
u
us
five
week
cross
design
two
week
washout
period
twentyfourhour
natur
void
urin
obtain
end
period
routin
condit
follow
applic
mildstressor
openfield
test
overnight
fast
blood
sampl
urinari
cortisol
serum
serotonin
concentr
measur
behaviour
test
perform
openfield
test
reaction
presenc
contact
unfamiliar
person
mix
model
repeat
measur
spss
use
analys
data
compar
control
diet
supplement
diet
effect
reduc
urinari
cortisol
almost
test
situat
p
compar
diet
u
diet
us
result
lower
urinari
cortisol
concentr
averag
overnight
fast
p
differ
routin
margin
p
diet
us
result
also
margin
increas
serum
serotonin
p
compar
two
diet
c
u
diet
u
result
higher
averag
score
unfamiliar
person
test
diet
us
mainli
increas
toler
presenc
unfamiliar
person
compar
c
conclus
supplement
diet
effect
reduc
stress
marker
cat
enhanc
effect
lemon
balm
fish
peptid
ltryptophan
supplement
compar
ltryptophan
alon
supplement
diet
may
also
help
improv
interact
unfamiliar
person
new
trial
conduct
cat
suffer
stressrel
disord
confirm
clinic
benefit
dietari
supplement
disclosur
report
use
probiot
believ
health
promot
effect
stabilis
gut
microbiom
increas
shortchain
fatti
acid
scfa
product
lower
circul
cholesterol
level
howev
probiot
supplement
may
also
affect
vitamin
b
metabol
indic
circul
cobalamin
may
deplet
level
refer
level
dog
yet
probiot
effect
highli
strain
specif
aim
studi
investig
effect
commerci
complet
diet
contain
enterococcu
faecium
ncimb
faecal
qualiti
faecal
scfa
acet
butyr
propion
concentr
well
serum
folic
acid
cobalamin
cholesterol
triglycerid
ten
healthi
client
own
dog
includ
random
prospect
doubleblind
crossov
studi
dog
went
day
acclimatis
period
gradual
transit
regular
diet
control
diet
acclimatis
period
follow
two
studi
period
day
studi
period
dog
randomli
assign
start
fed
control
diet
cd
probiot
diet
pd
control
diet
supplement
e
faecium
ncimb
cfukg
blood
sampl
rectal
faecal
sampl
collect
inclus
day
end
feed
period
day
faecal
qualiti
score
daili
owner
result
present
mean
ae
sd
differ
p
consid
signific
signific
reduct
serum
cholesterol
ae
vs
pd
ae
mmoll
increas
faecal
content
butyr
found
pd
rel
pd
cd
serum
cobalamin
significantli
reduc
ae
vs
cd
ae
pd
ae
ngl
within
refer
interv
ngl
faecal
concentr
acet
significantli
increas
compar
chang
found
serum
concentr
triglycerid
folic
acid
faecal
concentr
propion
faecal
qualiti
base
studi
e
faecium
incorpor
commerci
diet
potenti
health
promot
effect
dog
reduc
serum
concentr
cholesterol
increas
faecal
concentr
butyr
circul
cobalamin
decreas
follow
intervent
irrespect
whether
e
faecium
ncimb
includ
could
indic
dietari
factor
may
significantli
impact
cobalamin
level
disclosur
report
studi
fond
studi
diet
provid
bacterfield
gmbh
hamburg
germani
employ
one
author
theres
g
hosbjerg
relationship
sdma
creatinin
cat
subnorm
total
hyperthyroid
treatment
r
mack
szlosek
c
clement
coyn
idexx
westbrook
unit
state
america
iatrogen
hypothyroid
cat
associ
reduc
glomerular
filtrat
rate
increas
occurr
azotemia
shorten
long
term
surviv
previou
studi
support
conclus
limit
small
sampl
size
symmetr
dimethylarginin
sdma
shown
earlier
sensit
reliabl
renal
biomark
decreas
glomerular
filtrat
rate
creatinin
found
influenc
fluctuat
lean
muscl
mass
purpos
studi
util
big
data
character
relationship
sdma
creatinin
cr
subnorm
total
dog
includ
acth
stimul
test
perform
post
acth
cortisol
concentr
mmoll
result
serum
plasma
sodium
potassium
concentr
time
initi
present
also
requir
inclus
dog
exclud
receiv
trilostan
medic
known
expect
interfer
adren
function
test
dog
diagnos
atyp
hypoadrenocortic
na
k
ratio
time
present
fortyseven
dog
newli
diagnos
hypoadrenocortic
identifi
includ
case
includ
case
diagnos
atyp
hypoadrenocortic
case
diagnos
referr
practic
diagnos
atyp
hypoadrenocortic
case
diagnos
first
opinion
practic
diagnos
atyp
hypoadrenocortic
overal
percentag
case
diagnos
atyp
hypoadrenocortic
may
higher
previou
estim
percentag
newli
diagnos
case
hypoadrenocortic
referr
practic
atyp
diseas
appear
higher
percentag
atyp
case
diagnos
first
opinion
practic
absenc
electrolyt
abnorm
classic
associ
typic
case
hypoadrenocortic
particularli
na
k
ratio
index
suspicion
diseas
may
low
find
higher
percentag
patient
atyp
diseas
consid
popul
diagnos
referr
practic
rais
concern
case
may
go
undiagnos
first
opinion
practic
disclosur
report
one
author
employ
commerci
laboratori
allow
databas
search
order
identifi
case
commerci
laboratori
perform
measur
serum
cortisol
concentr
includ
case
predict
role
transtubular
potassium
gradient
ttkg
addison
syndrom
hyperkaliem
dog
crosssect
studi
petini
zoia
caldin
san
marco
veterinari
clinic
veggiano
itali
addison
diseas
character
defici
cortisol
aldosteron
lack
aldosteron
result
renal
sodium
wast
potassium
retent
lead
hyponatriemia
hyperkalemia
bodi
volum
deplet
effect
aldosteron
serum
potassium
excret
evalu
compar
urin
serum
potassium
concentr
correct
urin
potassium
concentr
reabsorpt
solutefre
water
kidney
estim
call
ttkg
thu
aim
studi
evalu
abil
ttkg
identif
dog
affect
addison
diseas
among
popul
hyperkalem
dog
crosssect
studi
retrospect
search
data
base
dog
serum
potassium
concentr
mmoll
refer
interv
present
decemb
februari
inclus
criteria
urin
ttkg
calcul
hospit
admiss
routin
done
laboratori
final
diagnosi
avail
base
final
diagnosi
dog
divid
newli
diagnos
naturallyoccur
addison
diseas
diagnos
acth
stimul
test
diseas
dog
exclud
studi
histori
corticosteroid
administr
andor
drug
affect
potassium
excret
eg
aceinhibitor
aldosteronereceptor
blocker
diuret
fludrocortison
iv
fluid
moreov
hyperkalem
dog
also
exclud
urin
osmol
mosmkg
urin
sodium
mmoll
preclud
valu
correct
ttkg
calcul
ttkg
compar
ttest
dog
addison
diseas
sick
hyperkalem
control
dog
final
roc
curv
analysi
use
identifi
best
cutoff
valu
youden
index
discrimin
dog
addison
diseas
sick
hyperkalem
control
dog
without
addison
diseas
analys
signific
set
eighti
hyperkalem
dog
includ
studi
addison
diseas
without
ttkg
dog
addison
diseas
significantli
p
lower
ae
ttkg
control
dog
ae
youden
index
identifi
roc
curv
analysi
ttkg
sensit
specif
auc
ci
p
present
studi
show
ttkg
hyperkalem
patient
use
diagnost
tool
initi
discrimin
dog
addison
diseas
hyperkalem
dog
without
addison
diseas
subset
hyperkalem
dog
ttkg
may
help
patient
manag
confirmatori
diagnosi
acth
stimul
test
avail
disclosur
report
comparison
differ
monitor
method
dog
hypercortisol
treat
trilostan
last
year
mani
differ
studi
investig
possibl
altern
method
conflict
result
singl
studi
compar
method
canin
popul
lack
aim
studi
evalu
previou
investig
monitor
method
better
correl
standard
publish
clinic
score
cs
obtain
owner
questionnair
could
repres
best
method
monitor
trilostan
therapi
conduct
prospect
multicentr
studi
dog
hc
treatment
trilostan
twice
daili
least
two
week
blood
sampl
categor
unwel
sick
overtr
dog
well
control
dose
dose
increas
requir
dog
respect
base
cs
result
cs
compar
serum
cortisol
concentr
pretrilostan
hposttrilostan
hposttrilostan
hpostacth
administr
plasma
acth
concentr
pretrilostan
administr
plasma
acthcortisol
ratio
serum
haptoglobin
concentr
hp
chemistri
variabl
alp
alt
ggt
urinari
cortisolcreatinin
ratio
urin
specif
graviti
urin
evalu
day
morn
day
plasma
acth
serum
urinari
cortisol
measur
chemilumesc
assay
immulit
reevalu
dog
includ
unwel
dog
exclud
analysi
haptoglobin
paramet
better
correl
cs
r
follow
alt
r
r
uccr
averag
urinari
sampl
r
roc
curv
analysi
identifi
concentr
hp
mgdl
concentr
dl
use
valu
discrimin
well
control
dog
specif
respect
hp
seem
best
paramet
monitor
trilostan
therapi
howev
hp
like
limit
capabl
identifi
overtr
dog
concurr
evalu
cortisol
pretrilostan
may
use
actual
lack
valid
studi
measur
felin
plasmat
adrenocorticotrop
hormon
acth
aim
studi
valid
commerci
avail
chemiluminesc
assay
measur
felin
acth
concentr
determin
normal
refer
interv
ri
assess
plasma
endogen
acth
concentr
cat
primari
hypoadrenocortic
ph
hc
cat
diseas
od
thirtythre
healthi
cat
cat
od
cat
diabet
mellitu
hyperthyroid
chronic
kidney
diseas
gastrointestin
diseas
acut
kidney
injuri
hypovolem
shock
septic
shock
hyperaldosteron
includ
prospect
studi
data
cat
ph
hc
pituitarydepend
hypercortisol
pdh
adrenaldepend
hypercortisol
adh
retriev
medic
record
three
referr
center
univers
bologna
zurich
utrecht
use
method
measur
immulit
left
sampl
collect
diagnost
purpos
use
intraassay
coeffici
varianc
cv
rang
interassay
cv
sampl
high
low
concentr
acth
respect
dilut
studi
perform
two
sampl
high
concentr
acth
use
diluent
provid
manufactur
show
excel
accuraci
r
ri
plasma
endogen
acth
healthi
cat
establish
use
robust
method
pgml
median
pgml
plasma
acth
concentr
rang
pgml
pgml
pgml
healthi
od
pdh
cat
respect
cat
adh
show
acth
valu
pgml
detect
limit
assay
cat
ph
concentr
acth
pgml
acth
concentr
show
signific
differ
healthi
od
group
cat
pdh
ph
significantli
higher
acth
valu
group
pdh
cat
result
rang
healthi
od
cat
immulit
chemiluminesc
assay
valid
techniqu
measur
acth
felin
plasma
ri
quit
wide
due
low
overlap
healthi
od
cat
ph
hc
measur
endogen
acth
seem
use
includ
diagnost
workup
ph
hc
suspect
disclosur
report
exclud
breed
least
ten
case
number
control
equal
greater
number
case
genotyp
three
loci
combin
identifi
dla
class
ii
haplotyp
affect
risk
dm
across
breed
individu
breed
togeth
p
use
fisher
exact
test
odd
ratio
confid
interv
entir
five
breed
identifi
one
dla
haplotyp
significantli
differ
dm
case
control
breed
bichon
frise
one
risk
haplotyp
labrador
retriev
one
risk
haplotyp
cavali
king
charl
spaniel
one
risk
haplotyp
cocker
spaniel
one
risk
haplotyp
one
protect
haplotyp
border
terrier
one
protect
haplotyp
combin
analysi
sampl
identifi
four
dmassoci
haplotyp
one
risk
three
protect
includ
one
protect
dladq
haplotyp
identifi
previou
studi
new
dla
associ
provid
evid
role
adapt
immun
system
canin
dm
highlight
potenti
differ
aetiolog
breed
disclosur
report
comparison
nine
canin
serum
thyroxin
measur
method
impact
crossreact
autoantibodi
l
copley
k
refsal
pa
graham
univers
nottingham
sutton
bonington
unit
kingdom
michigan
state
univers
east
lans
unit
state
america
serum
thyroxin
concentr
commonli
measur
assess
canin
thyroid
function
monitor
therapi
sever
refer
laboratori
inclin
immunoassay
commonli
use
pathogenesi
hypothyroid
may
result
endogen
crossreact
antibodi
sera
proport
case
may
interfer
analysi
aim
studi
compar
result
seven
totaland
two
freethyroxin
method
investig
invitro
effect
five
serum
pool
predict
equidist
concentr
cover
refer
interv
creat
use
sequenti
mix
initi
pool
low
high
concentr
surplu
canin
serum
analys
radioimmunoassay
ria
immulit
total
immulit
canin
total
thermomicrogen
total
idexx
catalyst
idexx
snapshot
tosoh
aia
two
free
method
antech
free
dialysi
immulit
veterinari
free
mix
pool
approach
allow
assess
intern
agreement
within
method
linear
well
comparison
method
determin
impact
pool
addit
analys
mix
posit
canin
surplu
serum
pool
total
method
agre
one
anoth
eg
highest
pool
vari
nmoll
two
method
ria
demonstr
good
linear
point
agre
predict
concentr
method
demonstr
less
good
intern
agreement
three
linear
result
match
predict
across
rang
two
nonlinear
linear
although
one
data
point
predict
invitro
effect
seen
method
includ
caus
fals
low
result
fals
high
ria
gener
midrang
nmoll
result
across
concentr
presenc
previou
genomewid
associ
studi
gwa
singl
nucleotid
polymorph
snp
found
associ
dm
lean
domest
shorthair
dsh
cat
polymorph
gene
associ
dm
overweight
dsh
cat
candid
gene
studi
suscept
gene
burmes
cat
breed
predispos
dm
identifi
initi
gwa
studi
attempt
overcom
limit
present
burmes
breed
due
inbreed
data
previou
gwa
dm
dsh
burmes
cat
combin
analysi
genotyp
perform
use
illumina
infinium
k
iselect
dna
array
qualiti
filter
diabet
nondiabet
control
dsh
cat
well
diabet
control
burmes
cat
includ
analysi
control
significantli
older
diabet
cat
p
bodi
condit
score
bc
known
cat
lean
obes
stratifi
analysi
use
cochranmantelhaenszel
cmh
test
within
strata
defin
multidimension
scale
md
logist
regress
md
coordin
use
bc
breed
covari
conduct
case
control
associ
test
pvalu
cmh
test
adjust
genom
inflat
felin
standard
genomewid
signific
set
p
max
permut
use
gener
correct
empir
pvalu
follow
logist
regress
signific
set
p
singl
signific
snp
p
raw
adjust
genom
inflat
identifi
stratifi
analysi
singl
signific
snp
p
genom
permut
identifi
logist
regress
snp
chromosom
associ
dm
previous
report
gwa
dm
lean
dsh
associ
snp
chromosom
breed
new
snp
locat
within
close
gene
respect
relat
enzym
involv
degrad
incretin
analysi
reveal
new
potenti
candid
gene
breed
highlight
use
altern
approach
gwa
analysi
implic
metabol
immun
function
suggest
investig
gene
pathogenesi
felin
dm
warrant
glycem
variabl
gv
refer
glycem
excurs
episod
hypoglycemia
hyperglycemia
throughout
day
differ
day
appar
causal
link
consid
indic
glycem
control
human
diabet
mellitu
dm
ad
glucagonlik
analogu
convent
therapi
result
signific
reduct
gv
cat
knowledg
gv
scarc
influenc
differ
treatment
modal
studi
object
studi
evalu
gv
cat
receiv
analogu
exenatid
extendedreleas
eer
addit
insulin
therapi
blood
glucos
curv
recent
prospect
placebocontrol
clinic
trial
evalu
gv
week
start
therapi
cat
treat
eer
salin
administ
subcutan
weekli
group
receiv
insulin
glargin
twice
daili
lowcarbohydr
diet
assess
gv
mean
glucos
concentr
standard
deviat
sd
calcul
compar
treatment
group
eer
group
cat
achiev
achiev
remiss
depend
variabl
mean
sd
analyz
use
repeat
mix
linear
model
includ
fix
effect
treatment
week
interact
repeat
anim
effect
data
report
leastsquar
mean
se
thirti
cat
newli
diagnos
dm
includ
receiv
eer
receiv
placebo
six
cat
achiev
remiss
eer
placebo
group
respect
p
mean
whole
studi
period
lower
eer
group
compar
placebo
ae
vs
ae
mmoll
p
consid
singl
time
point
mean
lower
week
ae
vs
ae
mmoll
p
gvsd
whole
studi
period
lower
eer
group
compar
placebo
ae
vs
ae
mmoll
p
eer
group
cat
achiev
remiss
lower
mean
ae
vs
ae
mmoll
p
lower
gvsd
ae
vs
ae
mmoll
p
achiev
remiss
conclus
analogu
eer
lead
reduct
gv
better
glycem
control
cat
dm
furthermor
lower
gv
associ
higher
remiss
rate
cat
treat
eer
result
studi
therefor
suggest
ad
analogu
convent
therapi
may
advantag
treatment
cat
dm
disclosur
report
twenti
dd
insulin
treatment
prospect
enrol
studi
fgm
place
neck
day
duringth
th
day
blood
glucos
curv
bgc
perform
simultan
hospit
fgm
valid
portabl
blood
glucos
meter
pbgm
optiumxce
abbott
th
day
owner
perform
bgc
use
fgm
home
bgc
perform
pbgm
fgm
hospit
perform
fgm
home
hospit
compar
bgc
evalu
optim
consid
valu
mgdl
glucos
nadir
mgdl
glucos
nadir
obtain
data
download
softwar
dd
fgm
scan
pbgm
compar
moreov
glucos
daytim
gdtn
nighttim
nadir
gntn
compar
evalu
bgc
perform
hospit
fgm
pbgm
led
decis
insulin
adjust
case
consid
percentag
valu
rang
mgdl
glucos
nadir
respect
evalu
bgc
perform
home
follow
day
hospit
fgm
led
decis
insulin
adjust
case
consid
percentag
valu
rang
mgdl
glucos
nadir
respect
glucos
nadir
identifi
case
dd
case
use
fgm
scan
pbgm
respect
median
gntn
significantli
higher
gdtn
hypoglycem
episod
obtain
dd
immedi
show
display
fgm
conclus
adjust
insulin
dose
base
bgc
obtain
fgm
pbgm
similar
fgm
detect
nadir
hypoglycem
episod
frequent
pbgm
allow
assess
glucos
variat
also
differ
consecut
day
therefor
fgm
potenti
valuabl
tool
monitor
canin
diabet
mellitu
disclosur
report
canin
diabet
mellitu
dm
preval
certain
breed
suggest
underli
genet
basi
although
environment
factor
may
also
involv
notabl
dog
breed
low
dm
risk
overrepres
studi
neoplast
transform
pancreat
betacel
insulinoma
suggest
betacel
surviv
may
import
contribut
factor
canin
dm
similar
gene
may
involv
canin
dm
insulinoma
previou
genet
work
canin
diabet
mellitu
dm
focus
candid
gene
genomewid
associ
studi
employ
casecontrol
design
within
individu
breed
howev
design
account
fact
within
high
risk
breed
fix
genet
risk
dm
may
exist
result
minim
genet
differ
case
control
aim
studi
develop
new
model
identif
genet
risk
variant
complex
diseas
order
identifi
new
canin
dm
gene
achiev
explor
genet
differ
dog
breed
high
risk
dm
samoy
odd
ratio
except
low
risk
dm
boxer
odd
ratio
part
canin
diabet
genet
partnership
initi
whole
genom
sequenc
wg
coverag
undertaken
diabet
samoy
boxer
insulinoma
use
illumina
hiseqx
technolog
six
samoy
boxer
without
dm
insulinoma
underw
wg
control
dna
extract
blood
sampl
surplu
requir
clinic
purpos
custom
bioinformat
pipelin
develop
annot
prioritis
variant
followup
base
genom
analysi
toolkit
variant
annot
accord
minor
allel
frequenc
breed
casecontrol
statu
predict
impact
gene
function
locat
near
region
plausibl
role
betacel
function
diabet
risk
samoy
breeduniqu
high
moder
impact
variant
identifi
present
one
samoy
found
exclus
diabet
group
boxer
breeduniqu
high
moder
impact
variant
identifi
present
one
boxer
found
exclus
insulinoma
group
replic
function
studi
progress
valid
candid
investig
underli
mechan
studi
demonstr
wg
offer
promis
rout
investig
complex
diseas
genet
risk
may
fix
high
low
level
within
breed
disclosur
report
author
member
canin
diabet
genet
partnership
support
dechra
veterinari
product
provid
financi
support
member
travel
cdgp
meet
three
time
year
act
industri
partner
phd
studentship
alic
denyer
cdgp
fund
petplan
charit
trust
fund
paid
whole
genom
sequenc
well
salari
author
attend
congress
bioinformatician
marsha
wallac
brian
catchpol
also
receiv
fund
phd
student
unrel
project
msd
anim
health
luci
davison
senior
author
present
fund
uk
medic
research
council
also
fund
bsava
petsav
work
unrel
abstract
also
alreadi
entitl
free
registr
meet
chair
ecvim
exam
committe
want
disclos
vicepresid
esv
involv
abstract
review
would
happi
provid
detail
request
author
cdgp
member
involv
wide
varieti
research
project
respect
institut
across
larg
number
field
numer
fund
sourc
none
fund
sourc
access
potenti
gain
data
present
cdgp
member
receiv
salari
consult
fee
role
cdgp
none
stand
make
direct
financi
gain
data
abstract
author
seen
inform
present
abstract
given
opportun
comment
interest
full
disclosur
pleas
note
preliminari
find
abstract
whole
genom
sequenc
canin
diabet
submit
canin
diabet
genet
partnership
accept
poster
present
canin
felin
genet
genom
meet
bern
howev
ecvim
abstract
submit
base
screen
variant
larger
data
set
use
data
addit
dog
breed
also
includ
bioinformat
improv
allow
better
quantif
annot
candid
genet
variant
evalu
glutar
acid
ester
dggr
lipas
assay
dog
natur
occur
hypercortisol
g
linari
f
dondi
segator
k
vasylyeva
f
fracassi
univers
bologna
bologna
itali
canin
pancreaticspecif
lipas
scpl
consid
sensit
specif
test
diagnosi
pancreat
dog
howev
rel
high
cost
long
turnaround
time
limit
everyday
clinic
use
access
serum
assay
avail
daili
usag
like
lipas
assay
total
lipas
tl
glutar
acid
methylresorufin
ester
dggr
lipas
assay
dggrl
recent
studi
compar
scpl
dggrl
obtain
high
agreement
reason
dggrl
actual
wide
use
recent
studi
observ
dog
hypercortisol
scpl
concentr
elev
result
fals
posit
result
pancreat
aim
present
studi
evalu
serum
dggrl
tl
activ
dog
affect
natur
occur
hypercortisol
dog
acut
pancreat
ap
healthi
dog
hd
use
control
left
sampl
use
diagnost
propos
store
c
select
retrospect
follow
stabil
period
recommend
analyz
dog
hypercortisol
ap
hd
respect
serum
ddgrl
tl
measur
use
autom
analyz
diagnosi
hypercortisol
perform
combin
typic
clinic
sign
posit
specif
endocrin
test
acth
stimul
test
andor
ldd
test
dog
hypercortisol
includ
absenc
clinic
ultrasonograph
sign
suggest
ap
diagnosi
ap
base
presenc
suggest
clinic
clinicopatholog
exclud
studi
variabl
ultrasonograph
find
data
express
median
rang
compar
use
nonparametr
statist
p
consid
signific
comparison
measur
free
thyroxin
concentr
chemiluminesc
analogu
immunoassay
equilibrium
dialysi
dog
nonthyroid
ill
subsequ
measur
subpopul
dog
select
rang
concentr
refer
interv
pmoll
pmoll
nmoll
total
respect
kruskal
walli
chisquar
test
use
statist
analysi
appropri
dog
nti
significantli
p
p
respect
lower
dog
sever
compar
mild
moder
nti
proport
dog
valu
refer
interv
significantli
p
respect
less
n
compar
n
total
proport
differ
significantli
p
total
among
dog
low
total
concentr
normal
dog
significantli
p
differ
among
dog
low
dog
normal
valu
blandaltman
differ
plot
reveal
underestim
overestim
free
concentr
measur
low
high
concentr
respect
consid
lack
agreement
observ
use
interchang
oppos
provid
diagnost
inform
gain
measur
total
dog
nti
base
result
recommend
differenti
nti
hypothyroid
dog
low
total
concentr
repres
popul
measur
free
concentr
commonli
recommend
disclosur
report
grow
patientderiv
tissu
cell
cultur
system
organoid
revolution
vitro
cancer
research
contrast
cell
line
organoid
grown
effici
conserv
import
featur
origin
tumor
tissu
architectur
cellular
heterogen
human
medicin
organoid
cultur
provid
uniqu
platform
person
cancer
therapi
studi
aim
cultur
character
organoid
deriv
follicularcel
thyroid
carcinoma
ftc
dog
tissu
sampl
follicular
type
n
compact
type
n
ftc
deriv
two
euthyroid
dog
frozen
dmsocontain
freez
medium
within
h
thyroidectomi
store
c
process
thaw
tissu
digest
collagenas
iv
dissoci
mechan
cell
subsequ
seed
cultrex
basement
membran
extract
cultur
organoid
advanc
dmem
supplement
nacetylcystein
supplement
egf
noggin
rockinhibitor
organoid
split
passag
everi
day
day
organoid
formalinfix
pellet
agaros
paraffinembed
process
hematoxylineosin
stain
immunohistochemistri
ihc
thyroid
transcript
thyroglobulin
tg
calcitonin
vimentin
perform
section
primari
tumor
organoid
organoid
ftc
cultur
effici
use
protocol
organoid
tumor
form
folliclelik
structur
compos
singl
epitheli
cell
layer
epitheli
cell
round
cuboid
variabl
distinct
cell
border
abund
eosinophil
foami
cytoplasm
anisocytosi
anisokaryosi
observ
either
organoid
line
present
ftc
compact
type
nuclear
express
organoid
line
confirm
thyroid
origin
organoid
deriv
compact
ftc
approxim
cell
posit
tg
show
tg
express
organoid
deriv
follicular
ftc
tg
express
cell
show
tg
express
organoid
vimentin
express
observ
organoid
line
cell
higher
primari
tumor
tumor
cell
posit
ihc
calcitonin
neg
organoid
line
organoid
deriv
natur
occur
canin
ftc
abl
conserv
histolog
immunohistochem
featur
primari
tumor
provid
interest
vitro
model
better
understand
pathogenesi
optim
treatment
thyroid
cancer
dog
cultur
protocol
like
requir
optim
disclosur
report
human
airway
narrow
due
asthma
copd
commonli
result
heterogen
deposit
aerosol
within
lung
consequ
uneven
distribut
inhal
medic
may
lead
variabl
inadequ
drug
level
certain
lung
area
current
known
effect
occur
dog
lower
airway
diseas
purpos
studi
evalu
effect
pharmacolog
induc
airway
narrow
pulmonari
deposit
nebul
radiopharmaceut
ie
amount
distribut
healthi
dog
prospect
studi
conduct
ten
healthi
beagl
radiopharmaceut
inhal
perform
occas
wash
period
least
week
experi
ie
without
immedi
induct
airway
narrow
narrow
airway
achiev
nebul
increas
concentr
carbachol
barometr
whole
bodi
plethysmographi
chamber
harbor
anim
airway
narrow
detect
system
buxco
finepoint
endpoint
increas
penh
baselin
occas
dog
inhal
dose
nebul
technetiumdiethylenetriaminepentaacet
acid
tcdtpa
aerochamb
medium
attach
custom
nosemuzzl
mask
minut
immedi
afterward
dog
scan
planar
scintigraphi
right
later
left
later
sternal
recumb
deposit
tcdtpa
head
region
lung
stomach
well
whole
bodi
distribut
record
quantifi
manual
isocontour
region
interest
roi
analysi
deposit
calcul
percentag
deliv
dose
roi
compar
distribut
deposit
within
lung
score
independ
blind
observ
degre
asymmetri
right
left
lung
patchi
individu
imag
well
possibl
differ
scan
imag
pair
ie
airway
narrow
random
order
analysi
individu
score
averag
mean
percentag
uptak
deliv
dose
lung
significantli
differ
airway
narrow
airway
narrow
averag
asymmetri
score
wherea
none
dog
patchi
distribut
score
airway
narrow
score
asymmetri
patchi
significantli
increas
respect
comparison
scan
imag
pair
airway
narrow
reveal
signific
differ
score
studi
indic
airway
narrow
dog
result
heterogen
aerosol
deposit
within
lung
although
overal
amount
drug
deposit
affect
disclosur
report
lectur
improv
hirt
lung
recogn
host
divers
low
biomass
bacteri
popul
identifi
lung
microbiota
lm
human
chronic
lung
diseas
cld
lm
alter
compar
healthi
patient
howev
whether
alter
caus
consequ
diseas
still
unclear
dog
lm
describ
mostli
healthi
experiment
beagl
howev
previou
work
team
impact
live
condit
andor
breed
suspect
healthi
beagl
west
highland
white
terrier
whwt
recent
studi
mice
hors
show
modif
lm
accord
live
condit
modif
lm
could
predispos
individu
certain
cld
aim
assess
breed
impact
influenc
live
condit
either
experiment
domest
lm
healthi
dog
result
show
bacteri
load
higher
eb
dog
p
amova
result
indic
differ
eb
group
compar
group
p
signific
differ
rel
abund
famili
genu
level
found
genu
hydrogenophilu
higher
eb
genera
brochothrix
limnohabitan
parabacteroid
curvibact
higher
whwt
compar
group
p
group
specif
genera
found
indic
discrimin
p
bacteri
rich
higher
whwt
eb
group
p
signific
differ
even
group
studi
demonstr
effect
live
condit
lm
breed
differ
also
shown
lm
modif
might
relat
breed
suscept
lower
respiratori
diseas
cipf
whwt
need
consid
futur
analys
role
lm
disturb
diseas
disclosur
report
studi
object
follow
perform
comprehens
analysi
canin
gastric
fluid
gf
proteom
compar
oropharyng
op
proteom
normal
vomitingregurgit
cough
dog
identifi
potenti
biomark
eer
aspir
compar
biolog
function
protein
site
twentythre
clientown
dog
prospect
enrol
canin
gf
sampl
n
op
swab
normal
n
vomitingregurgit
n
cough
n
dog
evalu
protein
digest
analyz
liquid
chromatographi
mass
spectrometri
lcm
data
search
ncbimu
databas
differenti
abund
da
protein
function
group
evalu
fisher
exact
test
anosim
respect
p
p
respect
consid
signific
correct
multipl
comparison
across
site
individu
protein
identifi
normal
spectral
abund
demonstr
pancreat
protein
increas
compar
pepsin
gf
signific
differ
da
group
note
p
gf
vs
normal
n
cough
vs
normal
n
refluxvomit
vs
normal
n
mark
betweendog
variat
observ
protein
da
function
proteom
dissimilar
group
p
conclus
proteom
composit
op
swab
vari
health
diseas
variabl
abund
may
impact
util
individu
gastric
protein
diseas
biomark
investig
biomark
panel
warrant
disclosur
report
result
suggest
serum
oh
significantli
decreas
dog
sna
well
potenti
immunolog
contributori
role
diseas
addit
result
support
pursuit
prospect
arm
studi
investig
potenti
mechan
decreas
serum
oh
dog
sna
role
treatment
outcom
disclosur
report
nineteen
dog
sepsi
n
critic
ill
without
sepsi
n
healthi
control
n
cohort
n
previous
measur
oh
concentr
randomli
select
plasma
mrna
extract
revers
transcrib
result
cdna
use
templat
realtim
pcr
use
specif
primer
canin
cathelicidin
signific
differ
cathelicidin
concentr
dog
sepsi
mean
sd
critic
ill
without
sepsi
healthi
control
p
oneway
anova
signific
correl
oh
cathelicidin
express
rs
p
spearman
correl
thirtythre
percent
critic
ill
dog
surviv
discharg
cathelicidin
concentr
predict
surviv
discharg
p
logist
regress
dog
sepsi
mean
sd
ngml
p
critic
ill
dog
without
sepsi
ngml
p
significantli
decreas
serum
oh
compar
healthi
control
ngml
oneway
anova
base
small
cohort
associ
plasma
cathelicidin
mrna
express
serum
oh
concentr
outcom
critic
ill
dog
neg
result
preliminari
investig
interpret
caution
number
dog
enrol
small
type
ii
error
might
contribut
factor
lack
associ
disclosur
report
hereditari
methemoglobinemia
dog
caus
cytochrom
reductas
defici
associ
variant
conclus
studi
reveal
clinic
metabol
molecular
genet
variat
seen
defici
dog
variant
appear
caus
sever
phenotyp
variant
dna
variant
identifi
readili
use
genet
screen
test
disclosur
report
differ
clinic
present
common
dog
breed
diagnos
primari
imha
canin
primari
immunemedi
haemolyt
anaemia
imha
common
haematolog
emerg
incid
differ
among
breed
unknown
whether
dog
predispos
breed
present
differ
degre
diseas
sever
differ
clinic
sign
differ
clinicopatholog
find
inform
could
use
clinic
guid
treatment
provid
prognost
advic
owner
primari
aim
retrospect
studi
identifi
differ
find
outcom
commonlyaffect
breed
hypothesis
spaniel
breed
would
find
associ
sever
diseas
poorer
outcom
compar
breed
electron
record
canin
patient
tertiari
referr
centr
search
year
period
imharel
keyword
recentlypublish
algorithm
use
assess
confid
diagnosi
imha
case
suffici
featur
imha
analys
exclud
investig
reveal
possibl
underli
diseas
incomplet
case
also
exclud
receiv
immunosuppress
blood
transfus
therapi
hour
prior
present
case
fulfil
inclus
criteria
frequent
five
breed
select
analysi
well
cross
breed
serv
control
group
data
collect
histor
clinic
sign
clinicopatholog
find
outcom
continu
variabl
oneway
anova
dunnett
multipl
comparison
test
perform
compar
breed
control
group
categor
variabl
ztest
use
compar
proport
record
identifi
contain
imha
keyword
fulfil
inclus
criteria
cocker
spaniel
n
springer
spaniel
n
labrador
n
jack
russel
terrier
n
shihtzu
n
select
final
analysi
alongsid
crossbre
n
control
group
labrador
significantli
older
compar
control
group
mean
v
year
p
surviv
cocker
spaniel
significantli
shorter
hospitalis
period
compar
control
group
mean
v
day
p
compar
cross
breed
greater
proport
jack
russel
terrier
surviv
discharg
v
p
spaniel
breed
appear
affect
sever
surviv
cocker
spaniel
requir
shorter
hospitalis
period
jack
russel
terrier
may
favour
outcom
find
could
confound
effect
treatment
requir
confirm
disclosur
report
diagnost
imag
find
referr
popul
dog
diagnos
immunemedi
haemolyt
anaemia
aim
studi
describ
chang
document
thorac
abdomin
imag
dog
confirm
imha
medic
record
referr
hospit
search
dog
diagnos
imha
underw
thorac
abdomin
imag
radiographi
ultrasound
comput
tomographi
ct
includ
complet
histori
clinic
routin
laboratori
examin
find
avail
well
total
client
own
dog
fulfil
inclus
criteria
includ
retrospect
studi
median
age
dog
year
rang
month
year
sexual
intact
femal
spay
femal
sexual
intact
neuter
male
respect
ct
thorax
abdomen
perform
radiograph
thorax
abdomin
ultrasound
dog
fine
needl
aspir
fna
collect
dog
popul
dog
imha
thorac
imag
abnorm
uncommon
hepatomegali
gallbladd
wall
thicken
periton
effus
common
abdomin
imag
find
bactibilia
confirm
one
third
collect
bile
sampl
hepatosplenomegali
abdomin
lymphadenopathi
uncommonli
associ
neoplasia
disclosur
report
determin
blood
group
dea
dea
dea
dal
kai
differ
canin
breed
contrast
reaction
dea
gener
less
agglutin
test
gel
column
test
discord
reaction
none
dog
kai
one
kai
daldog
found
cane
corso
dalmatian
doberman
maltes
mastiff
shih
tzu
pug
dog
variou
blood
group
pattern
observ
breed
first
extens
blood
type
survey
purebr
dog
europ
proport
posit
neg
blood
type
similar
us
newer
type
techniqu
seem
work
well
dea
card
improv
use
detect
prevent
specif
blood
type
incompat
clinic
disclosur
report
studi
part
ebelt
doctor
thesi
support
cat
shelter
includ
necropsi
perform
within
hour
death
liver
kidney
spleen
bile
obtain
necropsi
clinic
laboratori
result
retriev
avail
medic
archiv
aaamyloid
identifi
tissu
hematoxylineosin
congor
stain
confirm
immunoblot
shed
amyloid
fibril
investig
immunoblot
bile
sampl
descript
statist
nonparametr
test
use
deposit
aaamyloid
observ
liver
kidney
spleen
cat
die
shelter
particular
preval
cat
cat
cat
respect
cat
organ
involv
cat
organ
cat
organ
cat
organ
aaamyloidposit
sensit
specif
aaamyloid
identif
bile
respect
liver
involv
note
semiquantit
analysi
aaamyloid
bile
show
none
cat
without
organ
deposit
aaamyloid
score
score
identifi
cat
organ
involv
p
cat
aaamyloidposit
organ
medic
record
show
kidney
liver
involv
azotemia
proteinuria
hemoabdomen
due
spontan
hepat
ruptur
conclus
preval
system
aaamyloidosi
appear
elev
shelter
cat
shed
amyloid
fibril
occur
bile
cat
system
aaamyloidosi
like
shed
higher
amount
aaamyloid
whether
bile
excret
aaamyloid
indic
horizont
transmiss
relev
diseas
shelter
cat
remain
undefin
disclosur
report
treatment
nonlact
metabol
acidosi
hypovolem
normovolem
dog
chloridefre
isoosmolar
solut
elev
strong
ion
differ
versu
ringer
lactat
solut
r
rabozzi
oricco
c
odoardi
c
meneghini
p
iacobelli
accardi
p
franci
cvr
policlinico
veterinario
roma
sud
roma
itali
centro
veterinario
imperies
imperia
itali
degli
studi
di
torino
torino
itali
use
sodium
bicarbonatebas
solut
treat
metabol
acidosi
current
debat
alkal
effect
solut
elev
strong
ion
differ
sid
recent
describ
primari
aim
studi
evalu
safeti
efficaci
chloridefre
isoosmolar
solut
elev
sid
hypersid
compar
ringer
lactat
use
treatment
metabol
acidosi
hypersid
solut
prepar
ad
meql
sodium
meql
lactat
meql
potassium
meql
aspart
steril
water
inject
calcul
sid
meql
prospect
multicent
random
studi
evalu
efficaci
safeti
author
ethic
committe
hospit
dog
excess
base
meql
enrol
studi
baselin
lactat
level
greater
meql
patient
classifi
ultrasonograph
method
hypovolem
normovolem
random
random
number
gener
type
fluid
receiv
ringer
lactat
rl
group
hypersid
hsid
group
normovolem
hypovolem
dog
receiv
hour
infus
rate
ml
kg
hr
respect
blood
ga
analysi
fluid
infus
hour
compar
follow
paramet
beecf
ph
sodium
potassium
chlorid
lactat
sid
sid
normal
distribut
analysi
variabl
describ
evalu
use
nonparametr
statist
signific
level
set
forti
dog
includ
analysi
median
age
month
median
weight
kg
dog
classifi
hypovolem
rl
group
hsid
group
dog
classifi
normovolem
rl
group
hsid
group
basal
beecf
differ
treatment
group
p
normovolem
patient
median
increas
beecf
rl
hsid
group
meql
meql
p
respect
wherea
hypovolem
patient
respect
meql
meql
p
lactat
valu
greater
meql
document
patient
studi
hypersid
solut
prove
effect
superior
rl
solut
treatment
nonlact
metabol
acidosi
hospit
dog
sampl
subject
belong
hsid
group
side
effect
rais
lactatemia
report
infus
period
disclosur
report
serum
symmetr
dimethylarginin
dog
cat
acut
kidney
injuri
treat
intermitt
hemofiltr
c
amram
f
ferri
f
iavazzo
f
folatti
f
porporato
pesaresi
e
zini
istituto
veterinario
novara
granozzo
con
monticello
itali
degli
studi
di
padova
padova
pd
itali
serum
symmetr
dimethylarginin
sdma
concentr
shown
marker
renal
dysfunct
dog
cat
human
dialysi
lower
sdma
less
effici
urea
former
larger
distribut
volum
inform
concern
sdma
anim
undergo
extracorpor
renal
replac
therapi
yet
lack
aim
studi
describ
dynam
sdma
concentr
dog
cat
acut
kidney
injuri
treat
intermitt
hemofiltr
ihf
report
ihf
perform
octob
collect
medic
record
review
case
preand
postihf
biochem
profil
includ
ihf
perform
accord
standard
method
urea
creatinin
sdma
reductionratio
urr
crearr
sdmarr
calcul
ihf
dog
cat
separ
first
session
ihf
includ
group
second
session
group
b
third
session
group
c
urr
crearr
sdmarr
compar
within
group
nonparametr
test
overal
ihf
session
perform
dog
cat
specif
dog
cat
group
dog
cat
group
b
dog
cat
group
c
five
dog
cat
surviv
median
sdma
concentr
preihf
dog
rang
cat
rang
dog
median
valu
urr
crearr
sdmarr
rang
rang
rang
respect
cat
median
valu
rang
rang
rang
ihf
session
dog
sdmarr
either
neg
n
n
session
perform
dog
leptospirosi
poison
grape
ethylen
glycol
die
median
sdmarr
lower
urr
group
b
dog
p
p
differ
cat
group
dog
sdmarr
also
lower
crearr
p
differ
observ
speci
conclus
sdmarr
repres
accur
marker
assess
effici
ihf
dog
partial
inabl
ihf
clear
sdma
larg
distribut
volum
sdma
unknown
condit
affect
postihf
sdma
concentr
might
contribut
result
differ
sdmarr
may
reliabl
evalu
ihf
effici
cat
disclosur
report
nonobstruct
acut
chronic
kidney
diseas
cat
possibl
predict
surviv
aim
studi
determin
variabl
commonli
assess
azotem
cat
particular
context
could
accur
predictor
surviv
medic
record
year
azotem
cat
hospit
least
two
day
acut
sign
confirm
ckd
base
ultrasonograph
find
andor
previous
document
azotemia
retrospect
review
cat
potenti
toxic
neoplast
obstruct
caus
azotemia
includ
signal
clinic
sign
combin
clinic
sever
score
css
select
laboratori
diagnost
imag
result
outcom
regist
machin
learningbas
classif
regress
tree
method
use
assess
predictor
surviv
day
thirtytwo
cat
includ
studi
overal
median
surviv
time
day
rang
day
plasma
creatinin
concentr
day
hospit
crea
best
predictor
surviv
crea
less
mgl
best
predict
surviv
se
sp
day
crea
less
mgl
best
predict
surviv
day
crea
censor
analysi
lower
css
younger
age
also
predict
surviv
day
studi
confirm
crea
good
predictor
short
mediumterm
surviv
cat
ckd
present
urem
crisi
disclosur
report
speaker
veterinariu
effect
measur
locat
systol
blood
pressur
sbp
read
outpati
inpati
dog
acc
ferreira
mcbrearti
glasgow
univers
veterinari
school
glasgow
unit
kingdom
noninvas
blood
pressur
bp
measur
wide
use
diagnos
hypertens
yet
mani
factor
affect
measur
accuraci
acvim
guidelin
propos
standard
protocol
suggest
bp
perform
owner
present
studi
perform
evalu
dog
evalu
whether
sbp
vari
differ
hospit
locat
aim
determin
whether
sbp
differ
outpati
dog
measur
consult
room
owner
quiet
room
away
owner
determin
whether
sbp
measur
inpati
dog
differ
measur
kennel
quiet
room
away
dog
dog
bp
measur
use
high
definit
oscillometri
locat
consecut
outpati
consult
room
owner
quiet
room
inpati
kennel
quiet
room
measur
locat
order
random
blood
pressur
measur
method
standard
base
acvim
consensu
statement
instrument
manufactur
recommend
bp
cuff
place
tail
measur
taken
singl
veterinari
surgeon
use
cuff
bodi
posit
dog
locat
puls
waveform
visual
measur
valid
read
collect
averag
locat
descript
statist
perform
number
dog
differ
locat
calcul
addit
sbp
classifi
use
acvim
consensu
statement
hypertens
categori
outpati
sbp
mean
mmhg
sd
higher
quiet
room
dog
sbp
mmhg
differ
locat
higher
consult
room
fourteen
outpati
chang
hypertens
categori
locat
chang
higher
away
client
inpati
mean
differ
sbp
locat
mmhg
sd
howev
mmhg
differ
sbp
dog
higher
kennel
eleven
inpati
chang
hypertens
categori
locat
chang
higher
kennel
although
mean
differ
sbp
locat
small
inand
outpati
approxim
quarter
dog
group
differ
locat
approxim
half
chang
hypertens
categori
suggest
measur
chang
trend
individu
anim
locat
measur
kept
constant
disclosur
report
hdo
devic
bought
money
univers
glasgow
veterinari
fund
small
grant
scheme
immunecomplex
glomerulonephr
cat
retrospect
studi
base
clinicopatholog
data
morpholog
featur
endstag
ckd
focal
segment
glomerulosclerosi
global
mesangiosclerosi
glomerular
atrophi
renal
dysplasia
amyloidosi
eight
cat
nonicgn
grade
tubulointerstiti
damag
grade
grade
creatinin
upc
ratio
posit
associ
grade
p
p
cat
icgn
like
fiv
felv
infect
nonicgn
vs
p
higher
mean
upc
ratio
ae
vs
ae
p
mean
age
cat
icgn
lower
nonicgn
ae
vs
ae
year
p
conclus
mgn
mpgn
two
common
morpholog
diagnos
icgn
cat
clinic
laboratori
find
allow
differenti
cat
nonicgn
serum
creatinin
concentr
upc
ratio
associ
degre
tubulointerstiti
damag
confirm
previou
literatur
cat
retroviru
infect
higher
upc
ratio
younger
age
like
affect
icgn
nonicgn
disclosur
report
short
cours
immunesuppress
dose
prednisolon
associ
renal
hyperfiltr
chang
hydrat
electrolyt
statu
healthi
beagl
dog
object
assess
prednisolon
effect
renal
electrolyt
hydrat
statu
healthi
dog
urin
collect
total
bodi
water
content
tbwc
use
pharmacokinet
equat
glomerular
filtrat
rate
gfr
use
plasma
exogen
creatinin
clearanc
serum
symmetr
dimethylarginin
sdma
complet
plasma
biochemistri
urinalysi
includ
urin
proteintocreatinin
ratio
obtain
beagl
dog
blind
placebo
crossov
design
one
group
receiv
cours
immunesuppress
prednisolon
second
receiv
placebo
washout
period
group
switch
blood
urin
collect
treatment
period
washout
gener
linear
model
use
test
period
sequenc
treatment
dog
weight
effect
dunnett
test
use
evalu
effect
steroid
day
serv
control
correl
assess
use
pearson
coeffici
prednisolon
significantli
affect
bodi
weight
p
mean
differ
kg
gfr
p
mlkgmin
sdma
p
creatinin
p
urea
p
mmoll
chlorid
p
mmoll
bicarbon
p
mmoll
magnesium
p
mmoll
total
protein
p
gl
albumin
p
gl
tbwc
p
mlkg
urin
specif
graviti
p
void
urin
p
ml
sdma
r
creatinin
r
correl
significantli
p
gfr
variat
becam
nonsignific
washout
prednisolon
immunesuppress
dosag
rapidli
decreas
tbwc
bodi
weight
induc
relev
revers
renal
hyperfiltr
clinic
signific
variat
sever
analyt
disclosur
report
sdma
dosag
provid
idexx
laboratori
inc
westbrook
main
unit
state
america
character
vitro
suscept
clinic
felin
upec
isol
e
coli
probiot
potenti
therapeut
urinari
tract
infect
c
snell
j
gibson
c
zumpetta
j
byron
j
quimbi
harrison
justic
rudinski
ohio
state
univers
columbu
unit
state
america
nationwid
children
hospit
columbu
unit
state
america
rise
antibiot
resist
amongst
urinari
tract
infect
uti
cat
dog
underscor
need
nonantibiot
approach
uti
probiot
escherichia
coli
ecn
mani
benefit
includ
antimicrobi
activ
mani
human
pathogen
includ
uropathogen
e
coli
upec
aim
studi
phylogenet
character
upec
felin
uti
case
investig
vitro
suscept
isol
ecn
twentytwo
cat
posit
e
coli
urin
cultur
includ
studi
sampl
use
studi
obtain
surplu
urin
collect
routin
evalu
possibl
urinari
tract
infect
character
upec
isol
perform
clade
analysi
serotyp
virul
factor
analysi
multiplex
pcr
test
ecn
effect
upec
isol
test
vitro
use
microcidin
plate
analysi
upec
isol
felin
patient
similar
isol
human
patient
pathogen
suscept
genet
background
vitro
suscept
felin
upec
isol
frequent
suscept
ecn
probiot
growth
rate
characterist
andor
microcin
product
find
suggest
potenti
use
nissl
novel
therapeut
treat
felin
urinari
tract
infect
disclosur
report
grant
author
declar
conflict
interest
prognost
factor
dog
common
caus
proteinuria
f
baumgartn
f
boretti
b
gerber
vetsuiss
faculti
univers
zurich
switzerland
switzerland
littl
known
impact
increas
urin
protein
creatinin
ratio
upc
surviv
dog
differ
underli
diseas
associ
risk
factor
death
establish
therefor
aim
studi
assess
dog
sever
proteinuria
upc
least
diseas
measur
surviv
time
underli
diseas
possibl
prognost
factor
like
upc
time
diagnosi
creatinin
urin
specif
graviti
albumin
haematocrit
dog
sever
proteinuria
retrospect
analys
among
dog
diagnos
glomerulopathi
median
upc
rang
dog
cush
diseas
median
upc
rang
dog
leishmaniosi
median
upc
rang
dog
variou
diseas
median
upc
rang
dog
increas
upc
identifi
risk
factor
death
p
median
time
surviv
day
upc
time
surviv
differ
significantli
group
among
dog
glomerulopathi
identifi
signific
risk
factor
death
includ
increas
upc
p
increas
creatinin
p
low
haematocrit
p
low
urin
specif
graviti
p
dog
cush
diseas
urin
specif
graviti
signific
risk
factor
death
p
dog
leishmaniosi
increas
upc
creatinin
signific
risk
factor
death
p
p
increas
upc
risk
factor
death
dog
glomerulopathi
leishmaniosi
cush
diseas
explain
differ
pathogenesi
lead
proteinuria
disclosur
report
b
gerber
speaker
boehring
ingelheim
effect
dietari
sodium
urinari
calcium
calcium
oxal
rel
supersatur
caox
rss
dog
es
bijsman
v
biourg
royal
canin
aimargu
franc
calcium
oxal
caox
recurr
challeng
manag
dog
rel
supersatur
rss
measur
crystal
risk
lower
urinari
concentr
caox
precursor
decreas
caox
rss
urinari
dilut
primari
strategi
decreas
caox
rss
achiev
increas
sodium
content
pet
food
drive
water
intak
howev
human
caox
renolith
advis
decreas
sodium
intak
potenti
increas
renal
calcium
excret
could
increas
risk
diseas
aim
studi
compar
effect
two
dri
pet
food
differ
sodium
chlorid
content
urinari
volum
urinari
calcium
excret
concentr
caox
rss
crossov
studi
use
healthi
coloni
dog
base
diet
produc
sodium
content
fed
lsd
formula
supplement
nacl
achiev
highsodium
diet
hsd
sodium
fedcompar
commerci
avail
highsalt
urinari
diet
dog
fed
diet
day
follow
day
urin
collect
urinari
miner
measur
pool
sampl
use
ionic
chromatographi
caox
rss
calcul
use
supersat
soft
result
studi
support
increas
urinari
calcium
excret
increas
dietari
sodium
commerci
relev
level
increas
urin
volum
seen
high
salt
diet
decreas
urinari
calcium
oxal
concentr
could
explain
decreas
caox
rss
increas
dietari
sodium
therefor
decreas
risk
caox
urolithiasi
shortterm
feed
trial
studi
requir
assess
effect
increas
dietari
sodium
diet
fed
longer
period
time
disclosur
report
author
current
employe
royal
canin
mar
petcar
prolif
urethr
dog
longterm
follow
prognosi
thirteen
femal
dog
spay
met
inclus
criteria
median
age
month
median
bodi
weight
kg
main
clinic
sign
dysuria
stranguria
urethr
obstruct
detect
dog
dog
result
avail
urin
microbi
cultur
posit
dog
endoscop
evid
irregular
tissu
project
urethr
lumen
extend
along
entir
urethra
dog
es
urethr
strictur
note
case
es
dog
uo
es
histopatholog
lymphoplasmacyt
lymphoplasmacyt
neutrophil
granulomat
inflamm
detect
medic
treatment
start
dog
diagnosi
includ
antimicrobi
glucocorticoid
nonsteroid
antiinflammatori
immunesuppress
medic
median
surviv
time
month
shortterm
complic
includ
relaps
clinic
sign
recurr
uti
dog
requir
addit
intervent
surgic
treatment
restor
urethr
patenc
variabl
associ
surviv
age
hr
ci
p
bodi
weight
hr
ci
p
develop
uo
within
month
diagnosi
hr
ci
p
sever
es
time
diagnosi
affect
longterm
outcom
dog
pu
howev
small
size
older
dog
develop
uo
diagnosi
like
worst
prognosi
disclosur
report
detect
canin
felin
parvoviru
shed
asymptomat
shelter
cat
australia
use
minor
groov
binder
probe
realtim
pcr
assay
carrai
j
liu
ja
beatti
k
van
brussel
j
slapeta
n
decaro
vr
barr
univers
sydney
camperdown
australia
univers
sydney
camperdown
australia
univers
bari
valenzano
bari
itali
canin
parvoviru
cpv
felin
parvoviru
fpv
caus
sever
often
fatal
enter
host
uk
studi
report
faecal
shed
cpv
fpv
asymptomat
shelter
cat
contrast
australian
studi
util
similar
convent
pcr
cpcr
assay
report
cpv
shed
fpv
shed
asymptomat
shelter
cat
aim
longitudin
studi
determin
whether
lowlevel
parvovir
shed
undetect
cpcr
occur
australian
shelter
cat
residu
faecal
sampl
previou
australian
studi
n
collect
asymptomat
shelter
cat
three
sampl
day
n
n
n
month
test
occur
fpv
outbreak
parvovir
dna
detect
use
quantit
pcr
qpcr
minor
groov
binder
realtim
pcr
assay
differenti
fpv
parvovir
dna
detect
faecal
sampl
posit
sampl
fpv
respect
viral
load
x
median
x
templat
dna
lower
fpv
x
x
median
x
templat
dna
quantit
pcr
sensit
cpcr
detect
lowlevel
parvovir
shed
fpv
shed
asymptomat
shelterh
cat
fpv
outbreak
low
preval
cpv
shed
detect
present
studi
show
serum
present
cat
fpv
could
use
prognost
factor
predict
diseas
outcom
disclosur
report
clinic
epidemiolog
featur
first
report
outbreak
felin
caliciviru
virul
system
diseas
australia
vitro
efficaci
three
antivir
compound
nitazoxanid
cat
present
sign
consist
fcvvsd
outbreak
includ
viral
isol
whole
genom
sequenc
perform
residu
diagnost
oropharyng
swab
andor
necropsi
tissu
one
viru
outbreak
test
plaqu
reduct
assay
nitazoxanid
ntz
antivir
ec
determin
therapeut
index
ti
deriv
ec
half
maxim
cytotox
concentr
crfk
cell
twenti
case
nsw
n
qld
n
identifi
age
presenc
prevaccin
elisa
antibodi
associ
time
sinc
last
vaccin
p
outdoor
cat
like
titr
increas
elisa
p
mani
cat
prevaccin
fcv
antibodi
even
vaccin
perform
year
ago
preval
antibodi
depend
previou
vaccin
seem
increas
age
titr
increas
vaccin
rare
observ
influenc
lifestyl
disclosur
report
weak
posit
correl
height
antibodi
titr
mean
faecal
viru
load
spearman
r
p
antibodi
titr
significantli
higher
cat
shed
fcov
frequent
kruskal
walli
test
p
twentytwo
cat
rtpcrneg
four
faecal
sampl
cat
significantli
lower
antibodi
titr
cat
shed
continu
four
sampl
dunn
test
p
analys
fcovshed
cat
shed
least
cat
fcov
rtpcrposit
continu
four
sampl
significantli
higher
antibodi
titr
mannwhitney
u
test
p
significantli
higher
mean
faecal
viru
load
mannwhitney
u
test
p
cat
fcov
rtpcrposit
one
two
three
sampl
eight
cat
detect
antibodi
shed
fcov
height
antibodi
titr
correl
faecal
viru
load
chronic
total
dog
includ
studi
common
breed
german
shepherd
dog
n
common
organ
cultur
terreu
n
posit
cultur
treatment
start
dog
wherea
dog
receiv
specif
treatment
dog
lost
follow
twentyfour
dog
treat
itraconazol
firstlin
treatment
singl
agent
dog
total
nine
dog
treat
concurr
terbinafin
median
surviv
time
post
diagnosi
day
age
diagnosi
signific
effect
surviv
time
daili
hazard
death
da
dog
elev
serum
creatinin
concentr
diagnosi
ci
time
dog
normal
serum
creatinin
concentr
daili
hazard
death
da
dog
treat
itraconazol
ci
time
dog
treat
antifung
treatment
daili
hazard
death
da
dog
treat
terbinafin
ci
time
dog
treat
terbinafin
consist
previou
studi
found
da
case
german
shepherd
terreu
commonli
isol
organ
although
itraconazol
previous
drug
choic
treat
da
find
show
combin
therapi
terbinafin
newer
antifung
treatment
improv
surviv
time
serum
creatinin
use
prognost
indic
surviv
time
disclosur
report
giardia
duodenali
median
age
infect
dog
year
overal
clinic
sign
includ
diarrhea
weight
loss
hematochezia
inappet
vomit
polyphagia
intussuscept
diagnos
dog
two
dog
show
lethargi
clinic
sign
like
due
moder
sever
anemia
digest
sign
acut
less
day
dog
chronic
remain
dog
biolog
abnorm
includ
anemia
eosinophilia
hypoalbuminemia
nak
ratio
normal
acthstimul
test
four
percent
dog
neither
clinic
biolog
sign
differ
weight
loss
frequent
p
signific
associ
found
clinic
sign
biolog
abnorm
fe
howev
nak
ratio
normal
acthstimul
test
found
among
dog
massiv
fe
complet
recoveri
antiparasit
treatment
obtain
dog
avail
followup
n
one
dog
die
intussuscept
result
suggest
tv
pathogen
dog
lead
acut
chronic
digest
clinic
sign
hypoalbuminemia
anemia
electrolyt
disord
disclosur
report
antimicrobi
resist
increas
threat
human
anim
health
overand
misus
antimicrobi
foster
resist
object
retrospect
studi
investig
pattern
antimicrobi
use
select
canin
diseas
switzerland
case
frequenc
antimicrobi
prescript
decreas
p
declin
found
univers
clinic
p
well
privat
practicesclin
p
diseas
categori
aurtd
p
flutd
p
abscess
p
specif
prescript
critic
import
gener
cephalosporin
decreas
p
urin
analys
frequent
perform
privat
practiceclin
cat
flutd
p
despit
number
prescript
accord
guidelin
significantli
increas
aurtd
flutd
abscess
year
present
studi
report
reduct
antimicrobi
prescript
use
gener
cephalosporin
cat
switzerland
coincid
antibiot
stewardship
activ
includ
launch
antibioticscoutch
howev
adher
consensu
guidelin
still
poor
oral
prepar
nonpotenti
aminopenicillin
cat
avail
switzerland
could
hamper
complianc
guidelin
thu
although
present
studi
indic
trend
toward
less
frequent
prescript
antimicrobi
cat
effort
necessari
promot
antimicrobi
stewardship
small
anim
medicin
disclosur
report
studi
support
swiss
nation
scienc
foundat
project
evalu
hand
hygien
complianc
small
anim
clinic
practic
switzerland
use
cleanhand
applic
studi
indic
overal
poor
adher
hh
small
anim
clinic
practic
switzerland
hh
remark
poor
critic
area
preoper
prepar
area
clean
asept
procedur
contrast
observ
human
hospit
adher
hh
lower
nurs
staff
doctor
conclus
studi
highlight
need
promot
hh
small
anim
medicin
special
emphasi
train
nurs
staff
personnel
preoper
prepar
area
disclosur
report
studi
support
swiss
feder
food
safeti
veterinari
offic
fsvo
project
evalu
infect
prevent
control
standard
carriag
multidrugresist
organ
work
staff
small
anim
clinic
practic
switzerland
extendedspectrum
betalactamas
esbl
carbapenemaseproduc
enterobacteriacea
cpe
use
enrich
select
procedur
speci
identif
perform
malditof
ms
analysi
antibiot
resist
gene
identifi
pcr
sequenc
multilocu
sequenc
type
mrsp
frequenc
mdro
detect
hightouch
surfac
clinicspractic
ag
respect
clinic
high
environment
contamin
cpe
coli
bla
bla
cpk
pneumonia
bla
mrsp
meca
clinic
b
mrcon
meca
clinic
c
macrococcu
spp
mecb
mecd
mrcon
meca
clinic
e
predomin
ipc
audit
reveal
deficit
ipc
organ
cleaningdisinfect
handperson
hygien
medic
prepar
antimicrobi
use
guidelin
clinic
veterinari
personnel
faecal
carriag
colistinresist
e
coli
esblproduc
e
coli
cpe
coli
nasal
carriag
mrsa
mrsp
mrcon
found
mdro
carriag
associ
work
place
profess
person
cpe
coli
bla
staff
member
clinic
b
relat
environment
isol
studi
document
major
deficit
ipc
standard
small
anim
clinic
switzerland
extens
variabl
environment
contamin
mdro
report
first
time
detect
cpe
environment
sampl
small
anim
clinic
faecal
carriag
relat
cpe
isol
staff
member
present
studi
highlight
potenti
small
anim
clinic
spread
mdro
need
promot
ipc
concept
institut
disclosur
report
studi
support
swiss
feder
food
safeti
veterinari
offic
fsvo
project
preval
acquisit
persist
rectal
naso
carriag
multidrugresist
organ
dog
cat
present
veterinari
practic
owner
show
clonal
bla
suggest
transmiss
common
sourc
rather
de
novo
select
persist
esblproduc
cp
ecoli
k
pneumonia
shown
mdro
posit
anim
day
resist
bacteria
isol
owner
esblproduc
ecoli
mrcon
mrsa
carriag
persist
one
owner
day
transfer
esblproduc
ecoli
owner
dog
suspect
one
case
analysi
ongo
determin
related
isol
cohort
acquisit
rate
andor
cp
enterobacteriacea
high
vari
institut
mdro
carriag
observ
owner
carriag
persist
sever
month
find
show
veterinari
hospit
play
signific
role
select
transmiss
mdro
amongst
veterinari
patient
includ
bacteria
problemat
resist
profil
disclosur
report
hepat
encephalopathi
syndrom
neurolog
dysfunct
import
contributor
patient
morbid
dog
liver
diseas
prebiot
lactulos
nonabsorb
synthet
disaccharid
frequent
employ
treatment
canin
yet
incomplet
understood
mechan
action
human
link
dysbiosi
associ
worsen
morbid
mortal
impact
lactulos
amelior
heassoci
dysbiosi
gener
modul
intestin
microbiota
controversi
unknown
dysbiosi
present
canin
influenc
lactulos
intestin
microbiota
also
assess
dog
aim
studi
therefor
examin
chang
faecal
microbiota
composit
lactulos
treatment
healthi
dog
total
healthi
privat
own
dog
enrol
prospect
cohort
studi
femal
male
median
age
year
rang
complet
studi
fulli
faecal
sampl
collect
weekli
dog
either
usual
diet
week
follow
standardis
commerci
diet
week
ad
oral
lactulos
mlkg
everi
hour
week
faecal
bacteri
dna
extract
follow
pcr
amplif
region
rrna
gene
illumina
standard
librari
prep
sequenc
perform
miseq
platform
data
analys
use
pipelin
week
lactulos
treatment
week
significantli
lower
faecal
microbiota
richnessdivers
observ
base
alpha
divers
metric
observ
oper
taxonom
unit
shannon
index
pielou
even
beta
divers
base
unifrac
distanc
also
significantli
differ
week
compar
week
bacteri
phylum
famili
level
week
associ
signific
increas
firmicut
actinobacteria
veillonellacea
bifidobacteriacea
decreas
bacteroidet
fusobacteria
bacteroidacea
fusobacteriacea
ruminococcacea
alcaligenacea
compar
week
final
extrapol
cirrhosi
dysbiosi
ratio
cdr
calcul
lower
valu
associ
dysbiosi
link
wors
outcom
human
cdr
increas
week
compar
week
conclus
lactulos
induc
revers
qualit
quantit
chang
faecal
microbiota
healthi
dog
possibl
explain
potenti
benefit
manag
disclosur
report
bacteri
cholecyst
debilit
diseas
dog
presenc
bacteria
bile
ill
dog
would
signific
bile
consid
steril
howev
preval
bactibilia
healthi
dog
unknown
primari
purpos
studi
determin
preval
bactibilia
healthi
dog
secondari
aim
determin
differ
bactibil
nonbactibil
healthi
dog
occur
regard
serum
liver
enzym
activ
liver
gallbladd
histopatholog
fiftyf
healthi
abandon
dog
euthanas
nonmed
reason
includ
crosssect
prospect
studi
dog
deem
healthi
base
clinic
necropsi
examin
whole
blood
bile
gallbladd
wall
liver
sampl
collect
asept
dog
within
minut
euthanasia
submit
bacteri
cultur
cytolog
biochem
alkalin
phosphatas
alp
alanin
aminotransferas
alt
gammaglutamyl
transferas
ggt
histopatholog
analys
agreement
cytolog
cultur
assess
cohen
analysi
analysi
varianc
serum
liver
enzym
activ
dog
bactibilia
without
perform
use
mannwhitney
test
preval
bactibilia
dog
diagnos
cytolog
bile
cultur
poor
agreement
bile
cytolog
cultur
cohen
kappa
p
signific
differ
liver
enzym
concentr
found
bactibil
nonbactibil
dog
signific
hepatobiliari
histopatholog
abnorm
present
bactibil
dog
preval
bactibilia
asymptomat
dog
signific
elev
liver
enzym
histopatholog
chang
disclosur
report
coauthor
f
kettner
financi
relationship
indirectli
benefit
laboratori
servic
vetdiagnostix
use
studi
perform
bacteri
cultur
cytolog
biochem
histopatholog
analys
discuss
abstract
indirect
sharehold
vetdiagnostix
involv
manag
vetdiagnostix
cape
town
branch
hyaluron
acid
liver
function
test
ass
extrahepat
portosystem
shunt
closur
dog
surgic
attenu
dog
ehpss
sha
seem
promis
noninvas
biomark
determin
ehpss
closur
surgic
attenu
addit
might
also
valuabl
differenti
dog
ehpss
dog
liver
diseas
disclosur
report
rpca
ubtcc
utcc
stcc
significantli
p
often
found
neoplasm
lower
urinari
tract
kidney
howev
signific
differ
preval
brafmut
differ
site
tcc
urinari
bladder
andor
urethra
statist
correl
histolog
degre
tcc
lut
brafmut
obviou
brafmut
identifi
significantli
frequent
ubtcc
terrier
breed
p
utcc
breed
differ
brafmut
signific
probabl
due
small
number
terrier
case
dog
braf
mutat
conclus
renal
carcinoma
mostli
caus
brafmut
thu
tubular
pelvic
carcinoma
kidney
detect
brafmut
analysi
cell
excret
within
urin
contrast
brafmut
often
involv
pathogenesi
tcc
urinari
bladder
andor
urethra
use
excel
diagnost
tool
enorm
specifi
malign
site
carcinoma
lower
urinari
tract
disclosur
report
reirradi
get
recogn
treatment
option
patient
recurr
neoplast
diseas
howev
inform
efficaci
risk
chronic
side
effect
limit
veterinari
medicin
aim
studi
evalu
outcom
report
late
side
effect
dog
cat
receiv
reirradi
progress
tumor
recurr
small
anim
cancer
patient
treat
reirradi
includ
retrospect
studi
patient
characterist
tumor
type
local
pretreat
time
interv
initi
radiotherapi
reirradi
radiat
protocol
late
side
effect
caus
death
surviv
time
analyz
fortynin
patient
dog
cat
includ
studi
major
suffer
headand
neck
tumor
reirradi
protocol
one
except
palli
five
anim
receiv
second
cours
reirradi
fifteen
patient
initi
radiat
definit
anim
palli
intent
mean
time
interv
initi
radiotherapi
first
reirradi
day
first
second
reirradi
day
mean
total
biologiceffectivedos
late
respond
tissu
bed
gy
initi
radiotherapi
reirradi
late
side
effect
commonli
observ
skinhair
alway
score
mild
score
vrtog
chronic
ocular
side
effect
report
seven
patient
score
median
tumorspecif
surviv
time
patient
day
conclus
studi
demonstr
palli
reirradi
offer
treatment
option
incur
recurr
tumor
late
side
effect
mostli
mild
lifethreaten
disclosur
report
impact
repeat
cycl
egf
bispecif
angiotoxin
ebat
administ
reduc
interv
doxorubicin
chemotherapi
toler
surviv
dog
splenic
hemangiosarcoma
target
toxin
promis
agent
design
target
receptor
uniqu
highli
express
cancer
cell
improv
tumor
specif
reduc
advers
event
ae
name
impli
bispecif
ligandtarget
toxin
dual
target
abil
confer
greater
bind
affin
kill
abil
compar
monospecif
counterpart
ebat
bispecif
epiderm
growth
factor
egf
angiotoxin
develop
second
gener
biolog
drug
specif
target
tumor
cell
associ
vascular
inflammatori
stroma
sarcoma
therapi
consist
human
egf
target
egf
receptor
egfr
human
amino
termin
transferas
atf
urokinas
target
urokinas
plasminogen
activ
receptor
upar
genet
modifi
deimmun
pseudomona
exotoxin
lead
inhibit
protein
synthesi
previous
report
ebat
safe
improv
overal
surviv
dog
splenic
hemangiosarcoma
hsa
minim
residu
diseas
set
ad
standard
care
soc
therapi
singl
cycl
three
treatment
studi
pseudomona
exotoxin
human
suggest
repeat
cycl
administr
may
prolong
remiss
wherea
optim
time
administr
target
toxin
chemotherapi
unclear
sarcoma
bispecif
toxin
studi
describ
herein
undertaken
prospect
determin
multipl
cycl
ebat
biolog
activ
dose
ugkg
given
intraven
concomit
reduc
interv
administr
target
toxin
doxorubicin
chemotherapi
would
welltoler
improv
outcom
dog
splenic
hsa
elig
expand
dog
hsa
provid
macroscop
lesion
could
surgic
excis
treatment
includ
three
plan
cycl
ebat
administ
mondaywednesday
friday
schedul
start
upon
recoveri
splenectomi
continu
one
week
prior
doxorubicin
event
interv
first
ebat
given
day
first
doxorubicin
reduc
compar
previou
trial
use
singl
cycl
ebat
doxorubicin
start
day
instead
day
twentyf
dog
enrol
six
experienc
acut
hypotens
two
requir
hospit
selflimit
elev
alt
observ
one
dog
surviv
benefit
seen
studi
overal
surviv
compar
contemporari
control
group
dog
stage
hemangiosarcoma
treat
soc
alon
repeat
dose
cycl
ebat
led
greater
incid
sever
ae
reduc
efficaci
compar
singl
cycl
ebat
delay
commenc
chemotherapi
disclosur
report
sixteen
dog
includ
studi
cutan
mct
subcutan
mct
median
age
first
present
diagnosi
month
rang
month
rang
respect
male
entir
neuter
femal
entir
neuter
common
breed
labrador
golden
retriev
thirteen
cutan
mct
grade
ii
patnaik
grade
iilowgrad
patnaikkiupel
grade
iihighgrad
patnaikkiupel
highgrad
kiupel
mitot
index
median
mitot
index
three
subcutan
mct
two
infiltr
growth
pattern
mitot
index
region
lymph
node
assess
case
mean
cytolog
histopatholog
metastas
identifi
dog
cutan
subcutan
assess
case
cutoff
cutan
subcutan
mct
case
screen
ckit
mutat
identifi
cutan
exon
patient
underw
differ
treatment
modal
surgeri
corticosteroid
surgeri
chemotherapi
radiotherapi
radiotherapychemotherapi
infus
diphenhydramin
premed
commonli
use
histamin
releas
propos
mechan
doxassoci
arrhythmogenesi
studi
object
evalu
incid
sever
dox
infusionrel
cardiac
arrhythmia
dog
highgrad
lymphoma
effect
diphenhydramin
premed
arrhythmia
number
sever
dox
infus
dog
cytologicallyhistopatholog
confirm
highgrad
lymphoma
screen
echocardiogram
concurr
electrocardiogram
random
prospect
crossov
studi
groupa
receiv
premed
dox
premed
diphenhydramin
dox
groupb
receiv
diphenhydramin
dox
premed
dox
visit
holter
monitor
data
collect
hour
dox
hour
postadministr
analyz
burdick
holter
analysi
softwar
commerci
avail
softwar
use
normal
test
pairedsampl
analysi
individu
act
control
studi
demonstr
dog
appropri
pretreat
cardiovascular
screen
dox
infus
induc
signific
arrhythmia
furthermor
data
suggest
diphenhydramin
may
alter
arrhythmia
number
sever
canin
dox
recipi
disclosur
report
time
chang
stage
annarbor
system
canin
nodal
diffus
larg
bcell
lymphoma
clientown
dog
cytologicallyhistolog
diagnos
omm
elig
prospect
studi
pet
scan
headneck
use
fluorinefluorodeoxyglucos
ffdg
perform
follow
comput
tomographi
bilater
mandibular
lymphadenectomi
perform
histopatholog
assess
scan
evalu
two
independ
observ
first
observ
blind
primari
tumor
later
grade
subject
compar
ffdg
uptak
background
subsequ
observ
unblind
primari
tumor
inform
util
standard
uptak
valu
suv
quantif
evalu
interobserv
agreement
receiv
oper
characterist
roc
analysi
perform
twelv
dog
enrol
metastat
melanoma
identifi
mandibular
lymph
node
dog
interobserv
agreement
higher
suv
quantif
employ
k
versu
area
curv
improv
observ
use
method
vs
roc
analysi
identifi
suvmax
valu
cutoff
lead
sensit
specif
conclus
includ
assess
oral
caviti
use
quantif
improv
accuraci
pet
metastasi
detect
canin
patient
omm
disclosur
report
chemotherapyinduc
diarrhoea
cid
one
frequent
advers
event
associ
chemotherapi
dog
yet
current
consensu
regard
manag
metronidazol
frequent
prescrib
howev
evid
support
use
could
actual
associ
concern
gastrointestin
dysbiosi
diosmectit
natur
medic
clay
wide
use
treatment
acut
diarrhoea
human
strong
evid
vivo
vitro
multipl
speci
support
use
diosmectit
antidiarrh
aim
prospect
studi
investig
efficaci
diosmectit
manag
cid
dog
hypothesis
diosmectit
would
decreas
durat
cid
compar
standard
manag
dog
diagnos
nongastrointestin
neoplasia
undergo
maximumtoler
dose
chemotherapi
june
januari
randomis
group
diosmectit
standard
group
randomli
realloc
develop
anoth
cid
event
diosmectit
administ
gkgday
po
divid
dose
initi
start
cid
standard
manag
consist
cours
metronidazol
mgkg
po
initi
diarrhoea
improv
hour
dog
assess
weekli
standard
qualiti
life
qol
diarrhoea
diari
form
fill
owner
physic
examin
perform
clinician
waltham
faec
score
system
use
grade
diarrhoea
sixtyon
dog
recruit
studi
period
twentythre
grade
diarrhoea
event
record
among
diosmectit
standard
group
respect
median
durat
diarrhoea
significantli
shorter
versu
diosmectit
group
compar
standard
group
p
median
qol
score
significantli
higher
versu
diosmectit
group
compar
standard
group
p
manag
cid
dog
earli
administr
diosmectit
associ
faster
resolut
diarrhoea
compar
standard
manag
metronidazol
confirm
initi
hypothesi
diosmectit
appear
effect
firstlin
manag
cid
dog
lead
improv
qualiti
life
whilst
decreas
antiobiot
usag
disclosur
report
diosmectit
use
studi
kindli
provid
vb
direct
ltd
form
vb
clay
g
powder
pot
vb
direct
ltd
involv
design
perform
studi
write
abstract
decis
submit
present
contrastenhanc
ultrasound
sentinel
lymph
node
identif
routin
stage
canin
mast
cell
tumour
feasibl
studi
q
fournier
f
thierri
longo
j
bisson
wood
liuti
bavcar
univers
edinburgh
roslin
unit
kingdom
region
lymph
node
ln
assess
part
routin
stage
canin
mast
cell
tumour
mct
howev
region
ln
often
determin
base
anatom
locat
drain
ln
may
accur
identifi
order
overcom
issu
differ
techniqu
sentinel
lymph
node
sln
detect
report
contrastenhanc
ultrasound
ceu
describ
sensit
specif
techniqu
human
patient
wide
use
veterinari
medicin
primari
object
prospect
studi
report
sln
detect
rate
ceu
dog
diagnos
cutaneoussubcutan
mct
secondari
object
assess
safeti
techniqu
hypothesis
ceu
identifi
least
one
sln
dog
advers
reaction
would
occur
case
dog
undergo
routin
stage
cutaneoussubcutan
mct
june
march
recruit
routin
stage
includ
bloodwork
urinalysi
fineneedl
aspir
fna
region
ln
thorac
radiograph
abdomin
ultrasound
fna
liver
spleen
region
ln
assess
complet
ceu
identif
sln
premed
intramuscular
chlorpheniramin
administ
ml
sulfur
hexafluorid
microbubbl
inject
around
tumour
follow
local
massag
resid
train
diagnost
imag
examin
ultrasound
anatom
region
potenti
drain
ln
recommend
resid
train
oncolog
inject
site
check
follow
procedur
discharg
dog
owner
recommend
monitor
site
local
reaction
follow
coupl
day
sixtyf
dog
diagnos
cutaneoussubcutan
mct
recruit
least
one
sln
identifi
dog
sixteen
dog
sln
one
dog
sln
identifi
advers
reaction
procedur
record
among
dog
histopatholog
assess
sln
identifi
diagnos
nodal
metastasi
ceu
sensit
safe
techniqu
identif
sln
dog
mct
confirm
initi
hypothesi
techniqu
may
easili
incorpor
routin
stage
canin
mct
addit
studi
warrant
confirm
clinic
benefit
disclosur
report
dorsal
rhinotomi
dog
intranas
tumor
tumour
nasal
caviti
paranas
sinus
account
approxim
canin
neoplasm
treatment
choic
intranas
tumor
radiotherapi
rhinotomi
associ
morbid
shorter
surviv
radiotherapi
object
studi
retrospect
analyz
outcom
dog
nasal
tumour
treat
surgic
patient
clinic
lowgrad
nasal
tumour
defin
clinic
sign
persist
month
sign
beyond
local
diseas
treat
surgeri
eighteen
dog
includ
twelv
carcinoma
adenocarcinoma
transit
type
carcinoma
adenosquam
sarcoma
chondrosarcoma
peripher
nerv
sheath
tumour
haemangiosarcoma
main
complain
sneez
nasal
discharg
epistaxi
fiftyf
percent
n
dog
present
epistaxi
clinic
sign
report
month
year
mean
month
prior
surgeri
surgeri
sole
treatment
dog
radiotherapi
surgeri
dog
blood
analysi
surgeri
includ
haematolog
biochemistri
coagul
time
one
dog
plan
autotransfus
surgeri
ct
imag
perform
n
dog
one
rhinoscopi
dorsal
rhinotomi
perform
dog
without
seriou
complic
exclud
one
dog
requir
blood
transfusiion
surgeri
nasal
pack
place
left
hour
dog
develop
mild
moder
facial
emphysema
nasal
discharg
resolv
within
two
three
week
thirteen
dog
die
die
local
tumour
progress
one
die
gi
bleed
renal
carcinoma
two
dog
second
surgeri
follow
relaps
time
data
submiss
three
dog
still
aliv
day
two
dog
lost
follow
day
surgeri
overal
median
surviv
time
day
signific
differ
surviv
outcom
accord
carcinoma
sarcoma
diagnos
histor
canin
nasal
tumour
treat
surgic
achiev
median
suriv
time
month
inferior
outcom
report
use
radiotherapi
case
seri
sever
surgic
complic
infrequ
studi
reveal
patient
experi
prolong
surviv
follow
surgeri
intranas
tumour
studi
necessari
better
defin
patient
group
disclosur
report
use
lowdos
radiat
therapi
treatment
assess
present
month
diagnosi
endoscop
biopsi
histopatholog
featur
classifi
use
wsava
guidelin
score
moreov
four
morpholog
featur
evalu
presenc
crypt
distens
cd
lacteal
dilat
ld
mucos
fibrosi
mf
intraepitheli
lymphocyt
il
immunohistochemistri
perform
case
dog
classifi
respond
decreas
ccecai
cibdai
score
compar
nonrespond
decreas
ccecai
cibdai
compar
relaps
evalu
follow
clinic
score
differ
ccecai
cibdai
previou
closest
time
point
calcul
obtain
dccecai
cibdai
dccecai
cibdai
consid
relaps
associ
respons
relaps
categor
data
evalu
use
fisher
exact
test
chisquar
test
fiftyseven
dog
prospect
enrol
dog
belong
nonrespond
accord
cibdai
ccecai
score
respect
cibdai
ccecai
score
associ
clinic
respons
patient
relaps
dog
respect
cibdai
ccecai
associ
relaps
dog
histolog
wsava
moder
higher
respons
rate
sever
dog
p
howev
histolog
score
associ
relaps
rate
histolog
featur
associ
neither
respons
relaps
rate
presenc
il
associ
higher
cibdai
score
p
percentag
cell
associ
ccecai
cibdai
histolog
score
morpholog
featur
number
cell
differ
respond
nonrespond
relat
relaps
evalu
paramet
histolog
grade
seem
predict
clinic
respons
furthermor
none
clinic
histolog
paramet
includ
seem
predict
relaps
ire
dog
disclosur
report
preval
signific
increas
tli
concentr
clinic
practic
md
tabar
c
bertolani
climent
n
hospit
veterinario
san
vicent
san
vicent
del
raspeigalicant
spain
hospit
veterinario
cani
mallorca
spain
tli
lack
specif
individu
certain
gastrointestin
condit
previous
report
cat
intestin
andor
hepat
diseas
human
chronic
enteropathi
suggest
enterocyt
synthet
small
amount
trypsin
verifi
speci
aim
present
studi
evalu
preval
signific
increas
tli
cat
dog
clinic
practic
result
serum
tli
measur
retrospect
review
sampl
anim
evalu
differ
diseas
two
veterinari
hospit
perform
outsid
laboratori
idexx
barcelona
use
radioimmunoassay
felin
chemiluminescentassay
canin
clinic
record
patient
elev
tli
level
ngl
dog
cat
review
sampl
dog
cat
evalu
tli
increas
dog
cat
cobalamin
avail
review
total
patient
without
correl
cobalamin
tli
result
p
patient
increas
tli
cpli
also
determin
semiquantit
andor
quantit
analys
result
consist
pancreat
among
patient
normal
cpli
result
pancreat
suspect
base
pancreat
histolog
n
abdomin
ultrasound
n
noncirrhot
portal
hypertens
n
gastrointestin
diseas
n
diagnos
patient
gastrointestin
diseas
confirm
case
foodrespons
enteropathi
ibd
gastrointestin
neoplasia
pressumpt
patient
chronic
enteropathi
pancreat
suspect
patient
elev
tli
without
cpli
analys
patient
underli
diseas
confirm
gastrointestin
diseas
hepatopathi
renal
diseas
hypoadrenocortic
insulinoma
neoplasia
poliartr
patient
presumpt
diagnosi
like
underli
diseas
chronic
enteropathi
n
present
studi
case
increas
tli
without
pancreat
azotemia
confirm
suspect
underli
gastrointestin
diseas
coincid
previou
felin
human
find
fact
tli
perform
case
rule
exocrin
pancreat
insuffici
although
cobalamin
defici
link
increas
felin
tli
normal
supplement
studi
detect
signific
correl
cobalamin
tli
level
yet
undefin
mechan
like
explain
product
tli
absenc
pancreat
inflamm
tli
level
must
care
interpret
anim
gastrointestin
diseas
disclosur
report
comparison
group
correl
perform
use
appropri
parametr
nonparametr
statist
p
signific
descript
statist
reveal
compar
group
apart
conclus
pilot
studi
statist
signific
differ
oh
detect
group
disclosur
report
disclosur
report
neutrophiltolymphocyt
ratio
nlr
canin
patient
immunosuppressantrespons
enteropathi
ire
e
benvenuti
e
gori
pierini
c
lucarelli
p
ruggiero
g
luba
v
marchetti
univers
pisa
san
piero
grado
pisa
itali
associazion
professional
endovet
italia
rome
itali
human
ibd
neutrophiltolymphocyt
ratio
nlr
associ
activ
bowel
inflamm
correl
clinic
laboratori
indic
far
nlr
dog
evalu
oncolog
patient
septic
periton
aim
studi
evalu
nlr
canin
immunosuppressantrespons
enteropathi
ire
fortyon
dog
present
two
veterinari
facil
veterinari
teach
hospit
privat
veterinari
center
final
diagnosi
ire
retrospect
includ
canin
chronic
enteropathi
clinic
activ
index
ccecai
score
assess
dog
present
diagnosi
ire
set
histopatholog
perform
endoscop
biopsi
classifi
use
current
wsava
guidelin
lacteal
dilat
ld
crypt
abscess
cd
also
record
nlr
calcul
dog
serum
total
protein
albumin
cholesterol
creactiv
protein
crp
also
record
kruskalw
test
perform
evalu
nlr
differ
ccecai
categori
differ
histolog
grade
spearman
correl
test
perform
nlr
total
protein
albumin
cholesterol
crp
mannwhitney
utest
use
compar
nlr
dog
without
ld
cd
receiv
oper
characterist
curv
roc
built
obtain
optim
cutoff
valu
nlr
differenti
dog
without
ld
fisher
exact
test
perform
presenc
ld
nlr
group
nlr
significantli
differ
ccecai
score
categori
p
nlr
neg
correl
total
protein
p
r
albumin
p
r
cholesterol
p
r
signific
correl
crp
nlr
found
nlr
differ
histolog
grade
dog
without
cd
contrarili
nlr
higher
dog
ld
p
cutoff
valu
nlr
detect
ld
sensit
specif
far
first
report
evalu
nlr
ire
dog
result
suggest
nlr
could
easi
feasibl
econom
addit
tool
evalu
diseas
sever
ire
dog
moreov
nlr
seem
good
correl
essenti
biochemistri
paramet
evalu
dog
proteinlos
enteropathi
furthermor
interest
data
associ
nlr
histolog
lymphangectasia
disclosur
report
due
signific
influenc
drug
disposit
risk
sever
advers
drug
reaction
seen
defect
p
gp
function
routin
screen
drug
candid
pgp
transport
common
practic
human
drug
discoveri
howev
current
caninespecif
vitro
system
evalu
pgpmediat
drug
transport
veterinari
medicin
avail
laboratori
recent
develop
ex
vivo
canin
enteroid
ent
system
accu
show
apic
express
pgp
consist
vivo
observ
coincub
verapamil
significantli
reduc
fluoresc
lumen
ent
min
p
min
p
indic
pgpmediat
transport
success
block
summari
pgp
gene
express
local
function
canin
ent
similar
intestin
tissu
origin
deriv
novel
ent
model
serv
use
ex
vivo
system
oral
drug
transport
relat
safeti
studi
veterinari
medicin
disclosur
report
investig
efficaci
novel
diet
manag
chronic
enteropathi
dog
found
cibdai
significantli
decreas
follow
introduct
dietet
food
median
cibdai
score
pre
treatment
post
treatment
p
studi
demonstr
dietet
food
use
success
manag
ce
dog
disclosur
report
although
studi
fund
owner
got
food
hill
free
trial
effect
dietari
fat
content
mucos
microbiota
serum
metabolom
healthi
beagl
disclosur
report
erythrocyt
membran
lipidom
dog
chronic
enteropathi
hd
dog
male
neuter
femal
steril
median
age
month
ce
dog
male
femal
steril
median
age
month
among
ce
dog
diagnos
fre
ire
undergo
diagnost
trial
lost
followup
diminish
valu
palmit
acid
p
increas
valu
stearic
acid
p
decreas
total
sfa
p
observ
ce
group
among
ce
dog
show
increas
valu
dihomogammalinolen
p
arachidon
p
acid
differ
observ
level
two
group
unsatur
p
peroxid
p
index
found
significantli
increas
ce
dog
interestingli
dog
fre
ire
dog
similar
erythrocyt
membran
lipidom
profil
object
statist
analysi
due
low
number
dog
group
result
point
import
balanc
proinflammatori
arachidon
acid
antiinflammatori
dihomogammalinolen
acid
level
inflammatori
condit
ce
erythrocyt
membran
lipidom
dog
may
success
appli
dog
ce
provid
import
inform
lead
person
intervent
target
decreas
inflamm
increas
protect
compon
disclosur
report
hypercobalaminaemia
possibl
associ
diseas
sever
dog
retrospect
studi
case
percentag
median
variabl
compar
group
use
kruskalw
fischer
exact
test
one
hundredandsixti
dog
includ
studi
divid
three
group
hypocobalaminaemia
dog
normal
serum
cobalamin
concentr
dog
hypercobalaminaemia
dog
age
distribut
significantli
differ
group
p
hypercobalaminaem
dog
significantli
younger
median
age
month
rang
dog
hypercobalaminaemia
present
diarrhoea
vomit
inappet
lethargi
andor
weight
loss
significantli
differ
group
condit
associ
hypercobalaminaemia
includ
gastrointestin
hepat
neurolog
endocrin
renal
pancreat
miscellan
diseas
among
neoplasia
distribut
significantli
differ
hypocobalaminaem
normocobalaminaem
dog
significantli
dog
high
serum
folat
concentr
hypercobalaminaemia
group
compar
group
p
dog
hypoalbuminaemia
anaemia
high
alt
activ
andor
hypocholesterolaemia
also
compar
three
cobalamin
group
statist
differ
identifi
associ
found
hypercobalaminaemia
paramet
test
diseas
sever
result
suggest
hypercobalaminaemia
dog
commonli
seen
gastrointestin
hepat
diseas
speci
also
seen
endocrin
neurolog
condit
interestingli
hyperfolataemia
commonli
seen
hypercobalaminaemia
unknown
whether
reflect
activ
dysbiosi
disclosur
report
vitro
model
scime
studi
intestin
microbiota
dog
fresh
faec
collect
four
healthi
dog
inocul
scime
system
experi
last
day
conduct
duplic
give
two
differ
type
feed
donor
model
valid
evalu
analysi
microbi
activ
quantif
scfa
lactat
ammonium
composit
colon
microbiota
studi
qpcr
use
primer
target
firmicut
bacteroidet
bifidobacteria
lactobacilli
enterobacteriacea
illumin
sequenc
total
bacteri
popul
differ
effect
composit
canin
intestin
microflora
experi
time
promot
among
firmicut
result
obtain
highlight
abil
signific
increas
p
amount
acidaminococcacea
otu
ae
lumen
level
enterococcacea
p
bacteroidet
display
decreas
p
speci
belong
famili
bacteroidacea
otu
ae
lumen
level
addit
signific
growth
p
famili
coriobacteriacae
human
pancreat
cours
pancreat
releas
vitamin
e
blood
stream
due
necrot
process
tissu
may
discuss
speci
disclosur
report
author
employe
commer
laboratori
laboklin
studi
financ
laboklin
water
immers
vs
ga
insuffl
canin
duoden
endoscopi
futur
underwat
endoscopi
gastrointestin
tract
often
part
diagnost
protocol
canin
acut
chronic
gastroenteropathi
analyz
properli
intestin
wall
fundament
distend
lumen
usual
inflat
air
human
medicin
well
known
ga
insuffl
gi
air
carbon
dioxid
colonscopi
induc
pain
patient
frequent
use
warmto
touch
water
instead
air
distend
lumen
random
control
trial
suggest
introduct
water
distend
lumen
colon
decreas
spasm
musculatur
bowel
pain
significantli
increas
visual
mucos
textur
adenoma
detect
rate
studi
first
veterinari
medicin
compar
gi
water
immers
wi
duodenoscopi
anesthet
dog
order
evalu
eventu
differ
procedur
nocicept
qualiti
mucos
visual
twentyf
dog
subject
endoscopi
gener
anesthesia
includ
studi
evalu
differ
nocicept
anesthesia
heart
rate
arteri
blood
pressur
sistol
diastol
mean
measur
throughout
procedur
divid
four
step
baselin
water
air
outcom
random
sequenc
gi
wi
appli
dilat
duoden
lumen
everi
condit
mucos
imag
bowel
record
everi
dog
two
imag
gi
wi
record
subject
textur
analysi
use
imag
process
approach
like
skeleton
entropi
evalu
subject
blind
evalu
three
expert
endoscopist
consid
architectur
intestin
textur
systemat
signific
differ
detect
cardiovascular
paramet
textur
analysi
gi
wi
except
subject
evalu
endoscopist
identifi
wi
imag
qualit
better
result
studi
highlight
algic
answer
chang
two
method
mayb
influenc
drug
use
endoscopi
well
control
nocicept
give
deep
anesthesia
base
evalu
endoscopist
wi
allow
get
better
qualiti
imag
detail
visual
intestin
villi
still
confirm
object
textur
analysi
disclosur
report
heart
rate
variabl
dog
variou
stage
degen
mitral
valv
diseas
dog
receiv
physic
examin
fiveminutelong
sixlead
electrocardiographi
ecg
complet
echocardiographi
thorac
radiographi
bloodwork
shortterm
heart
rate
variabl
evalu
use
time
frequenc
domain
fiveminutelong
ecg
record
c
compar
group
n
paramet
includ
sd
normal
interv
sdnn
p
rootmean
squar
success
differ
normal
heartbeat
rmssd
p
percentag
adjac
normal
interv
differ
ms
p
addit
signific
increas
lowfrequ
lf
p
decreas
highfrequ
hf
p
band
observ
group
c
compar
group
n
lfhf
ratio
significantli
increas
group
c
p
rel
group
group
compar
sdnn
show
significantli
lower
valu
p
studi
show
dog
aclin
mvd
sympathet
parasympathet
tone
might
remain
unchang
clinic
sign
develop
despit
presenc
structur
remodel
onset
clinic
sign
like
trigger
an
imbal
due
sympathet
tone
activ
vagal
tone
withdraw
moreov
sdnn
independ
marker
risk
mortal
may
hrvrelat
paramet
abl
distinguish
aclin
dog
without
cardiomegali
find
may
futur
implic
regard
choic
made
around
best
time
pharmacotherapi
onset
well
around
effect
order
ad
specif
medic
ongo
pharmacotherapi
regimen
administ
dog
mvd
disclosur
report
comparison
serum
digoxin
concentr
blood
collect
vacutain
tube
without
gel
right
ventricular
rv
strain
analysi
use
speckl
track
echocardiographi
focus
assess
longitudin
strain
strain
rate
variabl
dog
howev
rv
contract
also
character
transvers
deform
strain
compon
investig
dog
therefor
evalu
abil
transvers
rv
strain
strain
rate
obtain
speckl
track
echocardiographi
healthi
dog
dog
pulmonari
hypertens
identifi
dog
pulmonari
hypertens
addit
examin
relationship
transvers
strain
strain
rate
variabl
heart
rate
age
bodyweight
healthi
dog
tricuspid
regurgit
tr
veloc
left
atrial
size
dog
pulmonari
hypertens
acquir
echocardiograph
cineloop
left
apic
view
optim
right
ventricl
analyz
transvers
rv
free
wall
strain
strain
rate
dog
healthi
dog
dog
pulmonari
hypertens
use
xstrain
softwar
dog
classifi
pulmonari
hypertens
base
tr
jet
veloc
msec
classifi
dog
moder
pulmonari
hypertens
tr
veloc
msec
sever
pulmonari
hypertens
tr
veloc
msec
exclud
analysi
low
qualiti
imag
healthi
dog
strain
strain
rate
show
relationship
heart
rate
bodi
weight
age
dog
pulmonari
hypertens
strain
strain
rate
show
weak
neg
relationship
tr
veloc
relationship
left
atrial
size
although
transvers
rv
strain
strain
rate
show
neg
relationship
class
pulmonari
hypertens
use
identifi
dog
pulmonari
hypertens
transvers
rv
strain
strain
rate
use
speckl
track
echocardiographi
obtain
dog
help
identifi
dog
pulmonari
hypertens
disclosur
report
potenti
renoprotect
effect
angiotensinreceptor
antagonist
dog
myxomat
mitral
valv
diseas
j
lee
w
kim
h
hwang
jeon
c
ahn
korea
anim
special
medic
institut
seongnam
southkorea
columbia
univers
new
york
unit
state
america
andant
anim
hospit
seoul
southkorea
blockad
reninangiotensinaldosteron
system
pivot
strategi
manag
congest
heart
failur
chf
angiotensinreceptor
blocker
arb
perceiv
offer
complet
neurohormon
suppress
treatment
chf
directli
occupi
angiotensin
ii
receptor
site
howev
whether
combin
therapi
arb
current
chf
treatment
clinic
increment
benefit
unknown
dog
myxomat
mitral
valv
diseas
mmvd
retrospect
cohort
studi
conduct
clientown
dog
symptomat
mmvd
treat
standard
protocol
control
n
addit
arb
case
n
irbesartan
mgkgday
n
telmisartan
mgkg
day
n
convent
treatment
initi
analysi
homogen
two
group
physic
examin
comprehens
blood
test
profil
cbc
serum
biochemistri
ntprobnp
sdma
radiograph
echocardiograph
data
collect
subsequ
clinic
indic
compar
time
point
arb
given
three
six
month
addit
surviv
analysi
also
perform
use
kaplanmei
curv
month
treatment
degre
increas
clinic
paramet
relat
renal
function
significantli
higher
control
case
group
p
bun
ae
vs
studi
includ
dog
five
underw
cathet
insert
femor
arteri
group
f
either
dorsali
pedi
n
caudali
median
n
peripher
arteri
group
p
group
f
requir
median
min
rang
min
cathet
insert
median
min
rang
min
cathet
remov
three
dog
group
f
bled
heparin
infus
surgeri
bleed
group
p
puls
palpabl
immedi
surgeri
good
pressur
waveform
obtain
periop
period
blood
collect
unev
advers
event
surgeri
group
oper
time
differ
significantli
two
group
result
suggest
periop
manag
peripher
arteri
open
heart
surgeri
effect
safe
disclosur
report
effect
inhospit
diuret
therapi
electrolyt
concentr
renal
function
surviv
dog
acut
congest
heart
failur
fourtyon
dog
experienc
cardiac
death
hospit
remain
dog
day
admiss
stepwis
backward
regress
demonstr
haemoconcentr
hr
disnatremia
hr
influenc
outcom
statist
signific
correl
pearson
seen
furosemid
dose
kalemia
r
p
bun
scr
r
p
correl
seen
furosemid
dose
variabl
scr
bun
htc
scr
htc
conclus
haemoconcentr
disnatremia
affect
outcom
dog
chf
haemoconcentr
associ
lower
risk
mortal
consid
target
chf
therapi
inhospit
diuret
therapi
increas
electrolyt
disord
due
loop
diuret
inhibit
renal
na
k
cl
cotransport
henl
loop
disnatremia
risk
factor
advers
outcom
diuret
dose
haemoconcentr
nt
play
direct
role
induc
renal
disfunct
disclosur
report
platelet
proteom
profil
dog
heart
failur
z
yilmaz
p
levent
saril
kocaturk
baykal
e
akgun
bursa
uludag
univers
veterinari
medicin
intern
medicin
bursa
turkey
acibadem
univers
medic
biochemistri
depart
istanbul
turkey
heart
failur
caus
haemostat
complic
due
platelet
overactiv
human
veterinari
medicin
especi
cat
hypertroph
cardiomyopathi
enough
inform
molecular
relationship
hemostasi
cardiovascular
diseas
dog
thu
studi
aim
elabor
hemostasi
coagul
chang
platelet
proteom
profil
dog
natur
occur
heart
failur
materi
studi
consist
total
dog
differ
breed
age
sex
two
differ
group
design
control
n
test
group
n
base
physic
laboratori
cardiolog
examin
result
dog
includ
control
healthi
group
dog
stage
c
heart
failur
accord
acvim
classif
enrol
test
group
platelet
isol
perform
dog
platelet
pellet
store
c
analys
platelet
proteom
identifi
use
uplcesiqtofm
method
global
clot
time
pt
aptt
measur
well
platelet
proteom
n
match
previous
describ
protein
cani
lupu
familiali
compar
control
least
p
level
chang
proteom
n
consid
statist
signific
compar
control
group
platelet
proteom
guanin
nucleotidebind
protein
subunit
apolipoprotein
ciii
apolipoprotein
aii
clusterin
level
increas
wherea
cxcmotif
cytochromecoxidas
cathepsind
serinethreonin
protein
phosphatas
catalyt
subunit
creatin
kinas
btype
myotrophin
level
decreas
testgroup
pt
aptt
valu
test
group
longer
control
valu
p
result
platelet
protein
identifi
present
studi
could
potenti
biomark
diagnosi
heart
failur
therefor
protein
need
valid
field
studi
also
proteom
provid
detail
inform
heart
failur
process
disclosur
report
hcm
cat
desmin
structur
disorganis
might
compromis
integr
contractil
apparatu
presenc
desmin
aggreg
suggest
protein
qualiti
control
measur
fail
restor
proteostasi
hcm
affect
heart
despit
correspond
increas
chaperon
protein
disclosur
report
preval
risk
factor
atrial
fibril
dog
myxomat
mitral
valv
diseas
conclus
studi
demonstr
import
la
volum
measur
ckc
dmvd
especi
among
dmvd
dog
result
suggest
categori
dog
rf
actual
show
la
dilat
howev
appar
use
la
ao
ratio
calcul
thu
potenti
lead
misdiagnosi
dmvd
stage
disclosur
report
conclus
result
show
red
blood
cell
abnorm
acanthocytosi
schizocytosi
common
dog
congenit
arteri
stenosi
thu
suggest
turbul
blood
flow
stenot
orific
induc
mechan
erythrocyt
damag
prospect
studi
need
better
document
find
elucid
precis
mechan
red
cell
damag
use
hematolyt
marker
eg
lactat
dehydrogenas
hemosiderinuria
etc
perform
human
patient
disclosur
report
use
torasemid
cat
congest
heart
failur
case
torasemid
loop
diuret
whose
safeti
efficaci
demonstr
dog
congest
heart
failur
chf
torasemid
character
longer
durat
action
potent
diuret
action
higher
bioavail
furosemid
howev
best
knowledg
studi
focus
efficaci
safeti
torasemid
cat
chf
object
retrospect
studi
therefor
describ
clinic
echocardiograph
characterist
document
clinic
outcom
cat
chf
treat
oral
torasemid
identifi
potenti
advers
event
relat
torasemid
administr
felin
popul
case
record
cat
treat
torasemid
review
studi
popul
consist
cat
median
age
year
interquartil
rang
iqr
maletofemal
ratio
major
domest
shorthair
cat
conclus
best
knowledg
first
descript
torasemid
use
cat
chf
drug
well
toler
case
case
seri
illustr
therapeut
interest
torasemid
cat
need
confirm
prospect
clinic
trial
disclosur
report
torasemid
loop
diuret
use
dog
congest
heart
failur
chf
altern
furosemid
studi
compar
furosemid
torasemid
dog
refractori
chf
spars
medic
databas
teach
hospit
review
search
dog
myxomat
mitral
valv
diseas
experienc
chf
receiv
torasemid
second
line
diuret
treatment
failur
furosemid
studi
group
dog
clinic
echocardiograph
radiograph
laboratori
find
annot
surviv
time
also
report
calcul
first
episod
chf
control
group
dog
dog
similar
cardiac
diseas
never
receiv
torasemid
also
select
data
collect
time
first
chf
first
examin
concomit
last
examin
avail
sex
distribut
equal
two
group
p
group
mix
breed
overrepres
besid
furosemid
torasemid
medic
use
control
cardiac
diseas
compar
admiss
differ
group
regard
age
p
bodi
weight
p
left
ventricular
diastol
intern
diamet
normal
bodi
weight
lviddn
p
left
atrial
aortic
ratio
la
ao
p
tricuspid
regurgit
peak
veloc
p
creatinin
p
potassium
p
serum
level
differ
preval
atrial
fibril
group
p
overal
number
decompens
experienc
dog
higher
studi
group
ae
compar
control
group
ae
p
last
examin
la
ao
higher
studi
group
compar
control
p
total
maxim
dose
furosemid
ae
mgkgday
studi
group
ae
mgkgday
control
group
p
initi
dose
torasemid
use
ae
mgkgday
compar
first
last
examin
within
two
group
bodi
weight
reduc
studi
group
p
la
ao
p
creatinin
p
increas
number
decompens
record
ae
ae
torasemid
initi
reduc
significantli
p
within
control
group
creatinin
increas
p
thirtysix
dog
die
cardiac
relat
caus
differ
surviv
two
group
p
median
surviv
day
studi
group
day
control
group
torasemid
appear
effect
second
line
diuret
chf
control
dog
myxomat
mitral
valv
diseas
offer
life
expect
compar
superior
furosemid
alon
disclosur
report
echocardiograph
predictor
first
onset
atrial
fibril
dog
myxomat
mitral
valv
diseas
disclosur
report
use
holterderiv
lorenz
plot
analysi
discrimin
differ
cardiac
rhythm
dog
lorenz
plot
lp
represent
heart
rate
variabl
summar
graphic
beattobeat
interv
record
holter
monitor
hm
use
lp
pattern
lpp
diagnos
rhythm
disturb
studi
peopl
littl
known
anim
aim
studi
analyz
graphic
featur
lp
evalu
diagnost
valu
lpp
identifi
arrhythmia
dog
hm
hour
valid
data
obtain
dog
sinu
rhythm
sr
differ
type
tachyarrhythmia
use
one
oper
blind
underli
rhythm
diagnosi
review
autom
analys
order
assess
hm
qualiti
manual
correct
softwar
misinterpret
make
rhythm
diagnosi
cardiac
rhythm
classifi
sr
sr
frequent
prematur
ectop
complex
sr
pec
either
supraventricular
ventricular
atrial
fibril
af
af
frequent
ventricular
prematur
complex
af
vpc
hm
lp
gener
softwar
use
rr
interv
lp
studi
qualit
quantit
distinct
lpp
creat
adapt
previous
recogn
pattern
human
diagnost
accuraci
lp
analysi
predict
underli
cardiac
rhythm
evalu
calcul
correspond
sensit
se
specif
sp
one
hundr
nineteen
hm
analyz
includ
sr
sr
pec
af
af
vpc
ten
distinct
lpp
identifi
comet
case
torpedo
case
yshape
case
diamond
case
diamond
central
silent
zone
case
twenti
holter
record
free
patholog
arrhythmia
ten
record
supraventricular
prematur
complex
spvc
complex
supraventricular
ectopi
ventricular
prematur
complex
vpc
complex
ventricular
ectopi
atrial
fibril
af
highgrad
second
degre
atrioventricular
block
avb
pace
rhythm
retrospect
evalu
util
onehour
lp
gener
beat
origin
color
code
pattern
found
arrhythmia
group
describ
arrhythmia
number
lp
shape
measur
specif
lp
pattern
identifi
common
cardiac
rhythm
dog
support
nonrandom
mechan
rhythm
understand
turn
may
advanc
understand
approach
diagnosi
treatment
arrhythmia
dog
disclosur
report
first
case
success
transcathet
pulmonari
valv
implant
dog
sever
pulmonari
regurgit
kg
clientown
beagl
dog
refer
followup
visit
percutan
balloon
valvuloplasti
perform
month
correct
sever
type
valvular
pulmon
stenosi
dopplerderiv
peak
transstenot
pressur
gradient
dp
mmhg
procedur
mmhg
hour
later
time
present
dog
letharg
echocardiographi
reveal
mild
pulmon
stenosi
dp
mmhg
associ
sever
pulmonari
regurgit
proxim
width
ratio
assess
colorflow
doppler
mode
secondari
major
right
ventricular
right
atrial
dilat
despit
medic
therapi
worsen
right
heart
dilat
observ
two
month
later
transcathet
pulmonari
valv
implant
use
valv
prestent
system
decid
contrastenhanc
cardiacg
comput
tomographi
scan
perform
one
week
surgeri
accur
assess
pulmonari
coronari
arteri
morpholog
perform
measur
pulmonari
annulu
right
ventricular
outflow
tract
maxim
diamet
aneurysm
pulmonari
trunk
plicat
arteri
wall
confirm
initi
minim
invas
approach
via
left
jugular
vein
selding
techniqu
unsuccess
due
size
outer
diamet
deliveri
system
therefor
convert
left
intercost
thoracotomi
transventricular
deliveri
approach
prep
time
neck
area
case
convers
dog
recov
unev
discharg
day
procedur
right
heart
dilat
disappear
within
day
dog
still
well
three
month
valv
implant
case
illustr
pulmonari
transcathet
stent
valv
implant
technic
feasibl
dog
sever
pulmonari
valv
diseas
stent
valv
altern
openheart
surgeri
sourc
tremend
develop
human
medicin
foreseen
veterinari
cardiolog
way
benefit
revolut
disclosur
report
melodi
valv
kindli
offer
medtron
minnesota
usa
normal
aortic
annulu
dimens
boxer
dog
accord
sex
bodi
weight
claretti
c
quintavalla
crosara
c
bussadori
clinica
veterinaria
gran
sasso
milano
itali
degli
studi
di
parma
parma
itali
regard
result
objectifi
aortic
annulu
dimens
increas
increas
bw
valu
obtain
test
sex
use
ttest
weight
quartil
sex
weight
interact
anova
test
bonferroni
correct
multipl
comparison
case
signific
level
p
lower
case
exclud
analysi
measur
annulu
less
mm
mostli
femal
p
averag
weight
lower
kg
se
p
compar
case
analys
conclus
say
bw
base
confid
interv
may
help
screen
dog
heart
diseas
discrimin
normal
aortic
annulu
dimens
disclosur
report
inflammatori
oxid
stress
marker
associ
surviv
canin
cardiovascular
patient
marker
analys
use
cox
proportionalhazard
model
hazard
ratio
hr
confid
interv
ci
correspond
p
valu
calcul
valu
p
consid
signific
logrank
test
perform
surviv
time
respect
diseas
type
mvd
dcm
signific
found
p
although
dog
mvd
median
day
averag
longer
surviv
time
dcm
median
day
univari
cox
proportionalhazard
model
perform
everi
marker
follow
marker
significantli
associ
surviv
hr
ci
p
valu
wbc
interpret
result
increas
neut
unit
l
increas
risk
death
increas
gpx
ug
haemoglobin
unit
decreas
risk
death
furthermor
cox
model
fit
isachc
addit
marker
covari
sinc
surviv
signific
respect
isachc
class
logrank
test
p
model
effect
marker
decreas
howev
gpx
neut
remain
significantli
associ
surviv
result
suggest
increas
inflamm
decreas
activ
antioxid
enzym
gpx
associ
decreas
surviv
canin
mvd
dcm
patient
even
isachc
consid
model
may
conclud
select
inflammatori
oxid
stress
marker
predict
surviv
disclosur
report
right
heart
remodel
brachycephal
obstruct
airway
syndrom
boa
fb
right
ventricl
larger
compar
asymptomat
fb
suggest
remodel
right
heart
higher
tv
e
veloc
might
suggest
higher
right
atrial
pressur
lower
st
might
suggest
decreas
right
ventricular
systol
function
boa
fb
lower
vena
cava
collaps
index
boa
fb
compar
asymptomat
fb
might
due
higher
right
atrial
pressur
boa
dog
breed
specif
refer
rang
recommend
evalu
right
heart
echocardiograph
differenti
boa
asymptomat
brachycephal
dog
seem
challeng
disclosur
report
effect
eleven
appar
healthi
cat
use
studi
cat
deem
healthi
basi
clinic
examin
cardiac
auscult
noninvas
blood
pressur
measur
blood
work
convent
echocardiographi
includ
rv
wall
thick
diastol
rv
intern
diamet
diastol
systol
short
axi
view
rv
fraction
shorten
fs
rv
area
diastol
systol
apic
view
fraction
area
chang
tricuspid
annular
plane
systol
excurs
tissu
doppler
imag
deriv
tricuspid
annulu
systol
wave
veloc
ra
maxim
minim
diamet
ra
fs
cat
scan
follow
standard
techniqu
gentli
manual
restrain
cat
scan
total
eight
time
differ
time
point
two
subsequ
day
first
day
cat
scan
time
hour
follow
day
cat
receiv
echocardiographi
time
hour
singl
dose
mg
pimobendan
administ
oral
none
cat
show
advers
reaction
drug
data
obtain
differ
time
point
day
time
day
time
day
time
pimobendan
administr
pool
togeth
statist
comparison
perform
two
global
time
point
pimobendan
administr
among
test
variabl
differ
pimobendan
administr
particular
heart
rate
p
rv
fs
p
rv
fraction
area
chang
p
tissu
doppler
imag
deriv
tricuspid
annulu
systol
wave
veloc
p
increas
significantli
side
rv
intern
diamet
diastol
p
systol
p
ra
maxim
p
minim
p
diamet
reduc
pimobendan
administr
pimobendan
appear
safe
administ
healthi
cat
abl
induc
signific
increas
rv
ra
systol
properti
disclosur
report
ambulatori
electrocardiographi
serial
cardiac
specif
troponin
measur
twentytwo
dog
envenom
european
adder
vipera
beru
aim
studi
describ
preval
natur
arrhythmia
detect
dog
first
fortyeight
hour
post
envenom
investig
associ
arrhythmia
grade
serum
cardiac
specif
troponin
ctni
marker
myocardi
cell
injuri
snakebit
sever
score
ss
score
present
twentytwo
dog
bitten
vipera
beru
includ
prospect
cohort
studi
ambulatori
ecg
aecg
place
dog
present
hour
arrhythmia
grade
assign
base
frequenc
sever
arrhythmia
aecg
record
modifi
previous
describ
grade
system
serum
obtain
present
h
h
h
day
post
bite
ctni
analysi
ss
score
record
upon
admiss
use
previous
describ
grade
system
four
dog
ss
score
mild
ss
score
moder
sever
observ
fourteen
four
dog
respect
seventeen
dog
rais
ctni
concentr
minimum
one
time
point
ten
dog
elev
ctni
present
h
h
h
nine
dog
arrhythmia
grade
nonpatholog
thirteen
dog
develop
patholog
arrhythmia
grade
arrhythmia
ventricular
origin
sever
complex
ventricular
arrhythmia
grade
observ
dog
grade
arrhythmia
persist
day
two
concentr
ctni
present
significantli
higher
dog
develop
patholog
arrhythmia
compar
p
one
dog
patholog
arrhythmia
normal
ctni
concentr
time
point
ss
score
significantli
associ
arrhythmia
grade
initi
ctni
concentr
peak
ctni
day
one
studi
show
rais
ctni
concentr
ventricular
arrhythmia
common
follow
vipera
beru
envenom
dog
highlight
valu
prolong
ecg
monitor
patient
dog
develop
patholog
arrhythmia
could
differenti
base
ss
score
normal
ctni
concentr
rule
develop
patholog
arrhythmia
studi
disclosur
report
respect
epss
significantli
higher
measur
rpsa
rpla
view
p
mean
differ
ae
mm
epss
measur
obtain
rpla
rpsa
view
might
use
interchang
greater
later
torsion
movement
heart
obtain
short
axi
view
respiratori
phase
cardiac
cycl
might
reason
higher
valu
epss
obtain
rpsa
view
find
could
taken
account
adequ
echocardiograph
evalu
diagnosi
studi
larger
canin
popul
warrant
confirm
result
disclosur
report
investig
report
effect
long
flightprolong
air
travel
dog
heart
mitral
valv
diseas
takahashi
takeuchi
uechi
jasmin
veterinari
cardiovascular
medic
center
kanagawa
japan
effect
long
air
travel
anim
heart
diseas
investig
studi
assess
chang
physic
condit
anim
mitral
valv
diseas
flight
databas
veterinari
clinic
retrospect
screen
dog
presumpt
diagnosi
ami
suspicion
base
echocardiograph
region
wall
motion
abnorm
hypokinesia
akinesia
dyskinesia
initi
present
followup
andor
elev
serum
cardiac
troponin
ctni
without
obviou
caus
thirteen
dog
presumpt
diagnosi
ami
identifi
histori
clinic
data
ctni
electrocardiograph
echocardiograph
find
review
data
express
median
rang
three
thirteen
case
west
higland
white
terrier
median
age
year
bodi
weight
kg
factor
predispos
thrombosi
identifi
dog
postop
neoplast
immunemedi
hemolyt
anemia
hypothyroid
common
clinic
find
arrhythmia
normal
heart
rate
tachycard
bradycard
weak
syncop
ctni
sever
elev
ngl
rang
test
case
identifi
ecg
abnorm
ventricular
arrhythmia
degre
atrioventricular
block
sinu
rhythm
right
axi
deviat
st
segment
abnorm
present
dog
region
wall
motion
abnorm
affect
variou
myocardi
segment
left
ventricular
free
wall
apex
interventricular
septum
observ
first
exam
followup
visit
dog
abnorm
segment
appear
thin
hyperecho
dog
followup
echocardiogram
systol
dysfunct
observ
dog
present
followup
three
dog
surviv
discharg
postmortem
exam
perform
dog
show
sever
extens
myocardi
necrosi
hemorrhag
andor
replac
myocardi
tissu
fibrou
tissu
histopatholog
largest
case
seri
dog
presumpt
diagnosi
ami
although
ami
remain
rare
condit
consid
differenti
diagnosi
dog
predispos
condit
arrhythmia
elev
ctni
andor
segment
wall
motion
abnorm
howev
find
may
becom
appar
acut
phase
disclosur
report
koizumi
hiros
n
tsuchiya
k
otsuji
teikyo
univers
scienc
tokyo
japan
teikyo
univers
scienc
tokyo
japan
accur
clinic
nutrit
assess
bodi
condit
score
dog
easi
subject
method
therefor
make
object
nutrit
assess
examin
morphometr
method
result
high
correl
coeffici
r
occur
length
sternal
process
sciatic
process
ideal
bodi
weight
ibw
studi
present
calip
estim
ibw
measur
length
appli
find
calip
prepar
length
ibw
appear
simultan
ideal
bodi
weight
calip
weight
correspond
either
bodi
fat
percentag
length
sternal
process
sciatic
process
measur
clinic
veterinarian
use
calip
ten
dog
visit
anim
hospit
use
veterinarian
ask
assess
ibw
determin
callip
differ
ibw
base
experi
correl
coeffici
bodi
length
ibw
r
ibw
correspond
bodi
fat
percentag
hand
correl
coeffici
two
r
ibw
correspond
bodi
fat
percentag
clinic
veterinarian
also
repli
questionnair
survey
bodi
weight
correspond
bodi
fat
percentag
closer
ibw
assess
experi
bodi
fat
percentag
bc
scale
correspond
median
suggest
japanes
clinic
veterinarian
evalu
nutrit
assess
set
ibw
higher
found
life
span
extend
dietari
restrict
dog
point
view
veterinarian
set
ibm
lower
assess
result
also
larg
differ
correl
coeffici
measur
bodi
length
measur
clinic
veterinarian
differ
caus
larg
variat
bodi
length
measur
veterinarian
regard
may
necessari
creat
manual
bodi
length
measur
dog
improv
measur
accuraci
disclosur
report
hypothyroid
associ
extra
hepat
biliari
diseas
dog
retrospect
casecontrol
studi
aim
studi
evalu
incid
extrahepat
biliari
diseas
hypothyroid
dog
record
dog
diagnos
hypothyroid
examin
presenc
absenc
extrahepat
biliari
diseas
mucocel
colecist
colelitiasi
gallblad
mass
forti
nine
dog
serum
elev
gamma
glutamyl
transferas
alkalin
phosphatas
alanin
aminotransferas
total
bilirubin
enlarg
gallbladd
fine
striat
immobil
stellat
bile
pattern
thicken
gallbladd
wall
biliari
sludg
hyperechogen
gallbladd
mass
older
dog
small
breed
overrepres
dog
present
nonspecif
clinic
sign
vomit
anorexia
lethargi
diarrhea
andor
fever
thirti
four
dog
diagnos
extrahepat
biliari
diseas
gallbladd
mucocel
n
dog
cholelitiasi
n
dog
colecyst
n
dog
upon
ultrasound
examin
histologicmacroscop
evalu
cultur
sensit
test
incid
gallbladd
mucocel
found
highest
follow
cholelitiasi
colecyst
studi
suggest
hyporthiroid
dog
present
acut
ill
laboratori
evid
hepatobiliari
diseas
undergo
evalu
presenc
extrahepat
biliari
diseas
biliari
mucocel
cholelitiasi
colecyst
disclosur
report
aim
retrospect
studi
describ
planar
spect
imag
result
canin
thyroid
tumor
compar
thorac
radiographi
detect
thorac
metastas
thyroid
scintigraphi
avail
dog
present
clinic
present
surgic
resect
dog
confirm
diagnosi
thyroid
neoplasia
base
histopatholog
cytolog
andor
abnorm
radionuclid
accumul
thirtynin
dog
unilater
tumor
bilater
ectop
tumor
one
dog
ectop
unilater
tumor
dog
bilater
mass
ectop
tumor
dog
tumor
extent
hinder
accur
local
uptak
rel
parotid
salivari
gland
thyroidsalivari
ts
ratio
increas
dog
median
ts
ratio
decreas
dog
median
ts
ratio
compar
salivari
gland
median
ts
ratio
dog
dog
multipl
mass
uptak
extent
differ
level
variou
mass
homogen
uniform
uptak
pattern
present
dog
heterogen
uptak
pattern
dog
dog
multipl
mass
variou
uptak
pattern
present
thirtyon
dog
euthyroid
hyperthyroid
hypothyroid
major
hyperthyroid
dog
dog
increas
radionuclid
uptak
spect
imag
avail
dog
dog
spect
reveal
tracer
uptak
level
thorax
suggest
distant
metastas
dog
thorac
radiograph
perform
metastas
detect
dog
major
dog
scintigraphi
perform
use
dog
scintigram
perform
dog
spect
imag
reveal
thorac
metastasi
clearli
identifi
studi
first
describ
planar
spect
imag
larg
number
dog
thyroid
tumor
result
suggest
spect
imag
superior
thorac
radiographi
detect
metastas
disclosur
report
ultrasonograph
evalu
adren
gland
thick
healthi
dog
dog
hyperadrenocortic
ultrasonographi
commonli
use
diagnost
workup
dog
hyperadrenocortic
hac
support
diagnosi
rule
nonadren
diseas
help
differenti
type
hac
studi
establish
refer
rang
ultrasonograph
adren
gland
thick
base
weight
categori
howev
use
rang
dog
hac
evalu
therefor
four
weight
categori
use
order
avoid
larg
variat
weight
within
group
aim
studi
establish
new
refer
rang
adren
gland
thick
healthi
dog
evalu
sensit
rang
detect
adrenomegali
dog
hac
describ
ultrasonograph
adren
find
dog
hac
total
clinic
healthi
dog
prospect
includ
adren
thick
sagitt
plane
measur
dog
use
follow
weight
categori
dog
kg
dog
kg
dog
kg
dog
kg
refer
rang
percentil
left
adren
gland
maximum
thick
follow
mm
dog
kg
mm
dog
kg
mm
dog
kg
mm
dog
kg
wherea
right
adren
gland
maximum
thick
follow
mm
dog
kg
mm
dog
kg
mm
dog
kg
mm
dog
kg
addit
dog
hac
retrospect
includ
overal
sensit
ultrasonographi
detect
adrenomegali
use
four
weight
categori
left
right
adren
gland
thick
although
dog
hac
ultrasonograph
find
consist
either
pituitaryor
adrenaldepend
hac
equivoc
adren
asymmetri
common
find
dog
hac
occur
dog
disclosur
report
ultrasonograph
accuraci
primari
adren
insuffici
retrospect
cohort
studi
dog
g
ledda
c
tullio
costa
l
angeloni
caldin
san
marco
veterinari
clinic
veggiano
padova
itali
clinic
relev
ultrasonographi
canin
primari
adren
insuffici
evalu
studi
retrospect
cohortstudi
evalu
larg
canin
popul
refer
facil
diagnost
perform
ultrasonograph
assess
adren
gland
dimens
distinguish
dog
primari
adren
insuffici
expos
group
dog
without
primari
adren
insuffici
non
expos
group
group
includ
consecut
clientown
dog
diagnos
primari
adren
insuffici
base
signal
histori
clinicopatholog
test
cbc
serum
biochemistri
urinalys
acth
stimul
test
result
includ
basal
plasma
acth
serum
aldosteron
preand
postacth
determin
group
includ
dog
without
primari
adren
insuffici
individu
match
group
dog
breed
sex
sexual
statu
age
ae
month
reduc
technolog
bia
group
dog
select
took
place
contigu
time
period
group
dog
recruit
dog
receiv
mitotan
trilostan
steroid
medic
aceinhibitor
clinic
evalu
exclud
group
studi
show
group
sonograph
adren
gland
measur
significantli
lower
compar
group
strengthen
role
adren
ultrasonographi
reliabl
screen
test
dog
suspect
primari
adren
insuffici
disclosur
report
effect
sampl
dilut
free
depend
physiolog
state
analyt
method
bind
capac
human
sera
thyroxin
absenc
condit
would
reduc
thyroid
bind
capac
tbc
eg
nonthyroid
ill
nti
pregnanc
free
fatti
acid
sera
may
dilut
without
affect
measur
result
free
use
appropri
analyt
techniqu
equilibrium
dialysi
howev
condit
associ
reduc
tbc
result
may
decreas
dilut
low
free
dilut
profil
use
determin
valid
free
method
human
dog
cat
tbc
much
lower
clear
equival
dilut
would
would
caus
decreas
measur
free
analyt
impact
physiolog
state
includ
nti
investig
analyt
method
less
resist
effect
sampl
dilut
may
suscept
interfer
lower
tbc
eg
nti
consequ
may
gener
diagnost
mislead
result
surplu
serum
sampl
dog
cat
select
physiolog
state
analys
equilibrium
dialysi
method
equilibrium
dialysi
antech
laboratori
analogu
chemiluminesc
method
immulit
veterinari
free
siemen
without
dilut
hepe
buffer
sampl
includ
normal
cat
nmoll
hyperthyroid
cat
suspect
canin
nti
normal
tsh
suspect
felin
nti
felin
lipaemia
percentag
decreas
could
calcul
sampl
report
limit
assay
howev
sampl
decreas
dilut
compar
decreas
dilut
sampl
percentag
decreas
could
calcul
steepest
declin
concentr
beyond
suspect
felin
nti
sampl
least
declin
normal
cat
veterinari
sampl
suscept
effect
sampl
dilut
therefor
condit
reduc
tbc
report
human
sera
method
suscept
dilut
method
human
physiolog
state
demonstr
greater
declin
measur
serial
dilut
studi
could
determin
whether
comparison
undilut
dilut
result
within
individu
sampl
could
differenti
nti
thyroid
dysfunct
diagnost
challeng
case
disclosur
report
nationwid
laboratori
consult
dechra
veterinari
product
consult
surviv
cat
diabet
mellitu
chronic
pancreat
preliminari
studi
case
associ
criteria
st
test
univari
analysi
log
rank
test
signific
set
p
median
age
studi
popul
year
recruit
cat
previous
overweight
weight
loss
frequent
biochem
abnorm
includ
elev
liver
enzym
hyperproteinemia
hyperbilirubinemia
hypokalemia
median
surviv
time
mst
day
mortal
rate
cat
least
one
us
find
compat
biliari
tract
diseas
significantli
higher
mst
also
time
shorter
p
studi
criteria
associ
st
longterm
outcom
cat
suffer
cp
dm
may
favor
howev
mst
cat
diagnos
concurr
diseas
least
one
ultrasonograph
find
compat
biliari
tract
diseas
shorter
cat
without
biliari
lesion
us
disclosur
report
prospect
baselinecontrol
multicentr
clinic
field
studi
evalu
efficaci
sid
administ
prozinc
insulin
dog
diagnos
dm
line
alivecriteria
seven
followup
visit
occur
period
day
veterinarian
permit
switch
twicedaili
bid
treatment
basi
clinic
sign
maximum
blood
glucos
bg
minimum
bg
obtain
bgcurv
satisfactori
diabet
control
defin
improv
glycem
laboratori
paramet
clinic
sign
thirti
dog
enrol
withdrew
earli
n
consent
withdrawn
n
complianc
n
lack
improv
overal
dog
show
satisfactori
diabet
control
day
sid
treat
dog
bid
treat
dog
dog
satisfactori
control
achiev
sid
bid
insulin
pretreat
dog
sid
bid
therefor
hypothesis
pituitari
tumor
size
brachycephal
morphotyp
associ
dog
cd
unit
referr
hospit
retrospect
evalu
inclus
criteria
clinic
sign
suggest
hyperadrenocortic
hyperadrenocortic
confirm
least
endocrin
test
brain
abdomin
ct
scan
indic
pituitari
origin
macroadenoma
diagnos
pituitari
heightbrain
area
ratio
pb
mm
skull
index
si
skull
width
calcul
differenti
bd
nonbrachycephal
dog
nbd
si
accuraci
distinguish
bd
nbd
breed
test
calcul
area
curv
auc
receiv
oper
characterist
roc
curv
optim
cutoff
select
base
valu
youden
index
correl
si
pb
evalu
use
spearman
test
hundr
twenti
dog
includ
median
rang
age
first
clinic
sign
year
accord
breed
bd
nbd
unclassifi
auc
confid
interv
roc
curv
si
distinguish
bd
nbd
use
cutoff
sensibl
specif
si
morphotyp
distinct
brachycephal
morphotyp
quantit
evalu
associ
pituitari
tumor
size
dog
cd
result
contrast
previou
studi
focus
pituitari
sampl
collect
mainli
necropsi
embrac
dog
without
cd
sole
inclus
dog
cd
studi
may
explain
discrep
possibl
predisposit
bd
undifferenti
rapidli
grow
nonfunct
pituitari
tumor
remain
assess
disclosur
report
studi
investig
frequenc
circi
system
inflammatori
respons
syndrom
sir
dog
associ
circi
hypotens
mortal
singlecent
prospect
studi
perform
decemb
may
ethic
approv
n
sir
diagnos
dog
present
least
two
follow
criteria
admiss
icu
rectal
temperatur
c
c
heart
rate
bpm
respiratori
rate
bpm
white
blood
cell
x
x
band
neutrophil
dog
exclud
histori
suspect
adren
ill
receiv
glucocorticoid
within
previou
hour
long
act
formul
within
previou
month
drug
known
affect
hypothalamicpituitaryadren
axi
acth
stimul
test
perform
dog
immedi
inclus
studi
dog
cortisol
differ
postacth
stimul
basal
cortisol
support
diagnosi
circi
noninvas
blood
pressur
ii
ramsey
medic
measur
dog
hypotens
defin
mean
arteri
pressur
map
mmhg
inform
surviv
day
admiss
collect
dog
divid
survivor
nonsurvivor
dog
euthan
financi
reason
exclud
dagostinopearson
test
test
data
normal
age
basal
cortisol
map
compar
dog
without
circi
cortisol
basal
cortisol
map
compar
survivor
nonsurvivor
use
ttest
fisher
exact
test
analys
pvalu
consid
signific
twentyon
dog
met
inclus
criteria
enrol
studi
circi
hypotens
detect
dog
respect
age
map
basal
cortisol
hypotens
similar
dog
without
circi
dog
die
within
day
admiss
independ
factor
hypotens
basal
hypercortisolemia
associ
higher
risk
death
p
p
respect
circi
seem
occur
frequent
sir
dog
howev
presenc
hypotens
basal
hypercortisolemia
associ
increas
mortal
risk
disclosur
report
prednisolon
induc
hyperglycaemia
diabet
mellitu
cat
nerhagen
h
moberg
b
glanemann
royal
veterinari
colleg
hatfield
unit
kingdom
prednisolon
commonli
use
drug
cat
potenti
advers
effect
includ
glucocorticoidinduc
hyperglycaemia
gih
diabet
mellitu
gidm
predispos
factor
develop
overal
incid
rate
gih
gidm
current
unknown
aim
studi
evalu
incid
rate
gih
gidm
evalu
predispos
risk
factor
gih
gidm
cat
receiv
prednisolon
electron
record
tertiari
referr
centr
search
cat
receiv
prednisolon
dose
mgkgday
week
durat
followup
data
avail
week
studi
period
januari
june
total
cat
includ
studi
cat
cat
diagnos
gih
gidm
nine
cat
develop
gidm
requir
insulin
therapi
euthan
due
diabet
ketoacidosi
remain
cat
identifi
gih
none
requir
insulin
treatment
twelv
cat
develop
gih
gidm
within
month
initi
prednisolon
therapi
remain
two
cat
develop
gidm
month
four
cat
develop
gidmgih
year
age
comparison
cat
develop
gih
gidm
show
statist
differ
baselin
preprednisolon
blood
glucos
presenc
glucosuria
bodi
weight
bodi
condit
score
trend
toward
cat
develop
gidmgih
receiv
mgkg
start
dose
seen
howev
statist
signific
p
conclud
tertiari
referr
popul
approxim
cat
receiv
prednisolon
develop
gih
gidm
atrend
toward
cat
receiv
higher
dose
prednisolon
like
develop
gihgidm
disclosur
report
accuraci
precis
insulin
administr
use
human
veterinari
peninjector
syring
e
malerba
f
fracassi
f
del
baldo
golinelli
ceccherini
barbarossa
univers
bologna
ozzano
dellemilia
itali
mani
diabet
dog
cat
requir
small
dose
insulin
may
administ
syring
peninjector
devic
import
small
dose
administ
accur
magnitud
potenti
dosag
error
appreci
aim
studi
compar
accuraci
precis
insulin
syring
pen
devic
determin
accur
precis
insulin
dose
deliv
u
dose
dispens
time
five
solostar
contain
insulin
glargin
five
flexpen
contain
insulin
detemir
five
kwikpen
contain
insulin
lispro
five
juniorstar
contain
insulin
glargin
five
vetpen
u
five
vetpen
u
contain
insulin
caninsulin
five
veterinarian
use
ml
uml
insulin
syring
dose
weigh
immedi
use
precis
balanc
resolut
g
intend
deliv
dose
compar
peninjector
tend
deliv
less
insulin
intend
dose
underdosag
invers
proport
dose
accuraci
differ
intend
deliv
dose
signific
use
juniorstar
vetpen
u
insulin
dosag
u
use
ml
insulin
syring
intend
dose
significantli
overdos
attempt
deliv
u
respect
significantli
underdos
u
respect
use
uml
syring
intend
dose
significantli
overdos
attempt
deliv
u
respect
six
peninjector
ml
uml
insulin
syring
coeffici
variat
precis
diminish
increas
dose
insulin
precis
six
peninjector
convers
precis
use
ml
u
ml
syring
insulin
dosag
u
respect
precis
improv
insulin
dosag
u
devic
except
juniorstar
vetpen
u
unaccept
inaccur
deliv
u
dose
insulin
accuraci
improv
higher
dose
dispens
deliveri
u
dose
result
suffici
accur
compar
intend
dose
use
uml
syring
conclus
peninjector
tend
accur
lower
dosag
syring
tend
accur
higher
dosag
disclosur
report
ultrasonographi
sensit
method
measur
adren
gland
size
reliabl
indic
adren
gland
size
maximum
diamet
caudal
pole
thick
howev
pituitari
hyperadrenocortic
increas
preval
smallbre
dog
inform
scientif
literatur
correl
bodyweight
age
size
adren
gland
dog
gener
upper
limit
mm
recent
one
retrospect
studi
suggest
mm
cutoff
valu
dog
kg
anoth
found
age
depend
size
aim
examin
adren
gland
thick
dog
retrospect
studi
result
dog
healthi
diagnos
pituitari
hyperadrenocortic
use
diagnosi
pituitari
hyperadrenocortic
base
clinic
symptom
dexamethason
supress
test
bodyweight
rang
kg
age
rang
year
correl
bodyweight
age
adren
gland
thick
analys
healthi
dog
n
subgroup
kg
n
compar
dog
diagnos
pituitari
hyperadrenocortic
kg
n
data
analysi
descript
statist
correlationand
regressionanalysi
hypothesistest
rocanalysi
use
p
signific
correl
adren
gland
size
bodyweight
entir
rang
kg
signific
correl
subgroup
dog
kg
age
depend
found
signific
differ
adren
gland
size
dog
kg
weight
adren
gland
size
normal
distribut
group
dog
weight
less
kg
thick
left
adren
gland
caudal
pole
mm
right
adren
gland
size
mm
normal
rang
left
adren
gland
size
mm
mm
right
one
ci
compar
data
healthi
dog
dog
pituitari
hyperadrenocortic
result
mm
optim
upper
cutoff
valu
dog
kg
valu
provid
sensit
specif
left
adren
gland
sensit
specif
right
one
diagnos
pituitari
hyperadrenocortic
use
ultrasonographi
differ
result
left
right
side
caus
difficult
imag
right
side
organ
result
strenghten
find
avail
literatur
regard
sizerang
bodyweight
correl
could
find
age
depend
disclosur
report
retrospect
studi
case
canin
nasal
polyposi
treat
endoscop
e
bottero
p
ruggiero
f
raponi
e
mussi
gruppo
endovet
italia
ceva
itali
nasal
polyposi
patholog
unknown
etiolog
rare
describ
canin
speci
provok
chronic
clinic
symptom
includ
discharg
sneez
stertor
diagnosi
base
diagnost
imag
endoscop
aspect
histolog
exam
nasal
biopsi
rhinotomi
despit
possibl
surgic
complic
possibl
relaps
date
first
choic
treatment
retrospect
studi
look
case
nasal
polyp
year
dog
princip
mix
breed
male
femal
adult
elderli
patient
less
year
old
present
sneez
stertor
nasal
discharg
clinic
exam
show
case
frontonas
deform
clear
presenc
newli
form
polypoid
tissu
nostril
open
nasolacrim
duct
xray
computer
tomographi
reveal
abnorm
compat
newli
form
endonas
tissu
case
respect
anterograd
rhinoscopi
reveal
newli
form
tissu
smooth
transluc
surfac
pink
color
elast
consist
complet
occupi
nasal
meatu
dog
nasopharynx
well
histolog
exam
show
exophyt
structur
bound
respiratori
epithelium
often
hyperplast
squamou
metaplasia
stroma
rule
myxoid
fibrillari
surround
serou
mucu
gland
present
highli
variabl
quantiti
corium
inflammatori
infiltr
polymorph
stroma
show
area
hyperplasia
mesenchym
andor
hyperplasia
dilat
vascular
system
seriou
dysplasia
observ
case
twelv
subject
underw
medic
treatment
underw
medic
treatment
endoscop
debulk
mix
techniqu
extern
grasp
forcep
plu
diod
laser
w
continu
rhythm
fiber
patient
underw
surgic
rhinotomi
dog
treat
prednisolon
despit
clinic
improv
constant
relaps
subject
underw
endoscop
debulk
show
clinic
improv
symptom
absenc
relaps
month
case
month
case
conclus
nasal
polyposi
infrequ
patholog
present
seriou
clinic
symptom
even
young
subject
tend
relaps
therapi
endoscop
debulk
less
invas
altern
tradit
surgeri
even
though
prevent
relaps
medium
long
term
disclosur
report
addit
hypophosphatemia
metabol
acidosi
common
complic
chronic
kidney
diseas
cat
use
standard
approach
metabol
acidosi
diagnos
base
concentr
hco
pco
arteri
blood
aim
studi
assess
possibl
use
valu
anion
gap
ag
correct
anion
gap
ag
corr
chlorid
sodium
ratio
cl
na
diagnosi
metabol
acidosi
studi
carri
cat
sex
year
old
control
c
group
consist
healthi
cat
cat
diagnos
ckd
base
blood
creatinin
sdma
urea
level
includ
studi
group
cat
ckd
divid
four
group
ii
iii
iv
depend
iri
stage
arteri
venou
blood
collect
anim
paramet
acidbas
balanc
abb
ph
pco
hco
measur
arteri
blood
concentr
na
k
cl
hco
albumin
measur
venou
blood
base
obtain
result
valu
ag
ag
corr
cl
na
calcul
use
follow
formula
ag
na
k
cl
hco
ag
corr
ag
gl
alb
akt
gl
gl
upper
refer
limit
serum
albumin
cat
alb
akt
measur
albumin
concentr
studi
cat
cl
na
cl
na
analysi
arteri
blood
reveal
presenc
metabol
acidosi
cat
group
iv
remain
group
abb
paramet
within
refer
rang
valu
ag
ag
corr
cat
group
ii
iii
iv
significantli
lower
group
c
cl
na
valu
cat
group
ii
iii
iv
significantli
higher
cat
group
c
follow
conclus
drawn
base
obtain
result
abb
analysi
base
classic
model
enabl
detect
abb
disturb
cat
stage
iv
kidney
diseas
analysi
ag
ag
corr
clna
valu
enabl
diagnosi
abb
disturb
cat
stage
ii
iii
iv
kidney
diseas
analysi
chang
ion
concentr
ckd
accur
tool
diagnos
abb
disturb
classic
model
disclosur
report
evalu
differ
clean
method
bacteri
decontamin
felin
aerosol
chamber
purpos
chamber
rc
chamber
rc
cegla
medizintechnik
n
aerokat
ak
trudel
medic
intern
n
evalu
standard
bacteri
contamin
perform
use
pseudomonasaeruginosasuspens
previous
establish
serial
dilut
aliquot
ml
appli
pipett
three
predefin
locat
chamber
hour
chamber
cleanedsteril
accord
manufactur
instruct
rc
includ
clean
procedur
use
special
bag
microwav
minut
watt
n
placement
boil
water
minut
n
ak
place
lukewarm
water
clean
deterg
minut
n
air
dri
chamber
swab
taken
three
defin
area
chamber
mask
valv
chamber
appli
muellerhintonagar
incub
hour
three
clean
protocol
bacteri
growth
could
detect
chamber
test
studi
show
manufactur
recommend
clean
procedur
adequ
bacteri
decontamin
felin
inhal
chamber
achiev
disclosur
report
evalu
clinicopatholog
alter
includ
leukocyt
ratio
surviv
rate
dog
imha
transfus
transfus
retrospect
studi
imhat
patient
show
sever
diseas
accord
tss
greater
acut
inflammatori
condit
coagul
defect
high
death
rate
among
imhat
patient
day
relat
critic
condit
probabl
desir
benefit
blood
transfus
nt
reach
howev
link
blood
transfus
relat
wors
clinic
sign
imhat
patient
could
ruledout
final
leukocyt
ratio
dog
affect
imha
assess
first
time
far
proven
use
marker
acut
inflamm
could
prognost
valu
disclosur
report
express
serum
exosom
mirna
dog
natur
infect
leishmania
infantum
wherea
total
protein
ldl
significantli
increas
affect
compar
healthi
dog
shown
experiment
studi
perform
mice
signific
decreas
express
seen
leishmania
infect
dog
compar
healthi
one
studi
suggest
alter
circul
lipoprotein
associ
low
express
exosom
indic
liver
dysfunct
dog
natur
affect
leishmania
infantum
disclosur
report
anemia
hypoferremia
cat
hepatopancreat
intestin
involv
sixtythre
cat
met
inclus
criteria
enrol
studi
patient
divid
two
group
accord
ultrasonograph
sign
cat
concurr
involv
pancrea
liver
intestin
group
n
cat
concurr
involv
two
organ
pancrea
liver
intestin
group
b
n
differ
group
statist
investig
mannwhitney
test
iron
unpair
ttest
anemia
paramet
categor
data
analyz
fisher
exact
test
twentynin
cat
show
anemia
frequent
mild
hct
moder
hct
normocyticnormochrom
nonregen
microcytosi
infrequ
find
two
cat
microcytosi
anemia
hypoferremia
concurr
hypoferremia
serum
iron
mcgdl
present
cat
concurr
anemia
observ
cat
without
associ
two
paramet
hypoferremia
anemia
sever
group
median
serum
iron
mcgdl
mean
rbc
p
group
b
median
serum
iron
mcgdl
mean
rbc
moreov
anemia
frequent
present
group
p
roc
curv
use
determin
optim
cutoff
serum
iron
identifi
cat
hepatopancreat
intestin
involv
cat
serum
iron
lower
mcgdl
frequent
belong
group
sensit
specif
p
plausibl
hypothesi
origin
anemia
presenc
chronic
diseas
decreas
serum
iron
level
may
consid
marker
inflamm
enteropath
cat
hepatopancreat
intestin
inflamm
may
caus
sever
hypoferremia
erythropoiesi
suppress
anemia
disclosur
report
lung
ultrasound
find
dog
use
region
base
protocol
vet
blue
versu
entir
thorax
scan
thirtyfour
dog
variou
clinic
problem
cardiac
diseas
cardiorespiratori
comorbid
respiratori
diseas
noncardiorespiratori
problem
recruit
prospect
studi
dog
uncoop
critic
ill
toler
two
scan
protocol
exclud
scan
perform
singl
clinician
complet
lu
train
session
thorax
dog
first
scan
vet
blue
protocol
et
without
hair
clip
compar
vet
blue
protocol
b
line
significantli
frequent
et
vs
p
assess
sever
b
line
absent
rare
numer
confluent
show
sever
et
b
line
vet
blue
protocol
p
nevertheless
final
conclus
drawn
base
posit
site
b
line
per
hemithorax
use
previou
studi
final
conclus
two
protocol
significantli
differ
p
agreement
two
protocol
substanti
kappa
detect
parenchym
lesion
two
protocol
significantli
differ
p
conclus
result
suggest
lu
find
vet
blue
protocol
substanti
agre
et
howev
brought
mind
sever
lesion
lu
may
underestim
use
region
base
protocol
disclosur
report
studi
support
ministri
scienc
technolog
taiwan
comparison
plasma
metabolom
profil
healthi
adult
cat
low
high
plasma
homocystein
concentr
drut
jm
chao
de
la
barca
p
nguyen
g
simard
mallem
oniri
nant
atlant
nation
colleg
veterinari
medicin
nant
franc
univers
hospit
anger
anger
franc
sever
prospect
observ
studi
provid
data
plasma
homocystein
concentr
healthi
cat
reveal
largerthanexpect
interindividu
variabl
investig
conduct
healthi
laboratori
cat
suggest
impair
homocystein
metabol
individu
use
methionin
load
test
aim
studi
determin
differ
metabolom
profil
healthi
cat
exhibit
low
high
plasma
homocystein
concentr
respect
use
leftov
frozen
plasma
sampl
clientown
healthi
adult
cat
previous
enrol
prospect
observ
studi
aim
determin
refer
interv
plasma
homocystein
concentr
felin
speci
extract
individu
high
plasma
homocystein
concentr
select
epidemiologicallymatch
individu
low
plasma
homocystein
concentr
plasma
sampl
subject
target
metabolom
analysi
use
absoluteidq
kit
biocrat
life
scienc
ag
assess
six
biochem
class
acylcarnitin
amino
acid
biogen
amin
glycerophospholipid
sphingolipid
hexos
disclosur
report
associ
immunemedi
hemolyt
anemia
imha
acut
pancreat
dog
present
frequenc
pancreat
significantli
p
higher
dog
imha
compar
control
respect
followup
period
dog
imha
develop
pancreat
imha
dog
pancreat
n
significantli
p
higher
hb
pf
median
gdl
rang
compar
imha
dog
without
pancreat
n
median
gdl
rang
youden
index
hb
pf
gdl
sensit
specif
auc
ci
p
dog
imha
hb
pf
concentr
gdl
result
increas
risk
pancreat
rr
ci
differ
mortal
p
imha
dog
without
pancreat
dog
imha
increas
risk
pancreat
sever
dog
develop
pancreat
diagnosi
imha
may
suggest
imha
may
caus
pancreat
hb
fp
trigger
disclosur
report
sepsi
lead
caus
death
veterinari
patient
remain
challeng
diagnosi
prompt
accur
manner
procalcitonin
pct
studi
extens
human
medicin
commonli
use
biomark
sepsi
littl
inform
regard
pct
biomark
sepsi
dog
exist
control
studi
evalu
kinet
pct
sepsi
aim
studi
evalu
respons
serum
pct
dog
experiment
induc
endotoxemia
hypothes
pct
would
rapidli
detect
serum
inject
lp
would
remain
elev
least
hour
six
healthi
mix
breed
dog
includ
studi
experiment
endotoxemia
induc
inject
healthi
dog
lipopolysaccharid
lp
ugkg
iv
vital
sign
monitor
serial
blood
sampl
collect
measur
serum
pct
hour
follow
lp
inject
differ
mean
serum
pct
serial
time
point
assess
use
mix
effect
model
result
current
studi
suggest
pct
express
respons
experiment
induc
endotoxemia
kinet
pct
express
favor
support
use
biomark
sepsi
dog
addit
chang
serial
measur
agreement
clinic
evalu
improv
pct
may
addit
role
prognost
therapeut
decisionmak
disclosur
report
fund
studi
provid
part
ontario
veterinari
colleg
depart
clinic
studi
effect
weight
loss
program
metabol
immunolog
profil
blood
leptin
level
cardiovascular
paramet
obes
dog
l
cortes
palatucci
v
rubino
giovazzino
filosa
g
ruggiero
g
terrazzano
piantedosi
univers
napl
federico
ii
napl
itali
depart
translat
medic
scienc
univers
napl
federico
ii
napoli
itali
depart
veterinari
medicin
food
product
univers
napl
fe
napl
itali
depart
scienc
univers
basilicata
potenza
itali
depart
veterinari
medicin
food
product
univers
napl
fede
napl
itali
last
year
increas
obes
incid
canin
speci
enshrin
relev
import
worldwid
diseas
recent
obes
associ
impair
immun
chronic
lowgrad
inflamm
human
well
mous
model
increas
concentr
leptin
proinflammatori
cytokin
describ
obes
dog
reduc
number
regulatori
cell
treg
report
viscer
adipos
tissu
blood
obes
human
recent
also
labrador
retriev
obes
dog
moreov
evid
address
possibl
impact
obes
cardiovascular
apparatu
dog
aim
studi
investig
effect
weight
loss
program
metabol
immunolog
profil
blood
leptin
level
cardiovascular
paramet
obes
dog
ten
overweight
dog
ob
bc
recruit
studi
underw
blood
test
complet
blood
count
serum
biochemistri
blood
level
assay
cell
ratio
measur
serum
leptin
speciesspecif
elisa
kit
assess
cardiovascular
function
blood
pressur
measur
electrocardiographi
echocardiographi
five
month
commerci
avail
weight
loss
diet
ten
normal
weight
bc
healthi
dog
repres
control
group
ctr
regard
metabol
profil
mild
signific
decreas
total
cholesterol
signific
decreas
triglycerid
serum
level
p
observ
obes
dog
signific
differ
biochem
paramet
well
haematolog
valu
two
observ
time
concern
cardiovascular
paramet
signific
differ
observ
particularli
systol
arteri
blood
pressur
valu
refer
rang
time
ob
elev
serum
leptin
concentr
decreas
significantli
p
weight
loss
howev
remain
higher
compar
ctr
ob
dog
show
signific
low
level
p
treg
compar
ctr
increas
weight
loss
data
suggest
derang
immuneregul
combin
high
leptin
level
might
character
obes
dog
absenc
cardiovascular
alter
furthermor
basi
result
may
suggest
probabl
dog
greater
reduct
fat
mass
longterm
weight
loss
program
necessari
order
restor
immunolog
balanc
disclosur
report
life
aim
retrospect
cohort
studi
determin
life
expect
caus
death
dog
seen
toulous
veterinari
teach
hospit
tvth
franc
effect
variou
factor
breed
gender
size
data
databas
tvth
search
dog
record
dead
septemb
record
screen
determin
age
death
classifi
caus
neoplast
cardiovascular
behavior
dermatolog
endocrinolog
gastroenterolog
hematopoiet
infecti
musculoskelet
neurolog
ophthalmolog
reproduct
respiratori
trauma
record
specifi
result
analyz
use
commerci
softwar
r
excel
log
rank
test
use
life
expect
effect
breed
gender
reproduct
statu
weight
categori
assess
test
multivari
analysi
year
common
caus
trauma
infect
compar
whole
popul
intact
femal
like
die
reproductiverel
endocrinolog
caus
neuter
femal
neoplast
disord
p
studi
suggest
canin
longev
highli
influenc
weight
domin
caus
death
french
dog
vari
breed
gender
reproduct
statu
studi
enlarg
first
opinion
practic
disclosur
report
comparison
sedentari
activ
establish
cut
point
high
activ
dog
spent
time
sedentari
activ
ae
boa
dog
ae
boasdog
ae
control
mean
sd
signific
differ
found
boa
normocephal
dog
sedentari
high
activ
percentag
p
ae
ae
p
respect
conclus
dog
mark
boa
sign
spend
less
time
high
activ
time
sedentari
activ
normocephal
dog
disclosur
report
conclus
regardless
presenc
alveolar
lesion
bb
may
suspect
cough
dog
normal
slightli
elev
crp
suggest
crp
good
marker
hep
guid
type
durat
treatment
bordetellosi
disclosur
report
polycythemia
uncommon
dog
chronic
hypox
pulmonari
diseas
statist
analysi
predict
persist
canin
sinonas
aspergillosi
endoscop
followup
compar
three
differ
score
system
retrospect
studi
case
treat
one
hour
clotrimazol
perendoscop
infus
undergo
endoscop
followup
aim
studi
investig
three
differ
score
system
canin
sinonas
aspergillosi
csa
order
predict
whether
indic
persist
csa
endoscop
followup
medic
record
dog
treat
csa
review
inclus
criteria
presenc
full
medic
histori
radiolog
investig
meticul
debrid
fungal
plaqu
endoscop
followup
day
treatment
fortyseven
dog
fulfil
inclus
criteria
includ
studi
dog
csa
grade
score
given
accord
sharp
time
diagnosi
rhinoscop
score
accord
zonderland
given
endoscop
examin
score
modifi
author
creat
three
categori
sever
mild
csa
score
moder
csa
score
sever
csa
score
amount
fungal
plaqu
consid
mild
countabl
moder
partial
occupi
sinonas
caviti
abund
obliter
sinonas
caviti
clinic
score
propos
schuller
modifi
use
assess
patient
prior
endoscop
followup
dog
classifi
clinic
sign
report
mild
occasion
sneez
occasion
revers
sneez
serou
mucoid
discharg
moder
mucopurul
discharg
frequent
sneez
frequent
revers
sneez
sever
sever
mucopurul
discharg
stertor
persist
revers
sneez
persist
sneez
epistaxi
gener
malais
clinic
sign
three
score
system
statist
analis
explicitli
address
question
chanc
predict
persist
fungal
infect
base
score
system
outcom
ye
score
method
consid
predict
fungal
infect
persist
conting
tabl
score
system
comput
null
hypothesi
independ
score
method
persist
fungal
infect
statist
test
fisherfreemanhalton
exact
test
accord
statist
result
sharp
grade
score
system
consid
significantli
associ
persist
persist
fungal
infect
endoscop
followup
therefor
consid
predictor
fungal
infect
persist
sharp
score
system
fisher
pvalu
endoscop
followup
strongli
recommend
assess
csa
treatment
effect
sharp
grade
score
use
predict
treatment
outcom
dog
treat
one
hour
clotrimazol
perendoscop
infus
sharp
grade
score
might
appli
also
differ
method
treat
csa
studi
warrant
disclosur
report
evalu
felin
pack
red
blood
cell
unit
obtain
blood
sediment
store
day
transfus
purpos
analysi
ecolog
index
show
bacteri
rich
p
p
significantli
higher
bc
group
compar
two
group
amova
analysi
indic
bc
group
differ
compar
dc
group
bc
vs
dc
p
bc
vs
p
differ
bacteri
load
group
effect
live
condit
nasal
microbi
popul
predominantli
compos
phyla
proteobacteria
mainli
repres
famili
moraxellacea
actinobacteria
firmicut
bacteroidet
agreement
previou
studi
howev
within
breed
group
rel
abund
phyla
highli
variabl
signific
differ
found
group
famili
level
rel
abund
pasteurellacea
significantli
higher
bc
group
distinct
speci
genera
found
indic
discrimin
p
among
speci
genera
bc
group
speci
group
studi
mainli
demonstr
signific
differ
nasal
microbiota
bc
group
compar
two
group
differ
might
associ
particular
facial
morpholog
andor
breath
pattern
brachycephal
dog
identifi
nasal
microbiota
breeddiffer
would
favor
breed
suscept
dolichocephal
dog
nasal
diseas
studi
need
investig
role
nasal
microbiota
variat
trigger
perpetu
factor
nasal
diseas
especi
dog
sinonas
aspergillosi
disclosur
report
canin
sinonas
aspergillosi
itali
case
cystin
urolith
primarili
found
bulldog
french
bullterri
studi
reveal
ce
cn
cohort
urolith
common
order
struvit
calcium
oxal
cystin
ammonium
urat
among
ce
breed
yorkshir
terrier
parson
russel
terrier
subject
calcium
oxal
pug
struvit
format
among
cn
breed
miniatur
schnauzer
bichon
poodl
subject
struvit
urolith
struvit
urolith
ce
cn
dog
occur
equal
femal
rate
substanti
higher
male
within
male
cn
dog
time
suscept
ce
counterpart
consid
role
ureaseproduc
bacteria
genesi
struvit
urolith
data
suggest
influenc
gender
well
habitat
calcium
oxal
urolith
time
preval
male
dog
femal
ce
cn
cohort
cystin
urolith
substanti
preval
male
femal
dog
ce
cn
cohort
notabl
male
ce
dog
time
suscept
cn
counterpart
overal
data
suggest
canin
urolith
format
wide
depend
breed
gender
environment
factor
like
diet
region
care
practic
disclosur
report
studi
strengthen
preren
proteinuria
rare
cat
ckd
frequent
caus
signific
proteinuria
speci
sever
hypertens
common
find
highlight
relev
sbp
measur
cat
fact
iri
stage
possibl
cat
still
reflect
poor
awar
veterinarian
classificationmor
contribut
better
knowledg
caus
proteinuria
studi
suggest
physiolog
preren
caus
induc
signific
proteinuria
cat
disclosur
report
aim
studi
assess
main
caus
proteinuria
dog
region
lisbon
order
estim
role
cvbd
dog
present
lisbon
veterinari
hospit
januari
decemb
identifi
signific
proteinuria
upc
ratio
establish
primari
diagnosi
select
base
medic
record
case
classifi
accord
proteinuria
origin
dog
select
femal
male
averag
year
old
rang
year
old
anaplasma
spp
whilst
preren
signific
proteinuria
uncommon
cvbd
main
caus
renal
proteinuria
dog
leishmaniosi
frequent
cvbd
identifi
serolog
despit
increas
prevent
measur
expect
result
sinc
cvbd
highli
preval
portug
studi
suggest
cvbd
common
differenti
diagnosi
renal
proteinuria
dog
lisbon
result
might
extrapol
endem
southern
european
countri
studi
need
confirm
disclosur
report
evalu
diagnost
valu
urinari
albumin
protein
ratio
proteinur
dog
renal
protein
loss
mainli
caus
either
tubular
glomerular
dysfunct
differenti
two
type
hold
high
diagnost
therapeut
signific
tubular
proteinuria
defin
loss
low
molecular
weight
protein
wherea
glomerulopathi
albuminuria
pronounc
hypothes
assess
urin
albumintotot
protein
ratio
uapr
abl
identifi
sourc
proteinuria
whether
sole
tubular
origin
glomerular
damag
present
well
proteinur
canin
leftov
urin
sampl
use
studi
sampl
belong
laboratori
beagl
clinic
patient
addit
urinari
protein
creatinin
concentr
determin
albumin
measur
immunoturbidimetr
method
urinari
albumintocreatinin
ratio
uac
urinari
proteintocreatinin
ratio
upc
ratio
uac
upc
uapr
calcul
find
compar
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
sdspage
sole
tubular
proteinuria
consid
tubular
mix
tubular
glomerular
glomerular
proteinuria
consid
nontubular
base
find
suggest
uapr
could
simpl
afford
method
identifi
sourc
proteinuria
thu
determin
uapr
may
help
diagnost
therapeut
decisionmak
proteinur
dog
gold
standard
differenti
tubular
glomerular
damag
histopatholog
thu
futur
plan
compar
uapr
histopatholog
diagnosi
disclosur
report
disclosur
report
nonsymptomat
bacteriuria
common
young
femal
boxer
dog
disclosur
report
antioxid
enzym
activ
dog
acut
uraemia
manag
haemodialysi
although
gpx
significantli
increas
p
hdg
compar
cg
dog
dic
n
show
significantli
lower
cat
p
gpx
p
level
dog
without
dic
n
cat
gpx
activ
patient
sir
n
appear
significantli
lower
patient
without
sir
n
cohort
dog
intermitt
hd
seem
significantli
affect
antioxid
enzym
activ
howev
reduc
enzymat
activ
urem
dog
dic
sir
worthi
investig
disclosur
report
disclosur
report
accuraci
refractometr
urin
specif
graviti
determin
cat
f
manczur
b
univers
veterinari
medicin
budapest
hungari
urinespecif
graviti
usg
use
proxi
urin
concentr
osmol
usual
determin
use
refractomet
long
held
belief
felin
urin
higher
specif
refract
disclosur
report
earli
detect
tubular
damag
dog
infect
leishmania
infantum
use
nag
glutamyl
transferas
ggt
unagcr
differ
statist
group
compar
control
differ
signific
differ
uggtcr
found
c
studi
show
unagccr
appear
good
biomark
earli
detect
renal
tubular
damag
earli
stage
canin
leishmaniasi
prior
presenc
azotaemia
proteinuria
contrari
uggtcr
appear
less
use
purpos
consist
elev
advanc
stage
leishmaniaassoci
chronic
kidney
diseas
disclosur
report
use
urin
neutrophil
gelatinaseassoci
lipocalin
ngal
cystatin
c
cysc
diagnosi
renal
diseas
dog
affect
leishmaniasi
canin
leishmaniasi
highli
preval
zoonot
diseas
spain
dog
affect
present
structur
andor
function
abnorm
kidney
rang
clinic
present
asymptomat
sever
diseas
individu
clinic
sign
creatin
proteinuria
use
assess
evolut
condit
evalu
marker
earli
renal
damag
could
use
redefin
diseas
classif
prognost
andor
therapeut
guidanc
purpos
moreov
dog
leishmaniasi
optim
natur
model
studi
tubular
damag
biomark
ngal
cysc
canin
chronic
kidney
diseas
aim
evalu
diagnost
power
urinari
ngal
cysc
earli
marker
renal
diseas
dog
diagnos
l
infantum
use
modifi
iri
chronic
kidney
diseas
stage
ngal
determin
use
canin
ngal
elisa
kit
abcam
usa
result
express
ngalcreatinin
ratio
ungalcr
cystatin
c
measur
use
turbidimetr
latex
assay
spinreact
spain
express
cysccreatinin
ratio
ucysccr
mannwhitneyu
test
use
run
comparison
due
nongaussian
distribut
data
p
consid
statist
signific
biomark
statist
signific
differ
found
control
group
rest
significantli
differ
compar
ngal
cysc
addit
cysc
valu
differ
significantli
result
demonstr
urinari
ucysccr
ungalcr
highli
sensit
biomark
detect
tubular
damag
nonazoem
nonproteinur
dog
affect
canin
leishmaniasi
disclosur
report
complic
uti
dog
uropathogen
antimicrobi
resist
comorbid
j
zambarbieri
f
celi
faverzani
pa
martino
p
scarpa
univers
milan
lodi
itali
aim
retrospect
studi
investig
preval
pathogen
suscept
pattern
comorbid
urinari
site
involv
detect
ultrasonographi
popul
dog
affect
cuti
four
hundr
thirti
one
urin
sampl
collect
cystocentesi
dog
underw
urin
cultur
diagnost
purpos
antimicrobi
sensit
test
obtain
kirbybau
method
comorbid
deduc
analysi
patient
clinic
ultrasound
report
control
group
dog
dog
affect
random
among
whole
canin
popul
examin
period
time
wilcoxon
kruskalw
chisquar
test
use
statist
analysi
one
hundr
forti
one
urin
sampl
dog
posit
cultur
crossbre
spay
femal
preval
mean
age
year
signific
higher
preval
among
utidog
observ
labrador
retriev
english
bulldog
golden
retriev
beagl
cocker
spaniel
spay
femal
dog
year
old
escherichia
coli
predomin
pathogen
follow
staphylococcu
pseudintermediu
staphylococcu
aureu
streptococcu
faecali
klebsiella
pneumonia
pseudomona
aeruginosa
speci
predomin
singl
isol
compar
polymicrobi
infect
observ
marbofloxacin
overal
effect
molecul
sensit
follow
cefovecin
ceftriaxon
enrofloxacin
pradofloxacin
escherichia
coli
show
high
rate
antimicrobi
resist
detect
could
lead
treatment
failur
poor
prognosi
addit
guidelin
need
public
health
concern
determin
zoonot
potenti
isol
bacteria
disclosur
report
cat
risk
spontan
ckd
affect
surviv
prognosi
p
scarpa
de
sancti
j
zambarbieri
univers
milan
lodi
itali
chronic
kidney
diseas
ckd
among
major
caus
morbid
mortal
cat
signific
preval
year
old
aim
retrospect
observ
studi
evalu
preval
death
surviv
time
risk
factor
popul
cat
risk
affect
ckd
one
hundr
thirti
three
cat
start
popul
year
includ
studi
one
follow
criteria
observ
first
clinic
examin
age
year
serum
creatinin
scr
mgdl
borderlin
patholog
urinari
proteincreatinin
ratio
upc
urin
specif
graviti
usg
furthermor
followup
data
obtain
onlin
questionnair
fill
owner
begin
nephropath
cat
stage
accord
iri
guidelin
nephropath
cat
includ
stage
wilcoxon
test
kaplan
meyer
surviv
curv
analysi
perform
median
age
popul
ae
year
male
overrepres
vs
domest
shorthair
predomin
breed
forti
nine
cat
includ
stage
stage
stage
stage
stage
mean
scr
valu
mgdl
ae
sixti
cat
natur
dead
euthan
time
survey
due
ckd
paramet
significantli
differ
two
group
dead
ckd
dead
diseas
serum
creatinin
higher
usg
red
blood
cell
rbc
white
blood
cell
wbc
hematocrit
ht
significantli
lower
dead
ckd
cat
surviv
time
nephropath
cat
relat
age
iri
stage
serum
phosphoru
rbc
wbc
ht
cat
stage
surviv
longer
cat
stage
comorbid
reason
consult
cat
lower
surviv
time
observ
cat
bodi
condit
score
differ
normal
higher
lower
lower
surviv
observ
hypertens
condit
whole
popul
cat
consid
ckd
one
scr
result
cbc
usg
keep
consider
prognost
evalu
cat
risk
affect
ckd
age
consid
risk
prognost
factor
disclosur
report
frequent
elderli
anim
epitheli
origin
local
invas
low
metastat
incid
subject
includ
multicent
prospect
studi
examin
june
decemb
rhinoscopi
reveal
new
tissu
format
nasal
caviti
nasopharynx
case
histori
includ
clinic
exam
laboratori
exam
xray
endoscopi
tomographi
histolog
therapeut
choic
followup
subject
collect
analys
dog
princip
dolichocephal
breed
male
femal
averag
age
averag
bc
subject
underw
symptomat
treatment
diagnosi
symptom
present
month
common
clinic
symptom
nasal
discharg
unilater
serosanguin
discharg
andor
epistaxi
present
case
stertor
facial
swell
deform
nasal
planum
andor
exophthalmo
endoscop
examin
found
neoform
unilater
case
nasal
nasopharyng
histolog
type
neoplasm
classifi
malign
epitheli
malign
mesenchym
benign
round
cell
tumor
subject
evalu
underw
endoscop
debulk
diod
laser
associ
grasp
forcep
metronom
therapi
debulk
metronom
therapi
radiat
treatment
radiat
metronom
radiotherapi
chemotherapi
surgeri
debulk
radiotherapi
specif
therapi
deceas
patient
averag
surviv
time
day
malign
epitheli
tumor
day
malign
mesenchym
tumor
patient
underw
debulk
metronom
therapi
averag
surviv
time
day
treat
debulk
alon
day
metronom
therapi
alon
day
therapi
day
date
subject
benign
neoplasia
aliv
conclus
studi
show
nasal
tumor
often
diagnos
late
nasopharynx
alreadi
affect
common
histolog
type
adenocarcinoma
benign
neoplasia
rare
describ
literatur
also
frequent
good
respons
nasal
debulk
combin
metronom
therapi
make
multimod
approach
worthi
evalu
reduc
cost
high
qualiti
life
patient
disclosur
report
show
high
baselin
level
induc
upon
treatment
cell
line
low
nondetect
baselin
express
level
show
strong
induct
upon
treatment
level
affect
addit
knockdown
affect
clonogen
htrt
howev
mrna
level
lower
heat
notabl
ex
vivo
treat
canin
soft
tissu
sarcoma
result
show
major
cell
line
radiosensit
vitro
indic
tumor
microenviron
respons
major
effect
hyperthermia
interestingli
discov
heatinduc
suppress
transcript
potenti
inhibit
homolog
recombin
repair
pathway
promis
light
futur
combin
hyperthermia
parp
inhibitor
disclosur
report
interest
associ
abdomin
ultrasound
alanin
transaminas
alt
measur
determin
hepat
infiltr
case
nodal
diffus
larg
bcell
lymphoma
dlblcl
lanor
p
vajdovich
j
borrego
f
mellet
moniot
j
laxald
j
bayl
cliniqu
allianc
bordeaux
franc
univers
veterinari
medicin
budapest
hungari
especialidad
veterinaria
paterna
spain
royal
canin
sa
aimargu
franc
canin
nodal
dlbcl
one
import
step
diagnosi
determin
presenc
hepat
infiltr
correspond
stage
iv
base
world
health
organ
stage
lymphoma
assess
liver
involv
classic
made
ultrasonographi
confirm
cytolog
remain
usual
procedur
efficaci
determin
hepat
infiltr
base
abnorm
imag
evalu
respect
sensit
specif
posit
prognost
valu
ppv
neg
prognost
valu
npv
crabtre
aim
work
evalu
associ
abdomin
ultrasound
alt
measur
help
determin
hepat
infiltr
complet
clinic
stage
prospect
perform
dog
examin
oncolog
referr
center
confirm
diagnosi
nodal
dlbcl
liver
ultrasound
cytolog
plasma
alt
measur
perform
dog
ultrasonograph
pattern
characterist
canin
lymphoma
liver
includ
coars
parenchyma
illdefin
hypoecho
area
hypoecho
nodul
diffus
hypoechogen
diffus
hyperechogen
without
hepatomegali
nyland
crabtre
alt
analysi
perform
inhous
result
interpret
laboratoryspecif
refer
rang
classifi
normal
vs
elev
ethic
approv
grant
royal
canin
ethic
committe
hepat
infiltr
confirm
cytolog
found
case
evalu
interest
associ
liver
ultrasound
alt
determin
infiltr
dog
classifi
posit
alt
outsid
laboratori
rang
combin
abnorm
ultrasound
imag
dog
find
consid
neg
sensit
specif
ppv
npv
respect
result
suggest
simultan
find
elev
alt
abnorm
ultrasonographi
allow
identifi
dog
hepat
infiltr
case
nodal
canin
dlbcl
confirm
find
research
need
studi
aim
understand
pet
owner
interest
psycholog
support
provid
directli
veterinari
hospit
survey
given
wait
room
singl
italian
veterinari
hospit
dog
cat
pet
owner
come
visit
sever
medic
reason
march
survey
includ
question
sociodemograph
data
emot
experi
owner
diseas
care
pet
opinion
psychologist
support
total
survei
administr
return
adher
studi
twelv
discard
incomplet
sampl
compos
femal
male
repres
age
group
year
dog
instead
cat
pet
present
depart
intern
medicin
follow
oncolog
emerg
sampl
declar
anxieti
concern
demor
health
anim
subject
report
would
appreci
receiv
help
someon
compet
contrast
declar
nondesir
support
report
motiv
decis
desir
live
emot
alon
sixtysix
sampl
would
use
servic
andor
suggest
famili
member
case
difficult
decis
poor
prognosi
emot
manag
particularli
claim
normal
feel
anxieti
concern
health
anim
among
would
like
use
servic
final
declar
probabl
beneficiari
servic
psycholog
support
consid
case
hilli
mourn
pet
compar
term
distress
ill
loss
love
one
survey
show
larg
percentag
owner
express
desir
follow
profession
figur
field
psycholog
support
treatment
pet
knowledg
aspect
never
investig
italian
veterinari
hospit
disclosur
report
evalu
myelosupress
effect
singl
dose
vincristin
dog
lymphoma
mosca
e
dobson
j
dobson
univers
cambridg
queen
veterinari
school
hospit
cambridg
unit
kingdom
lymphoma
common
haematopoet
neoplasm
canin
popul
chemotherapi
protocol
cop
chop
lopp
use
treat
lymphoma
due
chemosensit
natur
protocol
routin
involv
vincristin
current
literatur
report
common
vincristin
induc
toxic
gastrointestin
effect
also
suggest
degre
myelosupress
especi
combin
protocol
littl
research
focus
myelosupress
effect
vincristin
alon
singl
dose
neutropenia
lead
treatment
delay
dose
reduct
associ
longer
remiss
time
aim
studi
investig
myelosupress
effect
vincristin
dog
singl
administr
record
dog
previous
untreat
confirm
lymphoma
receiv
vincristin
juli
march
analys
patient
includ
haematolog
perform
prior
receiv
vincristin
repeat
within
day
prior
receiv
second
dose
chemotherapi
patient
exclud
receiv
chemotherapeut
medic
time
oral
prednisolon
therapi
permit
fortyfour
dog
treat
mgm
intraven
vincristin
includ
studi
dog
lymphoma
boxer
labrador
spaniel
overrepres
studi
popul
mean
age
year
rang
year
mean
bodi
weight
kg
rang
studi
show
small
proport
dog
receiv
vincristin
initi
sole
agent
part
chemotherapi
protocol
lymphoma
develop
signific
neutropenia
within
one
week
vincristin
administr
disclosur
report
circul
immun
complex
level
correl
progress
canin
leishmaniosi
jc
n
parodi
c
cacheirollaguno
c
osuna
renshawcalderon
c
alonso
laboratorio
leti
sl
tre
canto
spain
centro
de
molecular
severo
ochoa
csicuniversidad
de
madrid
spain
dog
main
domest
reservoir
l
infantum
leishmania
infect
dog
unabl
control
infect
larg
uncontrol
humor
immun
respons
elicit
ineffici
parasit
high
concentr
antibodi
circul
antigen
canin
leishmaniosi
result
format
circul
immun
complex
cic
deposit
tissu
associ
tissu
damag
especi
glomerulonephr
renal
failur
howev
littl
known
relationship
presenc
cic
progress
diseas
object
evalu
level
cic
correl
sever
diseas
serum
sampl
healthi
infect
anim
total
dog
classifi
accord
leishvet
criteria
healthi
n
infect
asymptomat
n
infect
symptomat
stage
n
ii
n
iii
n
iv
n
includ
studi
cic
isol
serum
sampl
use
slightli
modifi
pegprecipit
method
level
measur
elisa
protein
content
estim
bicinchonin
acid
bca
protein
assay
nanoparticl
track
analysi
nta
cic
done
order
investig
relationship
cic
molecular
size
distribut
progress
diseas
result
show
statist
signific
correl
cic
level
stage
patholog
infect
dog
expect
healthi
infect
asymptomat
anim
show
cic
relat
infect
direct
relationship
level
cic
total
protein
concentr
progress
diseas
also
confirm
correl
ifat
titer
cic
level
addit
data
show
dog
sever
clinic
sign
present
larg
size
protein
aggreg
wherea
higher
concentr
smaller
size
aggreg
observ
non
infect
asymptomat
dog
fact
demonstr
clear
posit
correl
clinic
stage
size
precipitatedc
first
studi
correl
cic
level
progress
diseas
canin
leishmaniosi
measur
cic
probabl
repres
valuabl
tool
diagnos
also
predict
diseas
progress
activ
asymptomat
seroposit
dog
even
follow
efficaci
treatment
even
measur
cic
biomark
progress
diseas
could
provid
interest
inform
vaccin
immunotherapi
treatment
confirm
control
diseas
disclosur
report
employe
laboratorio
leti
clinicopatholog
find
canin
leishmaniosi
associ
signal
age
sex
breed
seem
determin
type
clinic
manifest
dog
develop
well
outcom
infect
object
studi
defin
clinicopatholog
find
canl
associ
signal
total
dog
diagnosi
leishmaniosi
retrospect
includ
inform
obtain
clinic
histori
physic
examin
laboratori
test
dog
use
fill
databas
includ
signal
clinic
sign
laboratori
abnorm
clinic
stage
diseas
dog
studi
classifi
moder
clinic
stage
canin
leishmaniosi
young
dog
less
tendenc
develop
system
sign
p
renal
p
hematolog
p
abnorm
dermatolog
sign
appear
common
young
dog
compar
old
one
p
young
dog
show
proteinuria
less
often
older
dog
p
dog
younger
year
present
renal
azotemia
older
dog
show
occasion
renal
azotemia
p
younger
dog
mainli
classifi
stage
iimildmoder
diseas
rare
stage
iii
ivsever
sever
diseas
compar
dog
older
year
old
p
pure
breed
dog
seem
significantli
tendenc
develop
ulcer
dermat
compar
mix
breed
dog
p
studi
describ
first
time
age
appear
associ
differ
clinicopatholog
find
canl
young
dog
appear
present
less
sever
manifest
diseas
prone
develop
dermatolog
sign
adultold
dog
moder
clinic
stage
commonli
found
canl
disclosur
report
correl
molecular
epidemiolog
canin
babesia
speci
distribut
vector
tick
dog
taiwan
polymeras
chain
reaction
pcr
test
bgibsoni
perform
firstli
divid
dog
posit
dog
neg
dog
group
factor
includ
environ
season
breed
gender
intact
neuter
statu
live
lifestyl
extern
parasit
prevent
urin
color
mucou
membran
color
histori
babesiosi
analyz
use
chisquar
test
initi
variabl
pvalu
analyz
stepwis
multivari
logist
regress
analysi
differ
consid
statist
signific
associ
pvalu
odd
ratio
irregularli
extern
parasit
prevent
p
present
dark
brown
urin
p
respect
therefor
factor
like
associ
infect
result
reveal
regular
prevent
extern
parasit
observ
urin
color
import
babesiosi
epidem
area
disclosur
report
acantocheilonema
reconditum
hunt
dog
southern
itali
distribut
risk
factor
haematobiochem
find
l
pacifico
n
ferrari
g
sgroi
c
romeo
f
buono
b
neola
beall
j
buch
r
chandrashekar
v
veneziano
piantedosi
univers
napl
federico
ii
napl
itali
depart
veterinari
medicin
degli
studi
di
milano
milan
itali
depart
veterinari
medicin
anim
product
univers
napl
f
napl
itali
istituto
zooprofilattico
sperimental
del
mezzogiorno
portici
napl
itali
idexx
laboratori
inc
westbrook
unit
state
america
acantocheilonema
reconditum
parasit
transmit
flea
lice
tick
includ
among
filaroid
speci
infect
dog
contrari
wellstudi
dirofilaria
immiti
dirofilaria
repen
reconditum
believ
less
pathogen
adult
worm
local
subcutan
tissu
periren
fat
although
previou
studi
report
absenc
clinic
symptom
infect
dog
data
regard
haematolog
biochem
chang
could
potenti
caus
parasit
hunt
dog
frequent
expos
vectorborn
pathogen
aim
present
studi
assess
preval
risk
factor
potenti
hematobiochem
abnorm
associ
reconditum
infect
specif
canin
popul
blood
sampl
collect
hunt
dog
live
campania
region
test
modifi
knott
techniqu
count
identifi
microfilaria
dog
test
posit
reconditum
overal
preval
ci
number
microfilariaeml
rang
exclud
dog
coinfect
differ
filari
worm
speci
andor
vectorborn
pathogen
common
southern
itali
n
dog
show
reconditum
singl
infect
main
clinic
featur
observ
dehydr
n
fever
n
congest
mucou
membran
n
exercis
intoler
n
complet
blood
cell
count
result
reveal
leukocytosi
n
anaemia
n
thrombocytopenia
n
eosinophilia
n
biochem
data
show
increas
serum
valu
total
globulin
n
albumin
n
gamma
glutamyl
transferas
n
alkalin
phosphat
n
hypoalbuminemia
observ
one
dog
dog
coinfect
vectorborn
pathogen
includ
statist
analysi
live
area
p
type
hunt
speci
p
ectoparasit
infest
p
variabl
significantli
associ
reconditum
infect
live
caserta
provinc
ci
napoli
provinc
ci
hunt
wild
mammal
ci
ectoparasit
infest
ci
repres
risk
factor
concern
haematochem
paramet
infect
dog
signific
neg
correl
microfilaraem
load
serum
albumin
level
found
pearson
correl
coeffici
p
obtain
data
confirm
circul
reconditum
within
hunt
dog
popul
southern
itali
provid
inform
pathogen
potenti
filari
worm
disclosur
report
present
studi
therapeut
efficaci
human
antiretrovir
compound
use
acquir
immun
defici
syndrom
investig
treatment
cat
natur
infect
felin
immunodefici
viru
fiv
cat
present
symptom
recurr
infect
sinus
stomat
test
fiv
felv
statu
idexx
snap
fivfelv
combo
test
cat
includ
studi
test
posit
fiv
present
chronic
oral
nasal
inflamm
nine
cat
met
mention
inclus
criteria
tenofovir
virofob
alvogen
administ
oral
daili
dose
mgcat
day
alongsid
specif
treatment
experiment
group
day
day
measur
includ
complet
blood
count
ratio
bun
creatinin
one
nine
cat
toler
tenofovir
administr
exclud
studi
five
day
due
sever
hypersaliv
tenofovir
benef
effect
sever
oral
nasal
inflamm
induc
improv
gener
condit
fiv
infect
cat
cat
show
increas
lymphocyt
ratio
treatment
without
sign
nephrotox
myelotox
studi
suggest
tenofovir
human
antiretrovir
compound
effect
treatment
cat
natur
infect
felin
immunodefici
viru
fiv
side
effect
bone
marrow
activ
kidney
function
shortterm
administr
disclosur
report
lb
discov
accident
three
case
present
veterinarian
well
exam
vaccin
clinic
sign
appar
examin
veterinarian
owner
orthoped
disord
report
case
four
dog
show
gener
sign
diseas
kidney
failur
occur
four
case
one
dog
die
dilat
cardiomyopathi
one
suspici
dog
present
bark
troubl
respond
well
doxycyclin
specif
antibodi
level
bb
correl
clinic
sign
sever
diseas
use
followup
check
furthermor
concurr
specif
antibodi
bb
anaplasma
phagocytophilum
detect
case
borreli
dna
found
synovi
fluid
four
dog
orthoped
disord
one
heart
sampl
recoveri
antibiot
treatment
observ
dog
orthoped
gener
disord
dog
renal
cardiac
manifest
show
poor
prognosi
dog
cardiac
present
case
kidney
failur
die
applic
parasiticid
alway
record
dog
receiv
regular
treatment
treat
regularli
isoxazolin
system
product
fipronilbas
spoton
collar
one
flumethrinbas
one
unrecord
brand
studi
suggest
canin
lb
may
present
variou
clinic
form
consid
case
musculoskelet
problem
impair
gener
condit
also
case
renal
cardiac
disord
research
requir
investig
diseas
dog
disclosur
report
marina
gatellet
mari
varloud
employe
ceva
animal
consent
form
sign
veterinari
clinic
owner
prior
enrol
distribut
risk
factor
canin
hemotrop
mycoplasma
hunt
dog
southern
itali
common
present
clinicopatholog
abnorm
posit
case
increas
hepat
renal
valu
four
case
present
none
posit
case
present
pulmonari
haemorrhag
dyspnea
primari
leptospirosi
final
diagnosi
posit
case
six
case
unrel
final
diagnosi
neoplasia
n
biliari
mucocel
n
necrot
fasciiti
n
pericardi
effus
n
three
posit
case
final
diagnosi
chronic
renal
insuffici
two
secondari
congenit
dysplasia
three
case
final
diagnosi
chronic
hepatopathi
posit
case
predominantli
medium
larg
breed
dog
labrador
follow
beagl
cross
breed
border
colli
commonli
observ
posit
categori
conclus
prior
vaccin
antibiot
use
preclud
test
leptospirosi
contrast
case
report
mainland
europ
clinic
pulmonari
diseas
appear
featur
case
leptospirosi
appear
detect
incident
case
potenti
signifi
popul
dog
subclin
infect
disclosur
report
dr
gow
speaker
honorarium
companion
anim
magazin
acvim
ecvim
hwalker
msd
may
provid
assist
travel
involv
studi
design
data
collect
result
canin
urin
cultur
antimicrobi
suscept
pattern
eightyear
period
increas
antimicrobi
multidrug
resist
aim
present
studi
describ
preval
bacteri
uti
dog
identifi
commonli
isol
microorgan
analyz
progress
suscept
pattern
studi
period
result
canin
urin
cultur
antimicrobi
suscept
test
perform
januari
decemb
veterinari
teach
hospit
alfonso
x
el
sabio
univers
retriev
laboratori
databas
sampl
collect
cystocentesi
cultur
within
hour
collect
antimicrobi
suscept
determin
use
kirbybau
disc
diffus
method
multidrug
resist
defin
resist
least
one
antimicrobi
agent
three
differ
antimicrobi
categori
total
urin
sampl
identifi
posit
cultur
result
increas
frequenc
posit
bacteri
cultur
studi
period
interv
rel
risk
irr
ci
p
rel
effect
develop
uti
significantli
higher
femal
male
ci
p
commonli
isol
microorgan
escherichia
coli
staphylococcu
spp
enterococcu
spp
pseudomona
spp
streptococcu
spp
overal
preval
resist
within
enterobacteriacea
famili
cefazolin
pradofloxacin
trimethoprimsulfamethoxazol
cefuroxim
enrofloxacin
marbofloxacin
amoxycillin
clavulan
cefovecin
fosfomycin
preval
mdr
infect
rang
meant
increas
trend
mdr
bacteria
irr
p
high
frequenc
increas
trend
antibiot
resist
observ
studi
concern
implic
veterinari
public
health
result
emphasis
import
perform
urinari
cultur
antimicrobi
suscept
test
allow
appropri
select
therapi
although
resist
fosfomycin
compar
low
antimicrobi
agent
licens
veterinari
use
europ
given
use
human
mdr
methicillinresist
staphilococcu
aureu
infect
use
antibiot
must
reserv
human
medicin
disclosur
report
use
mri
gadoxet
acid
differenti
hepat
parenchym
hyperplast
lesion
dog
p
borusewicz
e
stanczyk
p
k
kubiak
j
spuzak
k
glinskasuchocka
jankowski
p
slawuta
kubiaknowak
univers
environment
life
scienc
wroclaw
poland
wroclaw
medic
univers
wroclaw
poland
magnet
reson
imag
mri
use
gadoxet
acid
gdeobdtpa
wide
use
human
medicin
character
hepat
nodular
lesion
veterinari
medicin
report
gdeobdtpa
use
liver
examin
dog
aim
studi
describ
contrast
enhanc
pattern
differ
type
liver
lesion
administr
gdeobdtpa
dog
studi
carri
six
dog
presumpt
diagnosi
focal
liver
lesion
clinic
examin
laboratori
blood
test
abdomin
ultrasound
carri
prior
mri
anim
examin
use
philip
mri
system
imag
protocol
consist
breath
trigger
precontrast
postcontrast
weight
sequenc
perform
transvers
plane
gdeobdtpa
administ
intraven
mlkg
follow
ml
salin
solut
postcontrast
sequenc
acquir
minut
contrast
administr
sampl
histopatholog
examin
collect
case
surgic
resect
case
coreneedl
biopsi
case
necropsi
case
parenchym
liver
metastasi
found
one
case
lesion
strongli
hypointens
compar
surround
liver
tissu
precontrast
sequenc
signalenhanc
follow
contrast
administr
observ
focal
nodular
hyperplasia
observ
one
case
isointens
compar
surround
liver
tissu
precontrast
sequenc
show
signalenhanc
post
contrast
similar
observ
surround
healthi
tissu
nonenhanc
central
scar
observ
within
lesion
hepatocellular
adenoma
diagnos
two
case
lesion
hypointens
hyperintens
precontrast
imag
compar
surround
liver
tissu
case
contrast
enhanc
mri
lesion
observ
one
case
hepat
carcinoid
found
liver
parenchyma
tumour
weakli
hypointens
precontrast
sequenc
weakli
hyperintens
strongli
hyperintens
centr
imag
contrast
enhanc
note
hepatocellular
carcinoma
also
diagnos
one
case
lesion
heterogen
precontrast
sequenc
moder
hypointens
moder
hyperintens
show
contrast
enhanc
remain
strongli
hypointens
compar
surround
tissu
obtain
result
indic
contrastenhanc
patter
dog
variou
hepat
neoplast
lesion
similar
human
enhanc
pattern
use
human
medicin
assess
hepat
hyperplast
parenchym
lesion
may
use
veterinari
medicin
disclosur
report
